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Executive Summary 
Background 
The introduction and dissemination of antiretroviral therapy (ART) has meant that HIV 
(Human Immnodeficiency Virus) has transitioned from being a fatal illness to chronic 
healthcare condition (Montaner et al, 2014). HIV has lifelong treatment implications 
and represents a burden for people with HIV (e.g. managing medication side effects) 
as well as contributing to significant healthcare costs (Laryea & Gien, 1993; Nakagawa 
et al, 2015).  
The United Kingdom (UK), had an estimated 101,200 people living with HIV in 2015 
and approximately 6,095 of these people were newly diagnosed in the same year 
(Public Health England (PHE), 2016; Wilson & Halperin, 2008). Despite various HIV 
prevention initiatives (e.g. increased HIV testing and earlier initiation of ART to reduce 
the infectiousness of HIV) between 2000 to 2013 HIV incidence rates remained 
relatively stable in the UK (Aghaizu et al, 2016; Birrell et al, 2013; Phillips et al, 2013). 
To the contrary, recent data has indicated that rates have steadily increased by 20% 
between 2007 and 2015 in those deemed most at risk in the UK; men who have sex 
with other men (MSM) (Phillips et al, 2013; PHE, 2017).   
Newer initiatives include the introduction of oral pre-exposure prophylaxis (PrEP). 
PrEP involves people who are HIV-negative taking an antiretroviral drug. When taken, 
if HIV exposure then occurs, this antiretroviral drug stops the virus entering cells and 
replicating (i.e. the person remains HIV negative) (Seifert et al, 2014). Current World 
Health Organisation (WHO) guidelines only advocate daily-dosing regimens (i.e. one 
tablet taken every day) for HIV negative MSM at high-risk of HIV acquisition. Research 
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suggests that for PrEP to be effective MSM sexually active individuals need to take at 
least four doses a week regardless of sexual activity levels (Grant, 2014). 
The safety and biological efficacy of PrEP to prevent HIV acquisition has been 
demonstrated by placebo-controlled trials within MSM and heterosexual samples 
(Grant et al, 2010; Grant et al, 2014; Baeten et al, 2012; Molina et al, 2015; 
McCormack et al, 2016a; Thigpen et al ,2012; Choopanya et al, 2013). However, when 
implemented PrEP has shown wide ranging effectiveness relative to placebo ranging 
from -49% to 86%. These wide-ranging results have been explained by varied 
adherence (Fonner et al, 2016). This means that PrEP implementation must be 
considered as bio-behavioural due to the factors (i.e. adherence) that moderate its 
efficacy (Kippax & Stephenson, 2012). At present, research has not concluded 
whether a specific theoretical model accurately explains PrEP adherence. In addition, 
Haberer’s (2016) review highlighted that few PrEP adherence interventions have been 
developed and evaluated. Understanding the predictors of PrEP adherence is crucial 
to the development of a theoretical framework, tailored adherence interventions and 
to help to ensure successful PrEP implementation.   
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Systematic Review 
The literature above highlights that adherence is critical for maximizing the 
effectiveness and public health impact of PrEP to prevent HIV infection.  
Understanding the factors associated with PrEP adherence/non-adherence is crucial 
to guiding the development of a theoretical framework as well as PrEP adherence 
interventions. Studies investigating medication adherence within different study 
populations (i.e HIV positive individuals), examining predictors of PrEP uptake or 
exploring hypothetical facilitators and barriers to PrEP use, have limited 
generalisability to understanding adherence amongst actual PrEP users. Therefore, 
the current systematic review synthesised the literature exploring factors related to 
PrEP adherence amongst MSM.  Studies were included if they reported statistical 
relationships with, or given reasons for, PrEP adherence/non-adherence amongst 
MSM PrEP users at high-risk of HIV acquisition.  Twenty studies (qualitative n=5, 
quantitative n=15) met the review’s inclusion criteria. The review described and 
evaluated the reviewed studies, synthesised the data, and the direction of 
relationships were examined. Across studies, twenty factors were measured and 
analysed in relation to PrEP adherence. Eleven factors showed inconsistent findings 
across studies and three factors were only measured once. Variables examined by 
three or more studies where the majority reported or showed a relationship with PrEP 
adherence included: older age, stable housing, higher levels of HIV risk perception 
and actual risk behaviours, routine and planning, lifestyle factors (i.e. less travel and 
being less busy), less anticipated stigma if PrEP use was disclosed, not being African-
American, less anticipated or actual side-effects and support from others. The review 
demonstrated that adherence to PrEP may be influenced by several factors at 
individual, interpersonal and structural levels. The review highlighted potentially 
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modifiable factors related to PrEP adherence which could be targeted in PrEP 
adherence interventions. It also highlighted factors which may vary within-individual 
dependent on the situation. Future research could examine modifiable situational 
variables (psychological and behavioural) to gain a clearer understanding of how these 
factors could impact adherence.  
 
Empirical Project  
The effectiveness of PrEP is variable, explained by differences in PrEP adherence.   
PrEP adherence is often inconsistent within individuals, whereas most studies only 
investigate adherence between individuals. Understanding psychological and 
behavioural correlates of PrEP adherence is important to develop effective adherence 
interventions.  This study investigated within-participant behavioural and psychological 
differences between adherent and non-adherent PrEP episodes in men who have sex 
with men (MSM), informed by theory (the Information-Motivation-Behavioural Skills 
model). Sixty-seven HIV-negative MSM at high-risk of HIV acquisition were recruited 
from two London sexual health clinics. All participants had followed a daily dosing 
PrEP regimen for at least three months and had shown inconsistent adherence (i.e. 
had one day when a dose was taken and one day when a dose wasn’t taken) in the 
previous month. Participants completed a questionnaire measuring psychological and 
behavioural variables for both an adherent and non-adherent episode.  Paired t-tests, 
McNemar’s chi-square tests and a conditional logistic regression (CLR) model were 
used to analyse associations between situational behavioural and psychological 
factors and adherent and non-adherent events. Lower reported information about 
PrEP, lower behavioural skills related to PrEP use and lower positive affect were 
associated with non-adherent episodes. There were no significant differences in 
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negative affect or PrEP motivation between episodes. A CLR model including 
information, behavioural skills and positive affect was significantly predictive of non-
adherent episodes, although only behavioural skills was statistically significant 
independently. Behavioural factors including weekend days, lack of reminders, non-
normality of the day, being out of the home, not being alone and substance use were 
also associated with PrEP non-adherence. Findings suggested that situational 
psychological factors are important for PrEP adherence. Theoretically, findings give 
support to some aspects of the IMB model to help explain PrEP adherence, however, 
also highlight predictors related to PrEP adherence which are not acknowledged within 
the model (i.e. situational behavioural factors such as location or positive affect). 
Adherence interventions should consider focusing on potentially modifiable situational 
variables (psychological and behavioural). 
 
Integration, Impact and Dissemination  
Integration 
The literature within the review highlighted the problem, that is, the issue of PrEP non-
adherence amongst MSM and its critical role in effective PrEP implementation to 
reduce HIV acquisition. This provided a clear rationale for the systematic review and 
empirical article which both focused on the issue of PrEP adherence within the MSM 
population. Specifically, both pieces aimed to examine the predictors of PrEP 
adherence. Opposed to previous reviews, the current review provided a summary of 
the key factors related to PrEP adherence amongst actual PrEP users which meant 
that review findings were more relevant to the empirical piece and could inform the 
factors which were explored. All studies included in the review used between-
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participants’ correlates of PrEP adherence (e.g. ethnicity) to make comparisons 
between ‘good-adherers’ and ‘poor-adherers’ which prevented the investigation of the 
factors related to variability in adherence across situations within an individual. This 
gave a clear rationale that by using a within-participant design the empirical article 
could expand upon the review and examine situationally-specific factors related to 
adherence.  The review highlighted that studies had not used theory to inform the 
variables which they measured in relation to PrEP adherence. Therefore, it felt 
necessary that the empirical piece was closely linked to a theoretical model of 
adherence.  
Impact 
The World Health Organization (WHO) cites HIV as a major global public health issue. 
Newer preventative approaches such as PrEP have been cited as a crucial strategy 
to provide effective prevention and dramatically reduce HIV acquisition. A barrier to 
successful PrEP implementation has been non-adherence. The current review and 
empirical research investigated the relationship between predictors of adherence to 
PrEP amongst MSM who are most at risk of HIV acquisition in the UK. This research 
contributes knowledge regarding the factors which may be related to PrEP adherence 
and indicates ways in which adherence interventions could be tailored to ensure 
successful PrEP implementation. The potential beneficiaries of this work are a) PrEP 
users and their sexual partners, b) support organisations, c) clinicians administering 
PrEP, monitoring PrEP use or delivering PrEP adherence interventions d) policy 
makers/professionals involved in PrEP implementation guidelines and e) researchers 
(e.g. health or clinical psychologists) in the PrEP field or examining situationally-
specific medication adherence on other conditions. 
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Dissemination 
It is planned that the current research will be made more broadly available by 
publishing results in a journal article (i.e. AIDS & Behaviour) and submitting the 
empirical abstract to the 2018 HIV Research for Prevention conference. Both give the 
opportunity for findings to be disseminated to multiple professionals specifically within 
this clinical/research domain.  
Service-user involvement will be crucial to establish which findings may be most of 
interest to the public and MSM population. I will attend LGBT/MSM specific service-
user groups to gain advice about the most relevant findings as well as how and where 
results should be presented.  Findings will be adapted for dissemination at relevant 
forums (i.e. LGBT and MSM specific service user groups as well as community 
events). This will help ensure that findings are disseminated to PrEP users, those who 
may not have heard of PrEP, those interested in PrEP uptake or those who have 
discontinued PrEP. Key findings will also be disseminated through online mediums 
(e.g. on recruitment sites social media platforms such as Facebook). To facilitate 
dissemination to clinicians it is planned that I will attend and present the key findings 
to team meetings and training workshops at London sexual health clinics.  It is planned 
that I will communicate via email with drug companies, key individuals writing PrEP 
guidelines and to journalists. Lastly, it would be helpful to prepare a poster to present 
at any unanticipated opportunities that may arise.  
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A systematic review of the correlates of PrEP adherence in men who have sex 
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Abstract 
Pre-Exposure Prophylaxis (PrEP) is a safe and efficacious HIV prevention tool. If HIV 
exposure occurs, this antiretroviral drug stops the virus entering cells and replicating 
(i.e. the person remains HIV negative). However, when implemented, PrEP has had 
variable effectiveness explained by varied adherence. Understanding the factors that 
are related to PrEP adherence amongst actual PrEP users is important to developing 
effective adherence interventions and ensure successful implementation.  This review 
investigated the factors related to PrEP adherence amongst men who have sex with 
men (MSM). Studies were included if they had statistically assessed relationships with, 
or given reasons for PrEP adherence/non-adherence amongst MSM PrEP users at 
high-risk of HIV acquisition.  Twenty studies (qualitative n=5, quantitative n=15) met 
inclusion criteria. The review described and evaluated the reviewed studies, 
synthesised their data and the direction of relationships were examined to answer the 
key objectives of the review. Across studies, twenty factors were measured and 
analysed in relation to PrEP adherence. Eleven factors showed inconsistent findings 
across studies and three factors were only measured once. Variables examined by 
three or more studies where the majority reported or showed a relationship with PrEP 
adherence included: older age, stable housing, higher levels of HIV risk perception 
and actual risk behaviours, routine and planning, lifestyle factors (i.e. less travel and 
being less busy), less anticipated stigma if PrEP use was disclosed, not being African-
American, less anticipated or actual side-effects and support from others. The review 
demonstrated that adherence to PrEP may be influenced by several factors at 
individual, interpersonal and structural levels. The review highlighted potentially 
modifiable factors related to PrEP adherence which could be targeted in PrEP 
adherence interventions. It also highlighted factors which may vary within-individual 
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dependent on the situation. Future research could examine modifiable situational 
variables (psychological and behavioural) to gain a clearer understanding of how these 
factors could impact PrEP adherence.  
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Introduction 
HIV: General Overview 
HIV (Human Immunodeficiency Virus) targets multiple cells of the immune system and 
replicates rapidly. Infection is associated with wide-ranging symptomology; varying 
from symptoms of primary infection (such as rash and fever), to serious diseases 
associated with a suppressed immune system (such as hepatitis) (Adler et al, 2012). 
The introduction and dissemination of antiretroviral therapy (ART), has changed the 
clinical picture of HIV; from fatal illness to chronic condition. However, these treatment 
initiatives require lifetime adherence to medication and represent a burden to the HIV 
positive individual (e.g. managing side effects) as well as having major economic 
implications for healthcare services (Laryea & Gien, 1993; Nakagawa et al, 2015). 
Globally, 36.7 million people were estimated to be living with HIV in 2016 (UNAIDS, 
2017). Levels of HIV acquisition vary notably across countries and population sub 
groups (UNAIDS, 2016). For example, some regions (e.g. Sub-Saharan Africa) are 
described as having a ‘generalised’ HIV epidemic (i.e. where HIV is firmly established 
in the general population) whereas other regions (e.g. Latin America, the Middle East, 
Europe, and Asia) there is a ‘concentrated’ HIV epidemic (i.e. where HIV has spread 
rapidly within specific sub-populations but is not well-established in the general 
population) (Wilson & Halperin, 2008).   
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The United Kingdom (UK) had an estimated 101,200 people living with HIV in 2015 
and approximately 6,095 of these people were newly diagnosed in the same year 
(Public Health England (PHE), 2016).  Between 2000 and 2013, there was no 
decrease in the incidence rates of HIV in the UK (Aghaizu et al, 2016). On the contrary, 
rates steadily increased by 20% between 2007 and 2015 in those deemed most at risk 
in the UK; gay, bisexual and men who have sex with other men (MSM) population 
(Phillips et al, 2013; PHE, 2017). Preventative strategies to reduce HIV transmission 
have included earlier initiation of antiretroviral therapy which may result in viral 
suppression (Vernazza et al, 2000; Wilson et al, 2009) and increased testing, which 
could result in HIV positive individuals changing their sexual behaviour, both reducing 
the risk of onward transmission (Fox et al, 2009). The lack of progress in reducing 
incidence rates, despite these ongoing healthcare initiatives, suggests that newer 
strategies must be implemented (McCormack et al., 2016a). 
 
Pre-exposure Prophylaxis (PrEP): General Overview 
One promising HIV prevention strategy is the use of oral Pre-exposure prophylaxis 
(PrEP). PrEP involves an antiretroviral drug and specifically those containing both 
tenofovir disoproxil (TDF) and emtricitabine (FTC) are currently recommended (WHO, 
2016). Once optimal concentrations have been reached (i.e. up to as much as seven 
days of daily use), if HIV exposure occurs, this antiretroviral drug stops the virus 
entering cells and replicating (i.e. the person remains HIV negative) (Seifert et al, 
2014).   
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There are two potential PrEP dosing regimens; daily or event-driven (i.e. intermittent 
dosing when sexually active). Evidence from iPrEX (Initiativa Profilaxis Pre-
Exposicion), a multi-national randomised controlled trial (RCT), suggested that for 
PrEP to be effective, sexually active MSM individuals following a daily regimen need 
to take at least four doses a week (regardless of sexual activity levels) (Grant, 2014). 
For event-driven dosing to be effective, individuals must take two doses of PrEP 
between two and twenty-four hours before sex, a third dose twenty-four hours later 
and a fourth dose forty-eight hours later (Molina, 2015). The European AIDS Clinical 
Society and British HIV Association guidelines (McCormack et al, 2016b) recommends 
the consideration of both regimens, however current World Health Organisation 
(WHO) guidelines only advocate daily-dosing regimens. Specifically, WHO (2016) 
advocate that all people at substantial risk of HIV infection (i.e. populations with an 
HIV incidence of about 3 per 100 person-years or higher) should be offered PrEP as 
one part of a package of HIV prevention approaches.  
Since the implementation of combined preventative strategies (i.e. increased testing 
and condom use, earlier initiation of ART and access to PrEP) Public Health England 
(2017) announced a 18% decline in HIV incidence from 2015 to 2016. This was 
particularly evident amongst MSM where a 21% decline was observed. This is one of 
the first significant shifts within this high-risk population seen in Europe. The decline 
was most evident in London where MSM have high testing rates and prompt access 
to services. PHE (2017) has attributed this progress to the combined preventative 
strategies and anticipates that these efforts will be reinforced further by the 
implementation of upcoming PrEP trials. 
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PrEP: Efficacy and effectiveness 
PrEP has been advocated based upon placebo-controlled RCT’s which have 
demonstrated the safety and biological efficacy of PrEP amongst MSM (Grant et al, 
2010), heterosexuals (Baeten et al, 2012; Thigpen et al ,2012) and drug users 
(Choopanya et al, 2013).  Despite promising findings, when implemented PrEP has 
shown wide ranging effectiveness; from -49% to 86% (Pool, Youssef, & Fisher, 2015). 
This common dilemma can be described as an ‘efficacy-effectiveness’ gap that is, 
when the biological efficacy of an intervention/product under optimal conditions differs 
when conducted in ‘real-life’ conditions (Masse et al, 2009). 
Studies using MSM samples; iPrEx a placebo controlled randomised control trial 
(RCT) of TDF/FTC (TDF=tenofovir, FTC=emtricitabine) found PrEP had 44% efficacy 
(Grant et al, 2010) and in the open-label extension (OLE) this increased to 49% 
efficacy (Grant et al, 2014). The iPrEx study used a large multi-national sample (Brazil, 
Ecuador, Peru, South Africa, Thailand and the United States (US)).  IPERGAY, a 
randomised trial (placebo vs TDF/FTC) using French and Canadian participants, found 
that PrEP had 86% efficacy (Molina et al., 2015). Similarly, the open-label PROUD 
RCT (TDF/FTC versus delayed waitlist) found that PrEP reduced the risk of HIV 
acquisition by 86% using a UK sample (McCormack et al, 2016a).  
When using female participants in Africa, Fem-PrEP (comparing placebo versus PrEP 
in Kenya and South Africa) and VOICE (oral arm comparing TDF versus TDF/FTC 
versus placebo in South Africa, Uganda, and Zimbabwe) blinded trials found PrEP was 
ineffective as a HIV prevention strategy (Corneli et al, 2014, VanDamme et al, 2012; 
Marrazzo et al, 2015). Other studies conducted amongst serodiscordant couples in 
Africa found between 67% and 96% levels of PrEP effectiveness; the blinded Partners 
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PrEP study (comparing TDF versus TDF/FTC versus placebo) found PrEP was 67% 
(TDF) and 75% (FTC/TDF) effective at reducing the risk of HIV transmission (Baeten 
et al, 2012) whilst the open-label Partners demonstration project (involving TDF/FTC 
and antiretroviral therapy) found PrEP was 96% effective at reducing HIV incidence in 
Kenya and Uganda (Baeten et al, 2016). Lastly, Thigpen et al’s (2012) double-blinded 
study (comparing TDF/FTC to placebo) found PrEP was 62% effective amongst 
heterosexual men and women in Botswana.   
Of note, the studies described above combined PrEP within a larger package of HIV 
prevention strategies and all apart from IPERGAY (who followed an event-driven 
dosing regimen) investigated the effectiveness of daily PrEP regimens (Pool, Youssef, 
& Fisher, 2015). 
 
PrEP: Prevention Cascade 
The literature above highlights that the efficacy shown in clinical trials can only be 
achieved if an intervention is delivered, taken up by the population and adhered to 
(Hargreaves et al, 2016). Therefore, research must investigate the demand for, supply 
of and adherence to HIV prevention strategies to ensure it has a population-level 
impact. Specifically, the development of a prevention cascade allows multi-disciplinary 
evidence and interventions to be organised around each stage of implementation 
(Krishnaratne, Hensen, Cordes, Enstone & Hargreaves, 2016). 
The implementation of PrEP can be conceptualised as a cascade which highlights the 
proportion of high-risk HIV negative individuals lost at each stage of implementation. 
Each stage in the prevention cascade represents a reduction in the effect of PrEP due 
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to lack of availability, unwillingness to use PrEP and non-adherence (Garnett et al, 
2016). Specifically, these intervention-centric stages include:  
 
i) all individuals who are at high risk of HIV  
ii) those who have PrEP available to them/are supplied PrEP,  
iii) high-risk individuals who take up PrEP,  
iv) high-risk individuals who do or do not adhere to PrEP and  
v) those who adhere to PrEP (and PrEP is efficacious).  
 
Prep: Adherence 
The varied results of effectiveness do not undermine the biological efficacy of PrEP 
but have been explained by the latter part of the prevention cascade; varied adherence 
(Van der Straten et al, 2012). Using meta-regression techniques, Fonner et al (2016)   
found that adherence was a significant moderator of PrEP effectiveness; when 
grouped, studies where less than 40% sample adhered well showed no preventative 
benefit whereas studies of adherence levels of eighty percent or more showed PrEP 
to be the most effective.  
Examining adherence specifically amongst MSM samples, iPrEX found a 51% 
adherence rate (as defined by plasma concentration levels) (Grant et al, 2010) whilst 
iPrEX OLE found a 71% adherence rate (i.e. 51% and 71% of all people who received 
PrEP and had blood plasma tested had a detectable level of PrEP) (Grant et al, 2014). 
IPERGAY, found 43% of participants had not taken PrEP as prescribed (Molina et al, 
2015). Similarly, PROUD showed 40% of MSM participants did not take medication 
100% of the time and 36% intentionally did not adhere for a period (McCormack et al, 
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2016a). High rates of adherence were found by Project PrEPARE, a pilot RCT which 
found 84% of US participants had drug levels consistent with daily use (Mayer et al, 
2014). Similarly, the Demo Project, a US demonstration project (i.e. adherence in ‘real-
life’ clinic settings) found that 73%-92% of MSM participants at different timepoints 
had drug levels that indicated four or more doses a week were taken (Cohen et al, 
2014).  However, Project PrEPare, a separate US demonstration study, found only 
34% of young MSM participants had drug levels needed for PrEP effectiveness (Hosek 
et al., 2017). 
 
Theoretical and Clinical implications 
At present, research has not concluded whether a specific theoretical model 
accurately explains PrEP adherence. In addition, Haberer’s (2016) review highlighted 
that few PrEP adherence interventions have been developed and evaluated. Overall, 
the four interventions identified highlighted that general and enhanced counselling (the 
latter for those who find adherence difficult) as well as technological methods (e.g. 
two-way texts) can effectively support PrEP adherence (Amico et al, 2012; Liu, 
Stojanovski, Lester, Amico, McMahan, & Goicochea, 2014; Mayer et al, 2014; Psaros 
et al, 2014).  All counselling interventions included addressing the facilitators and 
barriers to PrEP adherence. The development of these PrEP adherence interventions 
were informed by ART adherence interventions used for the HIV positive population. 
Despite this research providing a useful framework, factors associated with ART 
adherence may not be applicable to or capture all the relevant factors for PrEP 
adherence, given that predictors may differ between symptomatic (HIV positive) and 
asymptomatic (HIV negative) individuals (Marcus et al, 2014). Therefore, predictors of 
adherence must be explicitly explored within PrEP population. This could highlight 
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potentially modifiable factors which could be targeted within tailored PrEP adherence 
interventions as well as identify those most ‘at-risk’ of non-adherence.   Understanding 
and synthesising the predictors of PrEP adherence could also help theoretical 
development to understand PrEP adherence.  
Current state of knowledge re: predictors of PrEP use 
There do not appear to be any reviews which have examined the predictors of PrEP 
adherence amongst MSM PrEP users. Systematic reviews have focused earlier in the 
prevention cascade, exploring factors associated with the willingness/acceptability 
and uptake of PrEP. Peng, Su, Fairley, Chu, Jiang, Zhuang, & Zhang, (2017) found 
that demographic factors (i.e. younger age, more educated and higher wealth) and 
cognitive factors (i.e. prior knowledge of PrEP) amongst MSM were predictive of 
higher acceptance of PrEP. Other cognitive factors (i.e. low self-efficacy, specifically 
perceived inability to achieve good adherence, beliefs that doubt the efficacy of PrEP 
and concerns about side effects), structural factors (i.e. affordability) and social factors 
(i.e. societal stigma) were barriers. Similarly, another review by Koechlin et al (2017) 
found that across risk groups (women, female sex workers, serodiscordant couples, 
transgender women [TGW], young and adolescent women, people who inject drugs 
and healthcare providers) greater knowledge about PrEP was associated with more 
willingness to use PrEP. This review also examined the barriers and facilitators to 
PrEP uptake. Across all risk groups they identified that cognitive factors (i.e. the 
perception that drugs are for people who are ill, concerns about safety and potential 
interactive effects with other substances such as alcohol or drugs), social factors (i,e. 
HIV and ART stigma), behavioural factors (i.e. low HIV risk perception), structural 
factors (i.e. cost) and demographic factors (lower educational level) were barriers to 
26 
 
PrEP use. However, social factors such as peer support and behavioural factors such 
as disclosure of PrEP use to peers and pill discreteness facilitated PrEP use.  
One limitation of these reviews was that most studies included evaluated barriers and 
facilitators of hypothetical PrEP use or uptake. The factors which have been reported 
to facilitate or hinder PrEP use may not be generalisable to the actual PrEP taking 
population and predictors of adherence. The current review aims to overcome this 
limitation by examining correlates of adherence only in studies where PrEP was made 
available for actual use. This includes randomised control trials (RCT) where 
participants been a part of a placebo or an active arm which took PrEP medication. 
 
Predictors of ART adherence  
Antiretroviral therapy (ART) treatment for HIV positive individuals involves a 
combination of three drugs (referred to as highly active antiretroviral therapy or 
‘HAART’) taken every day.  ART has shown to have highly efficacy supressing HIV 
replication which has allowed HIV positive individuals to improve quality of life as well 
as lower mortality and morbidity rates (Montaner et al, 2014). However, ART requires 
near-perfect adherence, with this being a crucial moderating factor of HIV viral 
suppression and health outcomes (Adefolalu & Nkosi, 2013; Bangsberg et al, 2001; 
Katz et al, 2013). However, approximately 40% of people with HIV do not sufficiently 
adhere to their medication regimen (Spaan, van Luenen, Garnefski & Kraaij, 2018). 
Research has shown a range of factors which impacts ART adherence amongst HIV 
positive individuals. For example, reviews and meta-analyses have identified the 
following adherence barriers: affective factors such as mental health difficulties 
including depression (Gonzalez et al, 2011, Nakimuli-Mpungu et al, 2012; Uthman et 
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al 2014) and substance misuse (Mills et al, 2006; Hendershot, Stoner, Pantalone, & 
Simoni, 2009): behavioural factors such as a change to daily routine, being away from 
home (Shubber et al, 2016) or experience of side effects (Al-Dakkak eet al, 2013): 
social factors such as increased stigma (i.e. HIV stigma) (Langebeek et al, 2014) as 
well as lack of social support (Ammassari et al, 2002): demographic factors such as 
lower socioeconomic status (Vreeman, Wiehe, Pearce, & Nyandiko, 2008): and 
cognitive factors such as lack of ART information (Posse et al, 2006). This research 
(which highlighted predictors of ART adherence in HIV positive individuals) has been 
used to develop effective interventions to support adherence in this population. As 
described above, although this research may not be generalisable to the PrEP-taking 
population (e.g. motivations, side effects and support may differ) it highlights that a 
range of behavioural, social, cognitive and affective factors can affect ART adherence 
which may be relevant when considering predictors of PrEP adherence/non-
adherence (Haberer, 2016). 
 
 
 
 
 
 
 
 
 
 
 
 
 
28 
 
Aims and Objectives of the current review 
The literature has highlighted that adherence is critical for maximizing the 
effectiveness and public health impact of PrEP to prevent HIV infection.  
Understanding the factors associated with PrEP adherence/non-adherence is crucial 
to guiding the development of a theoretical framework as well as PrEP adherence 
interventions. Studies investigating adherence within different study populations (i.e 
HIV positive individuals), at earlier points of the prevention cascade (e.g. predictors of 
uptake) or those examining exploring hypothetical facilitators and barriers to PrEP use, 
have limited generalisability to understanding adherence amongst actual PrEP users. 
Therefore, the current systematic review will synthesise the literature exploring factors 
that are related to PrEP adherence/non-adherence in MSM. The following research 
question was generated for the review: 
i) Which demographic, social, behavioural, cognitive and affective factors are 
related to PrEP adherence/non-adherence? 
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Method 
Eligibility criteria  
Participants 
All studies including HIV negative MSM (including TGW who have sex with men), aged 
16 years or older and identified as being at high risk of HIV acquisition were included. 
Studies including other samples as well as MSM were included if MSM participants 
were a part of a specific sub-group analysis. All participants must have taken PrEP 
medication or been a part of a placebo arm in a randomised control trial (RCT) where 
the active arm took PrEP medication. Studies which only focused on willingness to 
take PrEP medication were excluded.  
 
Independent variable  
This review considered any variables statistically analysed in relation to, or given as 
reason for, PrEP adherence/non-adherence. These may be more specifically defined 
as demographic, behavioural or psychological including; social, cognitive and affective 
variables.  
 
Outcome variable 
The main outcome variable was PrEP adherence. All types of measurement for 
adherence were included in the review (e.g. self-report and blood plasma 
concentrations). Furthermore, all definitions of adherence/non-adherence were 
included (e.g. any missed dose of PrEP or four or more doses missed in one week 
may have been defined as ‘non-adherence’).  
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Types of Studies 
Primary empirical research studies, and all studies regardless of design (i.e. 
quantitative or qualitative methodologies; cross-sectional, longitudinal and 
intervention; within and between participant designs) were included. No date 
limitations or location restrictions were made. Articles were not required to be 
published in peer review journals. Only studies written in English were considered for 
review and no grey literature search took place. 
 
Sources of Information  
Studies were identified by searching electronic databases, PubMed and PsycINFO.  
Searches were completed on 2nd October 2017.  
 
Search Strategy  
The key words within the search strategy used for all databases was:  
• HIV preexposure prophylaxis OR PrEP OR oral PrEP AND  
• uptake OR motivations OR barriers OR uptake and use OR adherence AND  
• HIV OR HIV prevention OR HIV negative AND  
• MSM OR men OR men who have sex with men OR gay men.  
 
HIV pre-exposure prophylaxis / PrEP or oral PrEP were searched for as keywords in 
the title, with the other terms being searched for as keywords in the abstract or title. 
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Data collection 
The data collection process followed the practice guidelines of PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses) (Moher et al., 2009) (see 
Figure 1).  
• The author carried out the search for the identification of studies, using the 
pre-specified search criteria outlined above.  
• All duplications between databases were removed.  
• Titles and abstracts were independently screened for eligibility by two 
reviewers (the author and an undergraduate psychology student).  
• Articles considered relevant by either reviewer were retrieved in full text.  
• Both reviewers independently assessed the eligibility of the retrieved articles.  
• Exclusions were recorded in an Excel spreadsheet, with reasons given.  
• Any disagreements were resolved by a third reviewer (the internal supervisor) 
to result in a final group of studies for analysis.  
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Figure 1: Study Search Process 
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Data Abstraction  
For each included study the following details were extracted:    
 (a) Study information: 
Authors, year of publication, location, study design and sample characteristics 
(including sample size, gender identity (MSM/TGW), age, ethnicity, dosing 
regimen, sampling strategy and response rate).  
 (b) Assessment tools: 
Instruments used to measure adherence. 
 (c) Analysis: 
Multivariate analyses conducted (yes/no) and study attrition rate.  
Quality Assessment 
A bespoke assessment tool was used to ascertain the risk of bias for included studies, 
based upon the Mixed Methods Assessment quality assessment tool (Pluye et al, 
2011). For quantitative studies, the methodological elements assessed included two 
dimensions of external validity (sample representativeness and response rate) and 
three dimensions of internal validity (detection bias, attrition bias and confounding) 
(see Table 1). For qualitative studies, the methodological elements assessed included 
three dimensions; credibility, transferability and confirmability (see Table 2).  Both 
reviewers (the author and undergraduate student) independently conducted the 
quality assessment, with a third reviewer (internal supervisor) resolving disagreements 
in ratings. The biases highlighted were considered in the subsequent interpretation of 
the data.    
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Table 1:  Quality Assessment tool for quantitative studies 
External validity 
Sampling  
Representativeness of the sample for the 
target population 
• Was the sample a consecutive or random sample, or were all the population eligible?  
The percentage of selected individuals 
who agreed to participate 
 
• Were at least 80% of those eligible to participate recruited? 
Internal validity  
Detection bias  
Measurement of data collection methods • Were measures of adherence objective or shown/reported to have established reliability 
and validity?  
Attrition bias  
Number of withdrawals  
 
• Were withdrawals reported in terms of numbers? 
Percentage of participants included in 
final analysis 
 
• Were at least 80% of those invited to participate in the study included in final analysis (for 
intervention/cohort studies)? Or was loss to follow-up after baseline 20% or less? 
Control of confounding variables 
Extent to which possible confounding 
variables were measured 
• Were important differences between groups prior to the intervention measured/identified? 
Or were variables that vary across the sample that might influence the outcome (e.g. age, 
ethnicity, regimen) measured?  
 
Extent to which possible confounding 
variables were analysed  
• Were possible confounding variables appropriately considered in the design (e.g. 
stratification, matching) or analysis (i.e., was multivariate analysis conducted)? 
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Table 2:  Quality Assessment tool for qualitative studies 
Credibility 
Was the process for analysing qualitative 
data relevant to address the research 
question?  
 
• Was (a) the method of data collection clear (e.g. in-depth interviews); (b) the form of the 
data clear (e.g. tape recording) and; (c) were changes explained when methods were 
altered during the study. 
Did the representativeness of the data fit 
with the view of the participants? 
 
• For example, did the study give verbatim quotes, independent analysis of the data by 
more than one person, peer debriefing, outside auditors, sufficient data to support the 
findings or consideration of data saturation    
Transferability  
Were the findings transferable to other 
settings? 
• Was at least 2 of the following used: rich detail of study participants including contextual 
information and demographics, sampling strategy that shows that convenience sampling 
was not used, ≥80% response rate,  
 
Confirmability 
Was the analysis grounded in the data? 
Was appropriate consideration given to 
how the findings relate to researchers’ 
influence? 
• Was at least 2 of the following used: assessing the effects of the researcher during the 
research process, reflexivity (i.e. information about the researcher’s background, 
education, school of thought, assumptions about the topic of interest and how the 
research process is influenced by this) or has the researcher explained their reaction to 
critical events during the study.  
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Data synthesis/Analysis 
Inter-rater reliability for study eligibility was assessed using Cohen’s Kappa. There was 
substantial agreement between the reviewers on eligibility (Cohen’s Kappa = 0.67). 
 
Qualitative studies 
Qualitative study findings were analysed following the Joanna Briggs Institute (2014) 
guidelines. This process involved data extraction, evaluation and synthesis of findings 
across studies. To conduct the synthesis the author read and reread to identify 
emergent themes from each study. Findings were grouped into themes based on 
similarity in meaning. Themes that occurred at least twice across studies were 
grouped together and presented. 
 
Quantitative studies 
There was too much heterogeneity in the factors/variables examined and the method 
of reporting to combine quantitative study results for statistical analysis (i.e. meta-
analysis). Therefore, the current study described and evaluated the reviewed studies, 
synthesised their data and the direction of relationships were examined and compared 
to answer the key objectives of the review.  
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Results 
Of 312 citations identified through the initial search, 20 articles met inclusion criteria 
for review (see Figure 1).  
 
Overall Study Characteristics 
Study characteristics are described in Tables 3 and 4. There were more quantitative 
studies (n= 15) than qualitative (n= 5). All reports of multiple publications were 
included. Overall, the twenty studies relate to thirteen datasets; seven studies used 
data from one dataset, another two studies used the same dataset and the remaining 
eleven studies used separate datasets. All twenty articles were published between 
April 2013 and October 2017.  
Five articles described multinational research; four studies used data from one dataset 
which was conducted across Brazil, Ecuador, Peru, South Africa, Thailand and the 
USA and one separate study was conducted across France and Canada. Another 
twelve were conducted in the USA, two in Thailand (describing research from the 
same dataset) and one in Africa. Most studies were either RCT’s (n=6), open-label 
longitudinal studies (n=6) or cross-sectional (n=6) in design. One study used data from 
a dataset with both RCT and open-label components whilst one used a prospective 
longitudinal cohort design. Across all studies, samples sizes ranged from 24 to 1603 
(median; 225.5, inter-quartile range; 50.5-452.5) and overall 6,677 participants were 
included. Multiple publications were included therefore some participants could have 
participated in a number of studies. Detailed study characteristics for both qualitative 
and quantitative studies are described below.  
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How PrEP adherence was measured  
Seven studies measured PrEP adherence through self-report methods. Another four 
studies measured PrEP adherence through biological methods alone (i.e. plasma 
blood concentrations, dried blood spots or hair using liquid chromatography/tandem 
mass spectrometry).  Two studies used a combination of self-report and biological 
methods. One study used electronic pill counts and biological methods whilst another 
used electronic pill counts and self-report methods. Another two studies measured 
adherence through a combination of three methods; self-report, biological and pill 
counts/pharmacy refill dates. Lastly, one study used pill counts alone to determine 
PrEP adherence. Adherence levels in two studies were not measured.   
 
Levels of adherence across studies  
One study reported that at follow-up 17% of TGW and 35% of MSM had protective 
PrEP levels (i.e. 4 or more doses a week) (Deutsch et al, 2015) whilst another found 
protective PrEP levels amongst 83.1% and 65.5% of participants at weeks 4 and 48 
respectively (Landovitz et al, 2017). Furthermore, one study found 80-86% of 
participants had protective PrEP levels (Liu et al, 2016) and a sub-study similarly 
reported participants had protective levels 87% of the time (Gandhi et al, 2017). 
Parsons et al, (2017) reported that 98% of participants had on average taken four or 
more doses per week in the last month whilst Parisi et al (2017) stated at the 1-month 
medical visit 100% of participants had taken four or more doses the week before their 
medical visit. This decreased to 94.3% at the 3-month visit and increased to 96.6% at 
the 6-month visit. In one study 86% of participants self-reported they had taken four 
or more doses per week (Mugo et al, 2015).  
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Using blood plasma concentrations, one study reported PrEP was detected in 71% of 
PrEP users (Grant et al, 2014). In longitudinal analysis (i.e. participants with at least 
two drug levels available), another study found 31% never had drug detected, 30% 
always had drug detected, and 39% had an inconsistent pattern (Liu et al, 2014).  
 
Of those receiving a PrEP adherence intervention, 90% and 84% of participants 
achieved 100% adherence at 3-months and 6-months respectively (Mayer et al, 2017). 
Another study reported that 92.5% of PrEP users took their medication 6-7 days per 
week (Holloway et al, 2017). However, one study reported that on average only 59% 
of participants had used PrEP correctly (following an event-based regimen) during 
their most recent sexual intercourse (Sagaon-Teyssier et al., 2016).   
 
Two studies (using the same dataset) reported that 78% of participants achieved a 
‘stable’ level (i.e. average medication adherence was between 90%-100%), 20% 
achieved a ‘moderate’ level (i.e. average medication adherence was between 70%-
89%) and 2% achieved ‘poor’ level (i.e. average medication adherence was between 
40%-49%) (Tangmunongvoraul et al, 2013; Tangmunkongvorakul et al, 2016). One 
study reported that amongst those receiving PrEP, the median number of doses 
missed (out of possible 30) was 10 (Hosek et al, 2013) whilst another reported that 
participants did not take their PrEP on 0–1 (33.3%), 2–3 (16.7%), 4–5 (6.6%), 6–7 
(23.3%) and 8+ (20%) days over the last 90 days (Storholm et al, 2017).  Two studies 
measured but did not report adherence levels in the sample (Mehrotra et al, 2016; 
Parker et al, 2015) and in two studies adherence levels were not recorded (Gilmore et 
al, 2013; Arnold et al, 2017).  
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Data Synthesis 
Factors related to PrEP adherence/non-adherence were extracted from the included 
studies and grouped into three higher-order categories: individual-level, interpersonal-
level and structural-level factors. Individual-level factors describe those that relate to 
demographic variables (e.g. age, ethnicity, education, location or gender identity), 
motivation (e.g. attitudes to use PrEP), knowledge (e.g. knowledge regarding PrEP 
efficacy or use), mental health (e.g. depression) or behaviour (e.g. substance use). 
Interpersonal-level factors are those that relate to an individual’s interaction with others 
(e.g. enacted stigma or support from others). Structural-level factors relate to concepts 
in the environment (e.g. access to PrEP or PrEP services) which could influence PrEP 
use.  
 
Quantitative Studies: Study Characteristics 
In total, fifteen qualitative studies were included within the review (please refer to Table 
3 for a summary of the included studies).  
Five studies reported/used data from the multinational iPrEx study which consisted of 
a double-blind, randomised, placebo-controlled trial and open-label extension (OLE) 
(Grant et al, 2010). The open-label cohort trial enrolled MSM individuals previously 
enrolled in PrEP trials (i.e. iPrEX, ATN 082 and US Safety Study) (Grant et al, 2014). 
Two studies specifically used data from the double-blinded RCT component; one used 
data from active-arm participants across all multinational sites whilst another 
specifically analysed data from the Thailand iPrEX cohort (across both active and 
placebo arms). Two studies report data based on iPrEx OLE and one study used iPrEx 
data from both the RCT (active-arm only) and OLE.
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Table 3: Summary of Quantitative Studies 
Reference Location 
 
Design 
 
 
Sample  
 
Measure of 
adherence* 
Analysis  
 
Deutsch et al., 2015 
 
Multinational 
(Brazil, Ecuador, 
Peru, South 
Africa, Thailand 
and the USA) 
 
Longitudinal, 
double blinded RCT 
and open-label 
study.  
 
iPrEx study  
339 (RCT) and 192 participants (OLE) 
TGW  
Characteristics of RCT (n=339) participants: 
Age (mean): 26.2 years  
Ethnicity; Not reported 
Daily regimen 
 
Sampling strategy: Systematic 
Response rate: RCT- Not reported, OLE- 79%  
 
Biological Multivariate analysis: yes,  
 
Attrition rate: 0% 
 
Gandhi et al., 2017 USA  
 
  
Longitudinal, open-
label study 
 
Demonstration 
project 
 
280 participants, 
MSM (99%), TGW (1%) 
Age (range): median 34 years (19–65)  
Ethnicity; white (78%), Latino (23%), other 
(Asian, native etc) (13%) and Black (5%)  
Daily regimen. 
 
Sampling strategy: Opt-in design 
Response rate: 58%  
 
Biological 
Self-report 
 
Multivariate analysis: yes,  
 
Attrition rate: 5% 
 
Grant et al., 2014 Multinational 
(Brazil, Ecuador, 
Peru, South 
Africa, Thailand 
and the USA) 
 
Longitudinal, open-
label cohort study. 
 
iPrEx study 
1603 participants,  
MSM (89%), TGW (11%), 
Age; 18-24 (20%), 25-29 (27%) 30-39 (31%) 
and >40 (22%) 
Ethnicity; Latino (72%), Mixed/Other 
(70%)White (17%), Black (8%), Asian (5%)  
Daily regimen,  
 
Sampling strategy: Systematic 
Response rate: 62% 
 
Biological Multivariate analysis; yes 
 
Attrition rate: 16%  
*Biological methods refers to PrEP drug concentration levels as measured by; blood plasma concentrations, liquid chromatography, tandem mass spectroscopy or dried 
blood spots or as measured in hair by liquid chromatography or tandem mass spectrometry. 
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Table 3: Summary of Quantitative Studies continued 
Reference Location 
 
Design 
 
 
Sample  
 
Measure of 
adherence* 
Analysis  
 
Holloway et al., 2017 USA  
  
Cross-sectional 
survey 
 
 
761 participants 
MSM (97.5%), ‘Other’ (2.5%) 
Age; 18-24 (62%), 25-19 (38%),  
Ethnicity; Hispanic/Latino (32%), White (22%), 
Black/ African American (25%), Other/mixed 
(21%) 
Daily regimen 
 
Sampling Strategy: Convenience 
Response Rate: 43% 
 
Self-report Multivariate analysis; yes 
 
Attrition rate: Not 
applicable 
Hosek et al., 2013 USA  
 
Longitudinal, 
blinded pilot RCT. 
58 participants 
MSM 
Age (mean, sd):18-22 years (19.97,1.3),  
Ethnicity: Black/African American (53%) 
Native American/Alaskan Native (2%), white 
(7%), other/mixed race (38%) 
Daily regimen 
 
Sampling Strategy: Convenience 
Response Rate: 28% 
 
Biological  
Pharmacy Refill dates 
Self-report 
Multivariate analysis; no 
 
Attrition rate: 19% 
Landovitz et al., 2017  USA  
 
 
 
Longitudinal. open-
label, two-arm 
interventional 
cohort study 
301 participants 
MSM (n=300), TGW (n=1), 
Following demographics based on MSM only:  
Age; 18-25 (12%), 26-35 (46%), 36-45 (24%), 
46+ (18%),  
Ethnicity; White (50%), Hispanic (28%), Black 
or African American (11%), Asian (6%) and 
other (5%) 
Daily regimen 
 
Sampling Strategy: Not reported 
Response Rate: 98% 
 
Biological  
Self-report 
Multivariate analysis; yes 
 
Attrition rate: 25% 
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Table 3:  Summary of Quantitative Studies continued 
Reference Location 
 
Design 
 
Sample  
 
Measure of 
adherence* 
 
Analysis  
Liu et al., 2014 Multinational 
(Brazil, Ecuador, 
Peru, South 
Africa, Thailand 
and the USA) 
Longitudinal, 
double-blinded 
RCT.  
 
iPrEx study 
470 participants.  
Characteristics of active-arm participants (n= 
1251): 
MSM (n= 1088, 87%) TGW (n= 163,13%) 
Age (years); 18-20 (22%), 21-25 (31%), 26-30 
(19%), 31+ (29%).   
Ethnicity; Mixed race/other (68%), White 
(18%), Black (9%), Asian (5%).  
Daily regimen 
 
Sampling Strategy; Random and systematic 
Response rate: 100% 
 
Biological Multivariate analysis: yes  
 
Attrition rate: Unclear 
Liu et al., 2016 
 
USA  
 
Longitudinal, open-
label study.  
 
Demonstration 
project 
 
557 participants 
MSM (98.4%) and TGW (1.3%) 
Age; 18-25 (20%), 26-35 (38%), 36-45 (24%), 
45+ (18%) 
Ethnicity; White (48%), Latino (7%), Black 
(7%), Asian (5%), Other (6%) 
Daily regimen  
 
Sampling strategy: Systematic and purposive 
Response rate: 61% 
 
Biological  
Pill counts 
Self-report 
Multivariate analysis; yes 
 
Attrition rate: 22% 
Mayer et al., 2017 USA  
 
 
Longitudinal, open-
label pilot RCT  
50 participants 
MSM  
Age (mean, sd); 38.26 (12.6) years 
Ethnicity; White (86%), Hispanic/Latino (8%), 
Other (4%), Black/ African American (2%) 
Daily regimen 
 
Sampling strategy: Convenience  
Response rate: 98% 
 
Biological  
Pill counts 
 
Multivariate analysis; yes. 
 
Attrition rate: 22% 
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Table 3: Summary of Quantitative Studies continued 
Reference Location 
 
Design 
 
 
Sample  
 
Measure of 
adherence* 
Analysis  
 
Mehrotra et al., 2016 Multinational 
(Brazil, Ecuador, 
Peru, South 
Africa, Thailand 
and the USA) 
Longitudinal, open-
label study 
 
iPrEx study 
334 participants. 
MSM (89%) and TGW (11%) 
Age: 18-25 years (32%), 26-30 (23%), 31-39 
(24%), 40+ (21%). 
Ethnicity: unknown 
Daily regimen 
 
Sampling strategy: Systematic 
Response rate: 100% 
 
Biological  
 
Multivariate analysis; yes. 
 
Attrition rate: Not 
applicable 
 
 
Mugo et al., 2015 Africa  
 
Longitudinal, 
blinded RCT. 
  
62 participants 
Age (range): 18-38 years 
Ethnicity: unknown 
Daily and event-based regimen 
 
Sampling strategy: Systematic 
Response rate: Not reported 
 
Pill counts 
Self-report  
Multivariate analysis; yes. 
 
Attrition rate: 7% 
 
 
Parisi et al., 2017 USA  Longitudinal, open 
label study.  
171 participants. 
MSM (n=160), TGW (n= 8), unknown (n=3),  
Ethnicity; white (60%), black (14%), Hispanic 
(13%), Asian (9%), other/unknown (4%),  
Ages; 18-24 (12%), 25-34 years (46%), 35-44 
years (19%), 45-54 years (18%), 55+(3%),  
Daily regimen.  
 
Sampling strategy: Systematic 
Response rate: 100% 
 
Self-report  Multivariate analyses: yes 
 
Attrition rate: 51%   
Parsons et al., 2017 USA. 
 
Longitudinal, 
prospective, cohort 
study. 
995 participants 
MSM 
Age average (sd): 41.9 years (13.9) 
Ethnicity: White (72%), Latino (12%), Black 
(8%), Other/Multiracial (8%)  
Daily regimen 
 
Sampling strategy: Systematic 
Response rate: Not reported 
Self-report Multivariate analysis; yes. 
 
Attrition rate: 5% 
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Table 3: Summary of Quantitative Studies continued 
Reference Location 
 
Design 
 
 
Sample  
 
Measure of 
adherence* 
Analysis  
 
Sagaon-Teyssier et al., 
2016 
France and 
Canada 
Longitudinal, 
double-blind RCT  
 
  
400 participants 
MSM & TGW  
Age; 18-24 (n=29), 25-29 (n=28), 30-39 
(n=72), 
         40-49 (n=52), 50+ years (n=18). 
Ethnicity: White (n=183) 
Event-based regimen 
 
Sampling Strategy; Systematic 
Response rate: 97% 
 
Self-report Multivariate analysis; yes. 
 
Attrition rate: 12% 
 
 
 
Tangmunkongvorakul et 
al., 2016 
 
Thailand  
 
Longitudinal 
double-blinded 
RCT.  
 
iPrEx study 
114 participants,   
MSM (n=85), TGW (N=29)  
Age; 18-43 years,  
Ethnicity; unknown,  
Daily regimen 
 
Sampling strategy- Systematic 
Response rate- Not reported 
Pill counts 
 
 
Multivariate analysis; no 
 
Attrition rate: 0% 
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Quantitative Data Synthesis 
Quantitative findings were extracted from the included studies and grouped into three 
higher-order categories: individual-level, interpersonal-level and structural-level 
factors. Across three domains sixteen significant findings emerged across a broader 
range of other non-significant variables which either facilitated or acted as a barrier to 
PrEP adherence:  
 
• Age, ethnicity, gender identity, education, location, housing, lifestyle factors; 
(i.e. travel and lifestyle), regimen, side-effects, substance use, mental health, 
knowledge, higher levels of HIV risk perception and actual risk behaviour 
(individual-level factors) 
• Sexual behaviour (interpersonal-level factors) 
• Financial and adherence intervention (structural-level factors) 
 
The section below describes a description of each category from the reviewed studies.   
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Individual-level factors 
Age 
Seven studies reported an association between age and PrEP adherence. Two 
studies found no significant relationship between age and PrEP adherence (Liu et al, 
2016; Mugo et al, 2015). Five studies found a relationship between levels of PrEP 
adherence and older age (i.e. older individuals were more likely to have protective 
levels of PrEP (Gandhi et al, 2017; Landovitz et al, 2017; Mehrotra et al, 2016), any 
drug level detection (Liu et al, 2014) or higher drug concentrations (Grant et al, 2014).  
 
Ethnicity  
Four studies found that ethnicity was associated with PrEP adherence. Specifically, 
three studies found that African-Americans were less likely to have protective PrEP 
levels than those from any other ethnicity (Gandhi et al, 2017; Landovitz et al, 2017; 
Liu et al, 2016).  However, one study found no significant ethnic differences between 
those who had initiated PrEP (i.e. gained a prescription) but were not consistently 
adherent (i.e. taken 4 or more doses a week) compared to those who had initiated and 
maintained PrEP adherence (Parsons et al, 2017).   
 
Gender identity 
Three studies carried out specific analyses examining the relationship between TGW 
and PrEP adherence. One study found that being TGW was not associated with lower 
PrEP adherence (i.e. drug detection at week 8 or over time) when compared to MSM 
(Liu et al, 2014). 
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Another study found that TGW who used feminizing hormones were less likely to have 
protective levels or any PrEP drug detection in comparison to TGW who did not use 
feminizing hormones. However, there was no difference in adherence between TGW 
who used natural or synthetic oestrogen-based hormones. TGW with the highest risk 
of HIV (based on sexual practices) were less likely to have PrEP detected. Overall, 
TGW showed significantly less adherence (regardless of hormone use) than the rest 
of the MSM population (Deutsch et al, 2015). Lastly, one study found that TGW and 
MSM adherence was impacted differently by depressive symptoms (please see 
‘mental health’ section below) (Mehrotra et al, 2015).  
 
Education 
Six studies reported the relationship between adherence to PrEP and educational 
level. Four studies found no association between these two factors (Landovitz et al, 
2017; Liu et al, 2014; Liu et al, 2016; Mugo et al, 2015). However, two studies found 
drug concentrations were higher amongst those with a higher educational level (Grant 
et al, 2014; Mehrotra et al, 2016). 
 
Location 
Three studies found that PrEP adherence varied dependent on geographic location 
(Liu et al, 2014) or was associated with clinic site (Gandhi et al, 2017; Liu et al, 2016). 
However, after multivariate analyses clinic site no longer stayed significantly 
associated with adherence in one of these studies (Gandhi et al, 2017). Another study 
found no significant geographic differences between those who had initiated PrEP (i.e. 
gained a prescription) but were not consistently adherent (i.e. had not taken 4 or more 
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doses a week) compared to those who had initiated and maintained PrEP adherence 
(Parsons et al, 2017).   
Housing 
Three studies examined the relationship between housing/living situation and PrEP 
adherence. Two studies found that those with stable housing were significantly more 
likely to have protective PrEP levels (Gandhi et al, 2017; Liu et al, 2016) whilst another 
found that living situation or concern about having a place to live was not associated 
with PrEP adherence (Liu et al, 2014). 
 
Lifestyle factors: travel and lifestyle 
Two articles focused on travel and how it related to PrEP adherence. When combining 
both daily and event-based dosing regimens, one study found frequent travel (i.e. 
more than three nights on average per week) was significantly associated with lower 
adherence (Mugo et al, 2015) whilst another found ‘being away from home’ was one 
of the most common reasons for missed doses (Hosek et al, 2013). One study found 
that lifestyle factors were one of the most common reason for missed doses (i.e. being 
too busy) (Hosek et al, 2013).  
 
Regimen  
Only one study examined the relationship between different dosing regimens and 
adherence. Mugo et al (2015) found that daily versus event-based dosing regimen did 
not show any significant association with PrEP adherence.   
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Side Effects 
Four studies reported the impact of side effects on PrEP adherence. One study found 
no association between side effects (i.e. gastrointestinal symptoms or headache) and 
PrEP adherence (Liu et al, 2014) whilst another reported that only one out of 41 
participants who discontinued PrEP stopped because of side effects (Parisi et al, 
2017). However, two studies reported that amongst those who discontinued (Holloway 
et al, 2017) or interrupted their PrEP use (Liu et al, 2016) side effects was the most 
common reason reported by participants. 
Substance Use 
Five studies found no significant relationship between alcohol use or drug use and 
PrEP adherence (Grant et al, 2014; Landovitz et al, 2017; Liu et al, 2014; Liu et al, 
2016; Mugo et al, 2015). One study found drug use (i.e. amphetamine use) was 
significantly associated with adequate PrEP adherence in bivariate analyses but this 
did not maintain significance in multi-variate analyses (Gandhi et al, 2017).  
Mental Health 
Only one study examined the relationship between PrEP adherence and mental 
health. Mehrotra et al (2015) found that pre-existing anxiety was a strong predictor of 
PrEP adherence. Furthermore, amongst TGW participants, depressive scores above 
the clinical cut-off (i.e. scores of 16 or more on the CES-D [Center for Epidemiologic 
Studies Depression Scale] which categorize an individual as ‘at-risk’ of depression 
(Radloff, 1977)) were associated with decreased PrEP adherence. Amongst MSM 
individuals, compared to scores below clinical-cut off, scores between 16 and 26 were 
associated with increased adherence whereas scores of 27 or higher were associated 
with decreased PrEP adherence.  
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Knowledge  
Three studies commented on the association between PrEP knowledge and PrEP 
adherence. One study found that answering ‘don’t know’ to a question about belief of 
PrEP efficacy was associated with PrEP detection at some or all visits, when 
compared with individuals who never took their PrEP medication (Liu et al, 2014). 
Another study found “getting questions answered” was a commonly reported reason 
given by participants when asked what facilitated PrEP use (Parisi et al, 2017). 
However, one longitudinal study found no significant association between prior PrEP 
knowledge and adherence (Liu et al, 2016). 
 
Higher levels of HIV risk perception and actual risk behaviour 
One study found a relationship between PrEP adherence and greater HIV risk 
perception (Liu et al, 2014). Three studies reported that self-reported reasons for 
discontinuing/interrupting PrEP use were: low self-perceived HIV risk (Liu et al, 2016), 
reductions in HIV risk behaviours (Parisi et al, 2017) or the adoption of other HIV-
prevention strategies (Holloway et al, 2017).  
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Interpersonal-level factors 
Sexual behaviour 
Nine studies examined the relationship between adherence and sexual behaviour. Six 
studies highlighted no association between different sexual behaviours and 
adherence; one found that the number of sexual acts without a condom decreased 
over the study period but was unrelated to level of adherence (Tangmunkongvorakul 
et al, 2016). Three studies found that the type of sexual act or partner (Sagaon-
Teyssier et al, 2016), the number of sexual partners (Landovitz et al, 2017) and the 
number of condomless receptive anal sex partners in the last three months (Liu et al, 
2014) was not associated with PrEP adherence.  Lastly, a study in Kenya also found 
no significant associations between multiple sexual indicators (i.e. number of sexual 
partners, any occurrence of sex while drunk, sex with new partner, less than 100% 
condom use with new or HIV positive partner, receptive anal intercourse or insertive 
anal intercourse) and adherence (Mugo et al, 2015). One study found that TGW with 
the highest sexual risk behaviours (i.e. more partners, less condom use and more 
STI’s) were less likely to have PrEP drug detected in blood samples (Deutsch et al, 
2015). 
Five studies reported significant associations between PrEP adherence and sexual 
behaviours; four found that two or more condomless anal sex partners in the past 3 
months (Liu et al, 2016) or reported condomless receptive anal sex (Gandhi et al, 
2017; Grant et al, 2014; Liu et al 2014) was associated with PrEP adherence. Two 
studies found PrEP adherence was higher amongst participants who had history of a 
sexually transmitted infections (STI’s) or more sexual partners (Grant et al, 2014; Liu 
et al, 2014). Specifically, individuals who were in a relationship, had any HIV-positive 
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sexual partners (Grant et al, 2014) or had more male partners (Liu et al, 2014) were 
more likely to be adherent to their PrEP medication.  
 
Structural-level factors 
Financial income and insurance  
Four studies (where PrEP was study-funded) found that financial income (Landovitz 
et al, 2017; Liu et al, 2014; Liu et al, 2016; Mugo et al, 2015) or having financial 
responsibility for others (Mugo et al, 2015) had no significant association with PrEP 
adherence.  One study found that having health insurance was significantly associated 
with adequate PrEP adherence (i.e. four or more does a week) (Liu et al, 2016). 
However, another found that having public or no insurance coverage was not related 
to protective PrEP levels (Landovitz et al, 2017).  One study which examined PrEP 
use (in a location where PrEP required self-funding) found the second and fifth most 
reported reasons for discontinuing PrEP were being unable to afford a prescription or 
the required medical visits for PrEP (Holloway et al, 2017). 
 
Adherence Intervention  
One study found that individuals who received a PrEP adherence intervention (i.e. 
cognitive-behavioural orientated programme which consisted of six nurse-delivered 
sessions which included: education about PrEP and sexual risk behaviours for HIV 
and STI’s, establishing a regular dosing schedule and discussing the barriers to 
adherence) had significantly higher levels of PrEP blood plasma concentrations than 
those who did not at both 3 months and 6 months. However, after completer analyses 
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(i.e. an analysis where only those who completed the intervention were included), 
there were no differences between the control and intervention condition (Mayer et al, 
2017).  
 
Qualitative Studies: Study Characteristics 
 
In total, five qualitative studies were included within the review (please refer to Table 
4 for a summary of the included studies). Four out of five studies were conducted in 
the USA whilst the remaining study (Tangmunongvoraul et al, 2013) was conducted 
in Thailand. One study collected data through focus groups and interviews (Gilmore 
et al, 2013) whilst the remaining four used semi-structured interviews. In total, 182 
MSM individuals participated across studies and all studies used a cross-sectional 
design. Only one study examined a specific MSM subpopulation (i.e. substance-using 
MSM) (Storholm et al, 2017). 
 
Two studies directly explored the facilitators and barriers to PrEP use (Gilmore et al, 
2013; Tangmunongvoraul et al, 2013). One study explored factors which were 
associated with retention in PrEP care (Arnold et al, 2017) whilst another gained 
insight into the overall experience of using PrEP amongst MSM (Parker et al, 2015). 
Lastly, Storholm et al (2017) examined i) how PrEP use affected risk perception and 
sexual behaviour, ii) facilitators of PrEP adherence, iii) the relationship between 
adherence and substance use and iiii) the psychosocial impact of PrEP use.  
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Two studies recruited participants whom were involved in a larger double-blind, 
randomised, placebo-controlled trial (iPrEx). In one study, iPrEX participants were 
recruited during their follow-up visit to the sexual health clinic (Tangmunkongvorakul 
et al., 2013) whilst the other study did not specify how participants (who were enrolled 
at the iPrEx site) were approached (Gilmore et al, 2013).  Three studies recruited 
participants involved in PrEP programs in outpatient clinics in ‘real-life settings’ (Arnold 
et al, 2017; Parker et al, 2015; Storholm et al, 2017). Two studies used a grounded 
theory approach, one used an adapted grounded theory approach, one used 
deductive analysis and one used content analysis methods to analyse data. All studies 
measured PrEP adherence through self-report methods.  
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Table 4: Summary of Qualitative Studies 
Reference 
 
Location Data Collection Sample Measure of adherence 
Arnold et al., 2017 USA   Semi-structured interviews 
 
Grounded theory.  
30 participants 
MSM 
Age (mean, sd): 18+ years (26.6, 8.2)  
Ethnicity: Black/African American (n=25), 
unknown (n=5),  
Daily regimen 
 
Sampling Strategy: Purposive 
Response Rate: Not reported 
 
Self-report 
 
 
Gilmore et al., 2013 USA 
 
iPrEx study 
Focus groups and interviews 
 
Deductive analysis 
52 participants 
MSM 
Age: 22-36 years (median: 43 years) 
Ethnicity: white (66%), African American 
(12%), Latino/Hispanic (15%), and Asian 
(7%),  
Daily regimen. 
 
Sampling strategy: Unclear 
Response rate: Unclear 
 
Self-report 
Parker et al., 2015 USA  Semi-structured interviews 
 
Grounded theory. 
24 participants 
MSM 
Age (mean, sd): 33.2 (10.5) 
Ethnicity; White (75%), Hispanic/Latino 
(25%), Other (21%), African 
American/Black (4%) and Asian (0%),  
Daily regimen. 
 
Sampling strategy: Not reported 
Response rate: Not reported 
 
Self-report 
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Table 4: Summary of Qualitative Studies continued  
Reference 
 
Location Data Collection Sample Measure of adherence 
Storholm, Volk, Marcus, 
Silverberg, & Satre, 2017 
 
USA  
  
 Semi-structured interviews  
 
 
Adapted grounded theory approach. 
30 participants 
MSM 
Age (mean, sd): 20–35 years (27.5, 3.9) 
Ethnicity; White (40%), Latino (23.3%), 
Asian/pacific islander (20%) and African-
American (16.7%),  
Daily regimen. 
 
Sampling strategy: Purposeful 
Response rate: Unclear 
 
Self-report  
Tangmunkongvorakul et al., 
2013 
 
Thailand 
 
iPrEx study  
Semi-structured interviews and focus 
groups.  
 
Content analysis. 
46 participants,  
MSM (n= 29), TGW (n= 17) 
Age: 19-37 years  
Ethnicity: Not reported 
Daily regimen. 
 
Sampling strategy: Purposeful  
Response rate: 100%  
 
Self-report  
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Qualitative Data Synthesis 
 
Twenty-six themes were extracted from the included studies and grouped into three 
higher-order categories: individual-level, interpersonal-level and structural-level 
factors. Across these three domains seven themes emerged which either facilitated or 
acted as a barrier to PrEP adherence:  
 
• Substance use, routine and planning, social motivation, side effects and 
anticipated stigma (individual-level factors) 
• Support from others (interpersonal-level factors) 
• Finances and access to PrEP-related services (structural-level factors) 
 
Table 5 reports the categories and themes identified across studies with an example 
quote from the reviewed studies. The table also indicates whether the theme was 
identified as facilitator or barrier to PrEP adherence. The section below describes a 
description of each category.   
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Table 5: Synthesis of findings showing common categories and themes identified in the literature. 
Category Theme Barrier/ 
Facilitator 
Example 
Individual-level 
factors 
Substance Use Barrier “…the biggest reason we forget to take the medicine is from alcohol” (Tangmunkongvorakul et al, 2013; p. 964). 
Routine and 
planning 
Barrier & 
Facilitator 
“The only challenge is if I’m going over to a friend’s house to stay over for more than a day or going on a vacation 
where you kinda have to do some planning” (Gilmore et al, 2013; pg 562). 
“I have a little week of pills…whenever it’s empty, I refill it, and I keep it on my kitchen counter. And it’s kind of, like, 
right there. I can’t escape it” (Storholm et al, 2017; pg. 742). 
Social Motivation 
 
Facilitator “…I know that there is a 50_50 percent chance of having the real drug or placebo. But no matter what I am given, I will 
continue to take it as advised until the end of the study. Otherwise, there will not be accurate results for the study and 
for all people” (Tangmunkongvorakul, 2013; p. 962) 
Side effects Barrier “…The only side effect that I experienced was a bad headache when I first started takin’ it, and being nauseous. It lasted 
for the whole day. After I took PrEP the first time I stopped” (Arnold et al, 2017; p.5). 
Anticipated 
Stigma 
Barrier “I take [the pill] in private ‘cause I have friends that’s HIV negative and homophobic or positive-phobic and I know who 
those friends are so I just be real particular where I take my pills at” (Gilmore et al, 2013; pg.562).  
Interpersonal-
level factors 
Support from 
others  
 
 
Barrier & 
Facilitator 
“I was worried it might upset my partner that I was taking it because you should trust each other.” Arnold et al, 2017; 
p.5). 
“I think just having the human contact once a month of just having a counsellor and just sort of check in and think about 
behaviors and things like that. I think that had a really good impact” (Gilmore et al, 2013; p.962). 
Structural-level 
factors 
Financial  Facilitator “…I wouldn’t pay more than fifty dollars. I probably would not be able to afford to pay out of pocket” (Arnold et al; 2017; 
p.4). 
Access to PrEP-
related services 
Facilitator “…I know that we are guinea pigs. Nobody has done this kind of research before. But I feel that the compensation 
such as health check-ups, free medical services and money are worthwhile…” (Tangmunkongvorakul et al, 2013; p. 
963). 
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Individual-level factors 
 
Substance Use 
Two studies identified substance misuse as a barrier to PrEP adherence (Storholm et 
al, 2017; Tangmunkongvorakul et al, 2013). Both studies highlighted the use of alcohol 
as a barrier to consistent medication use. One study reported the significant negative 
impact drug use (i.e. methamphetamine and poly-substance drug use) had on their 
routine and subsequently their PrEP adherence (Storholm et al, 2017). 
 
Routine and planning 
Three studies identified routine as a factor which was related to PrEP adherence and 
non-adherence. All studies highlighted that having a routine facilitated consistent PrEP 
use. One study highlighted the role of reminders (e.g. use of phone alarms) as part of 
this established routine (Storholm et al, 2017).  Two studies highlighted that 
established medication management skills (i.e. pre-existing routines for other 
medications) facilitated PrEP adherence (Gilmore et al, 2013; Tangmunkongvorakul 
et al, 2013). The same two studies also highlighted changes in routine (e.g. travel, 
having a busier schedule than usual, going out or staying somewhere else) contributed 
to missed PrEP doses.  
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Social Motivation 
Two studies discussed that amongst MSM participants the personal sense they were 
“giving back to the community” acted as a motivating factor which facilitated PrEP 
adherence. In this sense, adherence was equated with study participation. By 
participating (and adhering well) participants had a sense they were contributing to 
results which could benefit their social group (Gilmore et al, 2013; 
Tangmunkongvorakul et al, 2013).  
 
Side Effects 
Two studies reported on the role of side effects which acted as a barrier to PrEP 
adherence. Both studies highlighted that anticipated side effects could undermine 
PrEP use. One study acknowledged that actual or perceived side effects of PrEP 
stopped PrEP use (Arnold et al, 2017). The other study highlighted that medicine 
concerns were exacerbated due to the uncertainty of PrEP or placebo use amongst 
participants. This meant that MSM participants felt non-adherence was more 
permissible (Tangmunkongvorakul et al, 2013). 
 
Anticipated stigma 
Three studies reported that stigma was a factor that acted as a barrier to PrEP 
adherence (Arnold et al, 2017; Gilmore et al, 2013; Tangmunkongvorakul et al, 2013). 
Across studies, MSM participants reported anticipated stigma in different domains (i.e. 
homophobia, being classed as HIV positive or sexually promiscuous) by friends, family 
or religious communities. Efforts to avoid this stigma (e.g. not carrying or taking PrEP 
in certain situations) acted as a barrier to adherence. 
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Interpersonal-level factors 
Support from others  
Three studies highlighted that support from others helped promote PrEP adherence. 
One study also highlighted that lack of support from family and friends could act as a 
barrier to PrEP adherence (Arnold et al, 2017). For example, when PrEP use was not 
supported by primary sexual partners (i.e. participants reporting anticipated or actual 
conflicts within the relationship) this would act as a barrier to PrEP use. However, 
supportive relationships with friends and family increased confidence in taking PrEP 
and promoted daily PrEP use (Arnold et al, 2017; Gilmore et al, 2013; 
Tangmunkongvorakul et al, 2013).  Two studies reported that supportive, non-
judgemental relationships with healthcare staff promoted PrEP adherence. Within 
each study, one dimension of this relationship with staff involved counselling, where 
the facilitators and barriers to PrEP adherence were discussed (Gilmore et al, 2013; 
Tangmunkongvorakul et al, 2013). 
 
 
 
 
 
 
 
 
 
 
 
63 
 
Structural-level factors 
Financial  
Two studies reported that access to financial support facilitated PrEP use. Both studies 
highlighted that participants could access financial support to help with PrEP costs 
which allowed ongoing PrEP use (Arnold et al, 2017; Parker et al, 2015). 
 
Access to PrEP-related services 
Two studies reported that access to other PrEP-related services facilitated PrEP use. 
By using PrEP, participants reported also having access to other facilities such as HIV 
and STI testing, health monitoring and physical examinations (Gilmore et al, 2013; 
Tangmunkongvorakul et al, 2013). 
 
Methodological Quality 
The methodological quality of both quantitative and qualitative studies is summarised 
in Table 6 and 7 respectively. A cross (x) indicates that the criterion was either not met 
or it was unclear if the criterion was met. 
 
Quantitative studies: Methodological Quality 
External Validity 
Eleven of the fifteen quantitative studies clearly reported that a convenience sampling 
strategy was not used.  Six studies reported good response rates, that is, at least 80% 
of those eligible to participate were recruited. Only four studies met both criteria for 
external validity. 
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Internal Validity 
Eleven out of fifteen studies measured adherence objectively, using biological 
methods (i.e. plasma blood concentrations, dried blood spots or hair using liquid 
chromatography/tandem mass spectrometry) and/or pill counts.  All but three studies, 
reported the number of withdrawals across the study. Ten studies were free of attrition 
bias, reporting that at least 80% of those invited to participate in the study were 
included in the final analysis. All fifteen studies measured potential confounding 
variables and all but two studies carried out multivariate analyses to control for 
potential confounding variables. In total, only two of the 15 studies provided evidence 
of meeting all criteria for internal validity.  
 
Qualitative studies: Methodological Quality 
All studies met all criteria for credibility, three out of five studies met transferability 
criteria whilst no study met the criteria for confirmability as no study 
detailed/considered the researcher’s influence on study findings.    
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Table 6: Methodological quality ratings for quantitative studies 
References External validity  Internal validity 
 
 Representativeness 
of the sample for 
the target 
population 
 
The percentage of 
selected individuals 
who agreed to 
participate 
 Objective 
measurement 
of data 
collection 
methods 
Number of 
withdrawals 
Percentage 
of 
participants 
included in 
final 
analysis 
Extent to 
which 
possible 
confounding 
variables 
were 
measured 
Extent to 
which 
possible 
confounding 
variables 
were 
analysed 
Deutsch et al., 2015 
 
✓ X  ✓ x ✓ ✓ ✓ 
Gandhi et al., 2017 
 
✓ X  ✓ ✓ ✓ ✓ ✓ 
Grant et al., 2014 
 
✓ X  ✓ ✓ ✓ ✓ ✓ 
Holloway et al, 2017 
 
x X  x ✓ ✓ ✓ ✓ 
Hosek et al., 2013 
 
x X  ✓ ✓ ✓ ✓ x 
Landovitz et al., 2017  
 
x ✓  ✓ ✓ x ✓ ✓ 
Liu et al., 2014 
 
✓ ✓  ✓ ✓ x ✓ ✓ 
Liu et al., 2016 
 
✓ X  ✓ ✓ x ✓ ✓ 
Mayer et al., 2017 
 
x ✓  ✓ ✓ x ✓ ✓ 
Mehrotra et al., 2016 
 
✓ ✓  ✓ x  ✓ ✓ ✓ 
Mugo et al., 2015  
 
✓ X  ✓ x ✓ ✓ ✓ 
Parisi et al., 2017 
 
✓ ✓  x ✓ x ✓ ✓ 
Parsons et al., 2017 
 
✓ X  x ✓   ✓ ✓ ✓ 
Sagaon-Teyssier et al., 2016 
 
✓ ✓  x ✓ ✓ ✓ ✓ 
Tangmunkongvorakul et al., 2016 
 
✓ X  ✓ ✓ ✓ ✓ x 
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Table 7: Methodological quality ratings for qualitative studies 
References Credibility   Transferability  Confirmability 
 Clarity of data 
collection and analysis 
 
Representativeness of 
the data 
 
 Are the findings 
transferable to other 
settings 
 Is the analysis grounded in the data? Is 
appropriate consideration given to how the 
findings relate to researchers’ influence? 
Arnold et al., 2017 
 
✓ ✓  ✓  x 
Gilmore et al., 2013 
 
✓ ✓  x  x 
Parker et al., 2015 
 
✓ ✓  x  x 
Storholm, Volk, Marcus, 
Silverberg, & Satre, 2017 
 
✓ ✓  ✓  x 
Tangmunkongvorakul et al., 2013 ✓ ✓  ✓  x 
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Discussion 
Overview of Study Findings 
This review aimed to synthesise the factors related to PrEP adherence amongst MSM. 
Twenty studies were included and across studies twenty factors were measured and 
analysed in relation to PrEP adherence. Eleven out of twenty factors produced 
inconsistent findings across studies. Most discrepancies were not due to differences 
in methodological design (e.g. whether blinded RCT or longitudinal open-label design), 
study location or sample size. The key findings from each higher-order category (i.e. 
individual, interpersonal and structural-levels) and their relation to previous reviews 
and theory will be discussed below: 
 
Individual-level factors 
Individual-level factors were the most commonly measured variables to examine in 
relation to PrEP adherence (n=16). Nine variables produced inconsistent findings 
across studies. The majority (six out of eight studies) found no relationship between 
alcohol or drug use and PrEP adherence. This is inconsistent with reviews and meta-
analyses that highlight substance use as a barrier to ART adherence (Mills et al, 2006; 
Hendershot et al, 2009). The Information-Motivation-Behavioural Skills (IMB) model, 
a theoretical model of adherence behaviours, proposes that situational variables such 
as substance use can act as a moderating factor to adherence behaviours. The model 
proposes that substance use could moderate the relation between IMB model 
constructs and adherent behaviours (Fisher, Fisher, Amico & Harman, 2006). 
Importantly, the theory specifies that the impact of these factors varies dependent on 
the level/intensity of the moderating factor. Therefore, inconsistent review findings may 
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reflect differences in the definitions and levels of substance use across studies which 
could have impacted PrEP adherence differently. 
 
Most findings (five out of eight studies) suggested a relationship between older age 
and PrEP adherence. This is consistent with the ART adherence literature where a 
meta-analysis found older adults are less likely to be non-adherent than younger HIV-
positive individuals (Ghidei et al 2013). This finding is different to reviews focused 
earlier in the prevention cascade which found younger age was predictive of higher 
acceptance of PrEP (Peng, Su, Fairley, Chu, Jiang, Zhuang & Zhang, 2017). It may 
be that there are different predictors at different stages of the PrEP cascade. The 
health belief model (HBM) is a value expectancy theory designed to predict health 
behaviours (Rosenstock, 1974). The model theorises that individual characteristics 
such as age are “modifying variables” which can indirectly impact health behaviours 
(i.e. adherence) by affecting a person’s beliefs about the perceived seriousness, 
benefits and barriers to action. This suggests that older-age PrEP users may have 
different beliefs from younger MSM users that may help to facilitate PrEP adherence. 
Future research could explore age-related beliefs that may be associated with PrEP 
adherence.   
 
Four of six studies reported a relationship between anticipated or actual side effects 
and less PrEP adherence. This has been echoed by both reviews earlier in the 
prevention cascade examining willingness and barriers to hypothetical PrEP use 
(Koechlin et al, 2017) as well as within the ART adherence literature (Al-Dakkak et al, 
2013). The safety profile of PrEP is high and side effects have shown to be in most 
cases mild, short-term (e.g. headaches) and/or reversible (Mugwanya & Baeten 2016). 
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This suggests that participants may not have had accurate information/support 
available in which to contextualise their anticipated or actual experience of PrEP side-
effects, which may have impacted their adherence. The IMB model of ART adherence 
theorises that individuals perceived or objective ability to minimise side-effects is one 
of many behavioural skills which can directly influence adherence behaviour.  
 
Three studies reported that participants felt that having an established routine and 
planning (i.e. use of reminders) facilitated PrEP adherence. Furthermore, studies 
found that lifestyle factors (i.e. frequent travel and busy lifestyle) were all associated 
with less PrEP adherence.  This is consistent with studies using HIV-positive 
individuals which found lifestyle factors (e.g. changes to daily routine or being away 
from home) may negatively influence ART adherence (Shubber et al, 2016). Overall, 
this highlights that lifestyle factors which may vary over time may influence PrEP 
adherence in particular contexts.  This finding is consistent with the IMB model of ART 
adherence which postulates perceived and objective behavioural skills (e.g. the ability 
to incorporate PrEP into everyday life, self-cue and self-administer PrEP) are the 
critical prerequisite for adherence for occur (Fisher, Amico, Fisher & Harman, 2008).   
 
All three studies supported that higher levels of HIV risk perception and risk behaviour 
were related to PrEP adherence. This suggests that PrEP use may be related to MSM 
individuals’ perceived risk or actual episodes of high-risk sexual behaviour. Koechlin 
et al (2017) also found that across risk groups low HIV risk perception acted as a 
barrier to hypothetical PrEP use. Risk perception is central to many health-specific 
behavioural theoretical models including the HBM model (Rosenstock, 1974), 
protection motivation theory (Rogers, 1975) and the extended parallel process model 
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(Witte, 1992). Consistent with current findings these theories suggest that an 
individual’s perceived susceptibility to a threat (e.g. the perceived likelihood of HIV 
acquisition) shape health behaviours (e.g. PrEP adherence).  
 
The review found a relationship between ethnicity and less PrEP adherence. Three 
out of four studies found African-Americans were less likely to be adherent than those 
from any other ethnicity. The one study which did not find this relationship had a very 
small sample size and therefore may have not have had the power to detect this finding 
(Parsons et al, 2017). Black MSM are disproportionately affected by HIV in the USA 
and disparities in physical health access and outcomes has been widely documented 
(relative to other ethnic groups) (Wheeler et al, 2016). The current review is consistent 
with a meta-analysis which found black HIV-positive US MSM were less likely to 
adhere ART than MSM from any other ethnicity (Millett et al, 2012).  This suggests 
that African-American MSM may be less likely to adhere than other ethnic groups, and 
may require additional clinical adherence support. Akin to age, the HBM model 
theorises that ethnicity is another modifying variable which can indirectly impact health 
behaviours (i.e. adherence). This suggests that PrEP users from different ethnic 
groups may have different beliefs which may impact adherence differently. Future 
research could also explore beliefs held by different ethnic groups that may be 
associated with PrEP adherence.   
 
One finding related to housing differed across methodological design; two open-label 
studies (one of which was a sub-study of the other) reported stable housing was 
associated with PrEP adherence whereas a study using a blinded RCT design found 
no association. The blinded RCT may have had more staff resources to promote 
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adherence in the study (e.g. consistent outreach) than the open-label demonstration 
projects reflecting ‘real-life’ resource settings (Patel et al, 2017). Therefore, aspects of 
the RCT design could have acted as a confounding variable to PrEP adherence and 
could explain why housing was not found to be significantly related to PrEP adherence 
in the blinded RCT study. A meta-analysis found a positive significant association 
between housing stability and ART medication adherence amongst HIV-positive 
individuals (Harris, Xue & Selwyn, 2017). This finding is consistent with research that 
has found lifestyle factors and routinization of daily activities were related to ART 
adherence (Wagner & Ryan, 2004). Housing stability could impact the extent to which 
an individual’s daily life has structure and routine and this may play a role in PrEP 
adherence. Theoretically, akin to substance use, housing stability is described as a 
moderating factor to adherence in the IMB model. 
 
Three studies found anticipated stigma (i.e. homophobia, being classed as HIV 
positive or sexually promiscuous) by friends, family or religious communities was 
reported to be a barrier to PrEP adherence. This is consistent with Peng et al’s (2017) 
review that found MSM with low perceived stigma from friends, society and healthcare 
providers about PrEP use were more likely to accept PrEP as a preventative 
healthcare intervention.  Furthermore, a meta-analysis found that HIV stigma (i.e. both 
anticipated and enacted) negatively influences ART adherence (Langebeek et al, 
2014). The IMB model that states that an individuals’ social motivation (i.e. perceived 
social pressure from friends, family and healthcare providers) can influence 
behavioural skills and adherence behaviour.   
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Interpersonal-level factors 
Eleven studies examined the relationship between interpersonal-level factors and 
PrEP adherence. Six studies found a relationship between PrEP adherence and 
sexual behaviour (i.e. indices of increased HIV sexual risk behaviours amongst MSM 
were associated with PrEP adherence). As highlighted above, risk perception is a core 
component of many theoretical models to explain health behaviour.  The HBM model 
(Rosenstock, 1974) theorises that an individuals’ risk perception is in part determined 
by their perceived susceptibility of harm. Therefore, findings that increased sexual-risk 
behaviour was related to PrEP adherence may be explained by increased HIV risk 
perception (i.e. increased sexual-risk behaviour increases HIV risk perception). 
 
Three studies identified that support from others (i.e. friends, family and healthcare 
staff) was a factor that was perceived to be related to PrEP adherence. This is 
consistent with review findings examining factors that facilitated PrEP use amongst 
hypothetical PrEP users as well as ART adherence amongst HIV-positive individuals 
(Ammassari et al, 2002; Koechlin et al, 2017). Furthermore, this finding is consistent 
with the IMB model that states that an individuals’ social motivation (i.e. perceived 
social pressure from friends, family and healthcare providers) can influence 
behavioural skills and adherence behaviour.  
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Structural-level factors 
Nine studies examined the relationship between structural-level factors and PrEP 
adherence. The review found that (where PrEP was study-funded) financial income 
was not related to adherence. However, one study (where PrEP was self-funded) 
showed that financial reasons were the main reason for discontinuation. Studies 
supported that PrEP adherence was facilitated by financial support and access to 
PrEP-related services. This finding is consistent with previous reviews that reported 
cost and affordability were barriers to willingness/acceptability and uptake of PrEP 
(Koechlin et al 2017; Peng et al, 2017). Theoretically, the IMB model conceptualises 
poor access to healthcare as a key moderating factor which can directly influence 
adherence behaviours. It highlights that the increased barriers to healthcare access 
adherence will be difficult regardless of an individual’s information, motivation or 
behavioural skills (Fisher & Fisher, 2002). Access to PrEP is context-specific, highly 
variable and ever-changing. These findings highlight that in locations where PrEP or 
PrEP-related healthcare services are not easily accessible then PrEP adherence and 
effectiveness could suffer.   
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Strengths and Limitations of the Review 
One of the main strengths of the review was its broad inclusion criteria. This was 
reflected in a comprehensive search strategy which included peer-reviewed journals 
with no regional restrictions. However, the search was restricted to English-language 
publications and no grey literature search took place. This could have decreased the 
sensitivity of the search and likelihood that all relevant studies were included. A 
strength of the current review process was that two researchers conducted the 
eligibility assessment for study inclusion and performed an assessment of bias upon 
the included studies. This reduced the possibility of the exclusion of relevant studies 
and provided inter-rater reliability for assessments made (Liberati et al, 2009).    
 
A limitation of the review was that there was overlap in participants across studies due 
to several studies reporting findings from the same dataset/trial. This lowers the 
variability and power of the review findings and may lead to over-interpretation of the 
findings. Another limitation of the review related to the grouping of independent 
variables which showed considerable heterogeneity in the measures and definitions 
used. Although there was overlap in the description of the synthesised constructs (e.g. 
substance use) the variability described may have impacted the internal validity of 
findings. Furthermore, this variability meant that it was not possible to carry out meta-
analysis limiting the substantiality of conclusions drawn. The inability to do this meant 
the current review findings have limited power as pooled estimates of effect size could 
not be identified, disagreements between study findings could not be resolved and 
moderation analysis could not take place. Additionally, potential publication bias was 
not assessed which could have impacted the interpretation of study findings.  
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Strengths and Limitations of the Included Studies 
A major limitation of the included studies regarded the varied definitions and tools used 
to measure adherence. Furthermore, there was large variability in the factors 
measured and analysed in relation to PrEP adherence across studies. This 
inconsistency makes synthesis and interpretation of the relationship between 
variables and PrEP adherence difficult.   
 
A third limitation was that studies did not document key behavioural context/factors 
which may have impacted adherence. For example, most studies did not record 
whether non-adherent episodes occurred within periods of risky sexual behaviour. 
This is crucial as periods of non-adherence in context of no sexual behaviour equates 
to low risk. By failing to conceptualise behavioural factors study findings are limited in 
how much they can inform knowledge regarding the relationship between these factors 
and adherence (van der Straten et al, 2012).  
 
Most studies have used between-participant correlates of PrEP adherence (e.g. 
ethnicity) to make comparisons between ‘good-adherers’ and ‘poor-adherers’.   Such 
designs prevent investigation of the factors related to variability in adherence across 
situations within an individual. This is important because individuals may go through 
phases of taking and intentionally or unintentionally skipping their medication (WHO, 
2003). The review highlights that many factors that relate adherence could be 
situationally-specific (e.g. changes in routine). As research did not examine factors 
related to specific adherent/non-adherent episodes these relationships went 
undetected.     
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A strength of the included studies was that the majority used a longitudinal design 
which allowed researchers to detect adherence over time and the overall range of 
designs used across studies increased the generalisability of findings (Caruana et al 
2015).  However, the use of RCTs (n=6) limits the generalisability of findings. For 
example, the increased resources available within RCT designs (e.g. increased 
monitoring) differ from what can be offered in real-life clinical settings. This means that 
these designs may overestimate PrEP adherence and when implemented in real-world 
setting predictors of adherence may differ (Amico, 2012). Alongside this, participants 
whom were recruited to RCT’s may not be representative of the general PrEP taking 
population (e.g. they may be more motivated to engage in preventative strategies). 
Lastly, most studies were conducted in large urban cities which may impact the 
generalisability of findings to other regional areas.  
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Theoretical Implications 
The studies included in the review did not use theory to choose variables to measure 
in relation to PrEP adherence. As a result of this, research has not concluded whether 
a specific theoretical model accurately explains PrEP adherence. The current review 
highlights that the theoretical development to understand PrEP adherence requires a 
model which incorporates multi-faceted components which may impact an individuals’ 
PrEP-taking behaviour. For example, the review highlights the potential utility of the 
theories such as the Information-Motivation-Behavioural Skills Model (IMB) (Fisher et 
al, 2006) to understand PrEP adherence. The IMB model, describes behavioural and 
psychological determinants of adherence-related behaviours (Fisher et al, 2006). The 
model recognises three individual constructs; information, motivation and behavioural 
skills which are needed for an individual to engage in a health behaviour (i.e. 
successful adherence) (Deakin et al, 2005; Fisher et al, 2006). The model also 
incorporates moderating factors which affect adherence including; psychological 
health, living situation, access to medical care and substance use (Amico et al, 2009). 
This model has been specifically adapted to explain antiretroviral adherence (Fisher 
et al, 2006) and given the overlap between predictors of PrEP and ART adherence 
highlighted above may have relevancy. Furthermore, the IMB model, describes a 
broad range of determinants of adherence as well as moderating factors which may 
be better placed to acknowledge the potentially situationally-specific and complex 
factors involved in PrEP adherence highlighted above (Amico et al, 2009).  
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Research Implications 
There were equal numbers of studies with a RCT and longitudinal open-label design. 
It is important future studies continue to examine the use of PrEP within real-world 
settings (e.g. in settings with typical resources for that location) to improve the external 
validity of findings. Notably, most studies were conducted in urban cities and only one 
study was conducted within a European country. Future research needs to continue 
to examine PrEP adherence amongst diverse populations and implementation 
settings to increase the generalisability and examine any cross-cultural differences in 
factors related to PrEP adherence. Lastly, research within diverse populations (e.g. 
TGW) and within MSM sub-populations (e.g. black and ethnic minority and older-aged 
MSM) would be useful to delineate specific facilitators/barriers to PrEP use and to 
inform individualised PrEP adherence interventions.   
 
As mentioned above, an important limitation was that studies reported adherence but 
did not record key behavioural context/factors which may have impacted adherence. 
Future research should report these variables (e.g. whether sex occurred) over 
periods of adherence/non-adherence to better understand patterns of adherence. It 
would also be useful if studies examined the role of situationally-specific factors using 
within-participant research which would allow more confident causal inferences to be 
made between potential adherence determinants and medication use.  Furthermore, 
development and use of standardised assessment tools to measure variables related 
to PrEP adherence and standardised definitions of adherence could improve the 
inconsistency and variability across studies. If future studies used a standardised 
definition of ‘adequate adherence’ and measured key behavioural/contextual factors 
this would allow recognition of factors related to clinically significant non-adherence. 
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This standardisation would also facilitate synthesis across studies and allow meta-
analysis to be performed. 
 
Practice Implications 
Due to the limitations highlighted above, the practical implications of the review are 
limited/expressed cautiously. At most, the review can suggest variables that could be 
targeted in interventions. The review highlights the need for tailored PrEP adherence 
interventions which address the wide-ranging facilitators and barriers to PrEP 
adherence which may vary dependent on an individual’s situation. Crucially, the review 
has highlighted potentially modifiable factors (e.g. routine and planning) which could 
be targeted within PrEP adherence interventions as well as used to identify those most 
‘at-risk’ of non-adherence. The finding that PrEP adherence may be impacted by 
anticipated or actual side effects as well as perceived or actual periods of low HIV risk 
highlights the importance of PrEP psycho-education. This would be crucial to 
contextualise and manage PrEP side-effects and ensure that situations that individuals 
perceive as low-risk for HIV acquisition correspond to actual low risk. Overall, this is 
consistent with WHO PrEP implementation guidelines (2017) that clinicians should 
support adherence by discussing, how to incorporate PrEP into daily routine, side-
effects and how to plan PrEP discontinuation safely.   
 
The review highlights the importance of support from others, including healthcare staff, 
which may facilitate adherence. Review findings support WHO guidelines (2017) that 
during PrEP follow-up appointments clinicians discuss potential stigma from others, 
show professional support of PrEP as a responsible choice and advocate disclosure 
of PrEP use to someone they trust so that they can offer support. The provision of 
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education and information (e.g. educational media campaigns in the general 
population) may be useful at a wider societal level to help facilitate support and reduce 
perceived stigma. The structural-level factors identified highlight that accessibility to 
PrEP may play an important role in PrEP adherence. This suggests that 
commissioners should consider the potential implications of financial barriers on the 
effective implementation of PrEP and thereby the reduction of HIV acquisition. 
Decisions to not make PrEP more widely accessible given the cost of this initiative 
must be balanced against the economic implications of potential lifetime adherence to 
ART medications.   
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Psychological and behavioural within-participant predictors of adherence to 
oral HIV Pre-Exposure Prophylaxis (PrEP) 
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Abstract 
Pre-Exposure Prophylaxis (PrEP) is a safe and efficacious HIV prevention tool.  When 
adhered to, if HIV exposure occurs, this antiretroviral drug stops the virus entering 
cells and replicating (i.e. the person remains HIV negative). The effectiveness of PrEP 
is variable, however, explained by differences in PrEP adherence.   PrEP adherence 
is often inconsistent within individual, whereas most studies only investigate 
adherence between individuals. Understanding psychological and behavioural 
correlates of PrEP adherence is important to develop effective adherence 
interventions.  This study investigated within-participant behavioural and psychological 
differences between adherent and non-adherent PrEP episodes in men who have sex 
with men (MSM), informed by theory (the Information-Motivation-Behavioural Skills 
model). Sixty-seven HIV-negative MSM at high-risk of HIV acquisition were recruited 
from two London sexual health clinics. All participants had followed a daily dosing 
PrEP regimen for at least three months and had shown inconsistent adherence in the 
previous month. Participants completed a questionnaire measuring psychological and 
behavioural variables for both an adherent and non-adherent episode.  Paired t-tests, 
McNemar’s chi-square tests and a conditional logistic regression (CLR) model were 
used to analyse associations between behavioural and psychological factors related 
to adherent and non-adherent events. Lower reported information about PrEP, lower 
behavioural skills related to PrEP use and lower positive affect were associated with 
non-adherent episodes. There were no significant differences in negative affect or 
PrEP motivation between episodes. A CLR model including information, behavioural 
skills and positive affect was significantly predictive of non-adherent episodes, 
although only behavioural skills was statistically significant independently. Behavioural 
factors including weekend days, lack of reminders, non-normality of the day, being out 
83 
 
of the home, not being alone and substance use were also associated with PrEP non-
adherence. Findings suggested that situational psychological factors are important for 
PrEP adherence. Adherence interventions should consider focusing on potentially 
modifiable situational variables (psychological and behavioural). 
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Introduction 
HIV and Pre-exposure Prophylaxis (PrEP): General Overview 
The introduction and dissemination of antiretroviral therapy (ART) has meant that HIV 
(Human Immnodeficiency Virus) has transitioned from being a fatal illness to chronic 
healthcare condition (Montaner et al, 2014). HIV has lifelong treatment implications 
and represents a burden for people with HIV (e.g. coping with HIV stigma and 
medication side effects) as well as being associated with significant healthcare costs 
(Laryea & Gien, 1993; Nakagawa et al, 2015).  
Globally, 36.7 million people were estimated to be living with HIV in 2016 (UNAIDS, 
2017). The prevalence of HIV varies across countries and population subgroups 
(UNAIDS, 2016). The United Kingdom (UK), considered as having a ‘concentrated’ 
epidemic (i.e. where HIV has spread rapidly within specific sub-populations but is not 
well-established in the general population), had an estimated 101,200 people living 
with HIV in 2015 and approximately 6,095 of these people were newly diagnosed in 
the same year (Public Health England (PHE), 2016; Wilson & Halperin, 2008). Despite 
various HIV prevention initiatives (e.g. increased HIV testing and earlier initiation of 
ART which can reduce HIV’s infectiousness) between 2000 to 2013 HIV incidence 
rates remained relatively stable in the UK (Aghaizu et al, 2016; Birrell et al, 2013; 
Phillips et al, 2013). However, recent data indicates that incidence rates have 
decreased particularly in those deemed most at risk in the UK; gay, bisexual and men 
who have sex with other men (MSM) (Aghaizu et al, 2016; PHE, 2017). This shift has 
been attributed to combined preventative strategies (i.e. increased HIV testing, earlier 
initiation of ART) which includes access to the newer initiative of oral pre-exposure 
prophylaxis (PrEP) (Brown et al, 2017).  
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PrEP involves people who are HIV-negative taking an antiretroviral drug. Specifically, 
those containing both tenofovir disoproxil (TDF) and emtricitabine (FTC) are currently 
recommended for all people at substantial risk of HIV infection (i.e. populations with 
an HIV incidence of about 3 per 100 person-years or higher) (WHO, 2016). When 
taken daily, it takes up to seven days for there to be high enough drug concentrations 
in a HIV negative MSM individual’s bloodstream, genital tract and rectum for PrEP 
efficacy. If HIV exposure then occurs, this antiretroviral drug stops the virus entering 
cells and replicating (i.e. the person remains HIV negative) (Seifert et al, 2014). 
Consistent with British HIV Association guidelines (McCormack et al, 2016b), UK 
health care services advise MSM at high-risk of HIV acquisition one of two dosing 
regimens;  
1) Daily regimen; one tablet taken every day. Research suggests that for PrEP to 
be effective MSM sexually active individuals need to take at least four doses a 
week regardless of sexual activity levels (Grant, 2014). 
2) Event-based regimen; two doses of PrEP between two and twenty-four hours 
before sex, a third dose twenty-four hours later and a fourth dose forty-eight 
hours later (Molina, 2015).  
PrEP differs from post-exposure prophylaxis (PEP) where ART medication is taken 
after a recent possible exposure to HIV has occurred. In these emergency situations, 
PEP is initiated within 72 hours and continued for a 28-day course (Young, Arens, 
Kennedy, Laurie & Rutherford, 2007). 
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The safety and biological efficacy of PrEP to prevent HIV acquisition has been 
demonstrated by placebo-controlled trials within MSM and heterosexual samples 
(Grant et al, 2010; Grant et al, 2014; Baeten et al, 2012; Molina et al, 2015; 
McCormack et al, 2016a; Thigpen et al ,2012; Choopanya et al, 2013). However, when 
implemented PrEP has shown wide ranging effectiveness in relation to HIV prevention 
relative to placebo ranging from -49% to 86%. These wide-ranging results have been 
explained by varied adherence (Van der Straten et al, 2012; Fonner et al, 2016). 
Studies using MSM samples found that between 16-43% of participants did not take 
their PrEP as prescribed (Molina et al, 2015; McCormack et al, 2016a; Mayer et al, 
2014) whilst others have reported that 27-66% of MSM participants did not have drug 
levels needed for PrEP effectiveness (Cohen et al, 2014; Hosek et al, 2017). For a 
detailed description of studies which have examined PrEP effectiveness and MSM 
adherence please refer to pages 21-24. Overall this literature has highlighted that the 
implementation of PrEP as a prevention strategy must be considered as bio-
behavioural due to the factors (i.e. adherence) that moderate its efficacy (Kippax & 
Stephenson, 2012). Understanding the predictors of PrEP adherence/non-adherence 
is crucial to the development of a theoretical framework and tailored adherence 
interventions. The systematic review presented earlier in this thesis synthesised the 
literature examining factors related with PrEP adherence amongst MSM who had 
access to PrEP or had been part of a placebo arm in a randomised control trial (RCT) 
where the active arm took PrEP medication. This highlighted various factors such as 
older age, stable housing, higher levels of HIV risk perception and actual risk 
behaviours, routine and planning, lifestyle factors (i.e. less travel and being less busy), 
less anticipated stigma, not being African-American, less anticipated or actual side-
effects and support from others were related to PrEP adherence.  
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Critique of existing literature 
Measures of adherence and behavioural factors  
Unfortunately, there has been heterogeneity in how adherence in context of a daily 
dosing regimen has been defined (e.g. one missed dose or over three missed doses 
being described as non-adherence) and captured (e.g. use of self-report or biological 
methods). Furthermore, there has been large variability in the factors measured and 
analysed in relation to PrEP adherence across studies.  Altogether, this makes 
synthesis and interpretation of the relationship between factors related to PrEP 
adherence difficult. A second limitation (regardless of how adherence was 
defined/measured), was that studies have not documented key behavioural 
context/factors which may have impacted adherence/non-adherence. For example, 
research has not recorded whether non-adherent episodes occur within periods of 
risky sexual behaviour. This is crucial as periods of non-adherence in the context of 
no sexual risk behaviour equates to low risk of HIV acquisition. By failing to 
conceptualise both behavioural factors and biological measures of adherence, these 
studies have been unable to inform knowledge regarding patterns of adherence as 
significantly as they could (van der Straten et al, 2012).  
 
Study Design and within-participant research 
Due to the different study designs used it is difficult to decipher the generalisability of 
findings. For example, blinded trials may report lower adherence levels because 
participants are aware that they may be receiving an ineffective placebo (Underhill, 
2011). However, well controlled RCT trials may also overestimate adherence due 
higher levels of monitoring (Amico, 2012).  Adding to the difficulty in understanding 
88 
 
adherence is the fact that research describes between-participant’ correlates of PrEP 
adherence relating to variables such as HIV stigma, ethnicity and age (e.g. Mehrotra 
et al., 2016; Liu, 2015). This is where comparisons are made between ‘good-adherers’ 
and ‘poor-adherers’.  Such designs prevent investigation of other factors related to 
variability in adherence across situations within an individual. This is important 
because individuals often intentionally or unintentionally skip their medication. For 
example, WHO (2003) highlighted 40-50% of individuals across medical conditions 
were inconsistently adherent and similarly, PROUD showed 40% of MSM participants 
did not take their PrEP medication 100% of the time and 36% intentionally did not 
adhere for a period (McCormack et al, 2016a). 
An alternate approach to examining adherence is to assess situational factors that are 
associated with specific episodes of medication use/non-use. Through this 
investigation, factors which may vary according to specific contexts for example, 
affect, behaviour and cognition, can be investigated whilst static demographic factors 
are controlled for (Wagner & Ryan, 2004). This approach allows more confident causal 
inferences to be made between potential adherence determinants and medication use 
than a between-participants design.   
There are no known published reports of episodic level adherence of PrEP in HIV 
negative individuals at high-risk of HIV transmission. However, research has shown 
the possibility of examining a number of episodes using a within-individual approach 
across a period of time to investigate predictors of ART adherence (Cook, Schmiege, 
Bradley-Springer, Starr & Carrington, 2017). Research using this ecological 
momentary assessment (EMA) methodology (e.g. daily diaries) allows measurement 
of the variable under investigation close to its actual occurrence, however, is limited in 
the amount of information obtained. Furthermore, evidence of this episodic-level 
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variation has been seen within Hawkins et al (2016), a quantitative study, which 
explored ART adherence in young adults with perinatally-acquired HIV. This study 
found there were variables significantly associated with non-adherence within the 
same person across different episodes for example, lower levels of positive affect and 
lower levels of behavioural skills.  Additionally, Vosper, Evangeli, Porter & Shah (in 
press) examined within-participant correlates of oral chelation adherence on a daily 
(episodic) basis amongst those with the life-long health care condition Beta-
Thalassaemia-Major. This study found that situationally-specific factors (i.e. higher 
self-efficacy) significantly predicted adherent episodes. Both studies highlight 
important behavioural and situationally-specific predictors of adherence within 
populations where medication is used for treatment. Situationally-specific factors could 
be explicitly explored within the HIV negative PrEP population where medication is 
used for primary prevention where predictors may differ (Marcus et al, 2014). 
 
The Information-Motivation-Behavioural Skills Model (IMB)  
The review highlighted that studies did not use theory to select variables to measure 
in relation to PrEP adherence. Research has not concluded whether a specific 
theoretical model accurately explains PrEP adherence. The application of a theory to 
understand PrEP adherence can help identify the active mechanisms underlying this 
behaviour within specific populations. A more comprehensive understanding of these 
variables can allow the development of tailored PrEP adherence interventions 
(Shrestha, Sansom, & Purcell, 2016).    
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The IMB model, describes behavioural and psychological determinants of HIV risk 
behaviours (Fisher & Fisher, 1992). This was then specifically adapted to explain 
antiretroviral adherence (Fisher et al, 2006). Informed by the Theory of Reasoned 
Action and the Theory of Planned Behaviour, the IMB model highlights three individual 
constructs; information, motivation and behavioural skills which are needed for an 
individual to engage in a health behaviour such as successful adherence (Deakin et 
al, 2005; Fisher et al, 2006). The IMB model of adherence behaviour defines 
‘information’ as the perceived knowledge about medication use in that situation, whilst 
‘motivation’ is described as both i) personal motivation (or treatment outcome 
expectancy and their perceived importance), and ii) social motivation, or the 
perception and importance of others’ wishes in relation to adherence. Lastly, the 
behavioural skills construct is defined as the objective skills in taking medication as 
well as perceived self-efficacy in using those skills (Fisher et al, 2006). The model 
postulates that information and motivational constructs have direct effects on both 
behavioural skills and health behaviour. Behavioural skills is also hypothesised to 
directly impact health behaviour. As it describes motivational and behavioural skills 
which could change situationally, the IMB model is particularly well-suited to within-
participant research. The model also incorporates moderating factors which are 
thought to affect adherence including; psychological health, living situation, access to 
medical care and substance use (Amico et al, 2009). A diagrammatical representation 
of the IMB model of ART adherence can be found below (Figure 2) (Fisher, Amico, 
Fisher, & Harman, 2008). 
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Figure 2: The Information-Motivation-Behavioural Skills Model of ART 
Adherence (from Fisher, et al, 2006) 
 
The IMB model has been used frequently when exploring medication adherence in 
HIV positive samples (Amico et al, 2005; Horvath, Smolenski, & Amico, 2014; Starace 
et al, 2006). For example, Hawkins et al (2016) found non-adherence was not 
significantly associated with information or motivation but was significantly associated 
with behavioural skills. Non-adherence was also associated with variables not 
specified in the IMB model; lower positive affect and situational variables i.e. lack of 
routine, being out of the home and weekend days. Although, tentative a priori 
predictions can be made (i.e. that these behavioural/situationally specific variables 
would also be associated with PrEP adherence in high-risk HIV negative populations) 
researchers have suggested that the motivations to adhere to PrEP should not be 
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extrapolated from HIV positive samples as reasons are likely to differ (HIV negative 
populations are uniquely engaging in preventative medication strategies) 
(Tangmunkongvorakul et al., 2013).  
At present, research has not concluded whether the IMB model is applicable in the 
context of PrEP adherence. The only related study was conducted by Shrestha et al 
(2016) who was the first study to empirically test and highlight the utility of the IMB 
model. Specifically, the study examined willingness to use PrEP (rather than actual 
use) amongst high risk HIV negative drug users in treatment. Consistent with Hawkins 
et al (2016), they found that there was no significant relationship between willingness 
to use PrEP and information or motivation but was mainly predicted by behavioural 
skills.  
 
PrEP Access: Current UK context 
In April 2017, Scotland became the first UK nation to approve NHS provision of PrEP 
to those at high risk of HIV transmission (Scottish Medicines Consortium, 2017).  In 
the same month, NHS Wales committed to a three-year trial of PrEP to all high-risk 
populations (Welsh Government, 2017). Similarly, NHS England made £10 million 
available to Public Health England (PHE) to conduct the PrEP Impact clinical trial 
delivered through existing sexual health clinics. The PrEP Impact trial plan to enrol 
10,000 participants over the next three years to address outstanding implementation 
questions for example, uptake and adherence within daily and event-based dosing 
regimens (NHS England, 2016). Alternatively, HIV negative MSM have two main 
routes to continue/initiate PrEP use: through a research trial or private prescription. 
The Gilead DISCOVER research trial, aims to compare Truvada (emtricitabine and 
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tenofovir disproxil fumarate, F/TDF) to Descovy (a new version of Truvada; a 
combination of emtricitabine and tenofovir alafenamide, F/TAF). This multi-national 
double-blinded RCT aims to test whether Descovy is as safe and effective as Truvada 
when used by MSM as a pre-exposure prophylaxis within a daily dosing regimen. 
Lastly, sexual health clinics at present offer clinical monitoring to patients who are 
using PrEP on private prescriptions, whether purchased on-line or from the clinic. 
 
The proposed study 
Overall, the literature above has highlighted that pharmacological interventions have 
a crucial behavioural component; adherence within the given population. As shown, 
the efficacy and need for HIV preventative methods does not guarantee their uptake 
and adherence. Thus, research must consider the social context in which these 
initiatives take place to ensure successful implementation (Dearing et al, 2013). 
Bridging the efficacy-effectiveness gap by understanding and optimising adherence is 
key to ensure funding and maximise public health impact (Baeten, Haberer, Liu & 
Sista, 2013).  From the systematic review conducted it suggests that factors such as 
routine and planning and higher levels of actual risk behaviour could be between-
participant predictors of PrEP adherence. However, it is not known if variation in these 
variables can explain inconsistent adherence observed within-individuals.  
 
The current exploratory study aims to investigate within-participant situational 
differences in adherent and non-adherent episodes, informed by theory (the 
Information-Motivation-Behavioural Skills [IMB] model) in a cross-sectional study 
about retrospective adherence episodes. This aims to address the aforementioned 
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gap in the literature concerning determinants of adherent and non-adherent episodes 
in this population. No a priori predictions were made as previous research has not 
explicitly investigated the within-participant predictors of adherence within the PrEP-
taking population. Previous researchers have suggested that the motivations to 
adhere to PrEP should not be extrapolated from other populations (e.g. HIV positive 
samples) as reasons are likely to differ (Tangmunkongvorakul et al, 2013).  
The main research questions the study investigates are: 
 
a) Which psychological factors (including those informed by the Information, 
Motivation, Behavioural Skills (IMB) Model), differentiate episodes of PrEP 
adherence versus PrEP non-adherence within participants? 
 
b) Which behavioural factors (e.g. change in routine or day of the week) 
differentiate episodes of PrEP adherence versus PrEP non-adherence within 
participants? 
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Method 
Design  
A within-participants design was used.  
Settings 
Participants were recruited using convenience sampling from two London sexual 
health clinics (referred to as site 1 and site 2) who were both participating in the PrEP 
Impact and DISCOVER trials. 
Inclusion criteria common to both Impact and DISCOVER trials were; MSM and 
transgender women (male at birth), HIV negative status and at high risk of 
HIV transmission. Inclusion criteria specific to the Impact trial were; transmen or 
heterosexuals; over the age of 16; willing to adhere to the recommended PrEP 
regimen (daily or event based) and re-attend the clinic every 3 months.  Inclusion 
criteria specific to DISCOVER was; 18 years and older; have at least one of the 
following i) engaged in condomless anal intercourse with at least two male partners in 
the past 12 weeks (partners must be either HIV-infected or unknown HIV status), ii) 
history of syphilis or iii) rectal gonorrhoea or chlamydia in the past 24 weeks; adequate 
renal, liver and hematologic function.  Impact is an open-label trial whereas 
DISCOVER is a blinded trial. 
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Sample 
Participants 
Participants had enrolled in the PrEP Impact or DISCOVER trials at either recruitment 
site or had attended one site for a general sexual health appointment or monitoring for 
a private PrEP prescription (either purchased online or in clinic). All recruited 
participants were approached between September and December 2017.  The only 
reason given for not taking part when deemed eligible was insufficient time. The 
response rate was not able to be calculated. This was because the author was only 
referred potential participants whom were eligible and interested in taking part in the 
study. The number of times the study was discussed with eligible PrEP users who 
declined participation was not reported by the clinical team at either site. 
 
Sample Size Calculation 
Paired t-test analyses were used to inform an a-priori power calculation to estimate 
the required sample size. There have been no comparable within-participant studies 
which have examined PrEP adherence. Therefore, a study using similar methodology 
was chosen to calculate the effect size; Hawkins et al (2016) used a within-participant 
approach and applied the IMB model to explore antiretroviral medication adherence in 
young adults with perinatally-acquired HIV. The study found there was a small to 
medium effect size for difference in motivation to adhere between adherent and non-
adherent episodes (d=0.38). There was a large effect size for the difference in 
behavioural skills between episodes (d=0.91). Therefore, to allow, both constructs to 
be examined together in the current study, the minimum number of participants 
required was 56 based on the smaller effect size. 
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Inclusion/ Exclusion Criteria 
Inclusion criteria for the study was partly based on national eligibility for PrEP (NHS 
England, in press): 
 
• HIV negative status 
• Clinically assessed and deemed to be at high risk of HIV acquisition 
• MSM or transgender women who have sex with men 
• At least 16 years of age. 
 
Other inclusion criteria included: 
• Following a daily dosing regimen 
• Prescribed and taking oral PrEP medication for at least three months.  
• Must have shown inconsistent adherence in the previous month, that is, had 
one day when a dose was taken and one day when a dose wasn’t taken within 
the last month  
• Participants had to be under the care of an outpatient clinic where the research 
was conducted. 
• Able to read English to understand and respond to questionnaire items. 
 
The exclusion criteria were: 
• Individuals deemed by the clinical team as not having the capacity to consent 
or to have emotional problems to a degree that might impact their ability to 
engage in the questionnaire. 
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Participants had to have taken PrEP for at least three months to ensure the study 
examined factors related to general PrEP adherence as opposed to habit formation. 
A non-adherent episode was determined by asking participants if they had one day in 
the last month where they did not take their PrEP medication. In context of a daily-
dosing regimen the study used one missed dose as a marker for non-adherence. This 
definition was seen as way to maximise recruitment when compared to using the 
suggested level needed for PrEP effectiveness (four doses a week) as a marker for 
non-adherence (Grant, 2014). The period of one month was decided to balance the 
needs between using a shorter interval (to improve recall of the adherent/non-adherent 
episode) with a longer interval (to capture less frequent non-adherent episodes). 
Literature suggests that when collecting self-report medication adherence data an 
estimated adherence over 30 days may be the best time frame to balance the needs 
of shorter and longer intervals (Stirrat et al, 2015).  Previous research has shown that 
self-reported antiretroviral adherence may be more accurate (i.e. less over-reporting) 
when one-month recall periods are used compared to three or seven-day periods (Lu 
et al, 2008).  A recent PrEP implementation study (which measured adherence 
through biological and self-report methods) suggested that MSM can provide accurate 
self-report data over a 30-day period (Landovitz et al, 2017).  Lastly, recall of a specific 
adherent/non-adherent episode may be more reliable and valid than estimates of 
behaviour over a longer period (Wilson, Carter & Berg, 2009).  
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Characteristics of the sample 
Demographic information of the 67 recruited participants is presented in Table 8. 
Table 8: Demographic Information 
Variable   
Age Mean (sd) 37.1 (10.2) 
 Median (IQR, range) 35.4 (30-45, 18-62) 
Occupational Status Employed Full Time  57 
 Employed Part Time  4 
 Unemployed 0 
 Student Full Time 1 
 Student Part Time  1 
 Retired  1 
 Other  3 
Highest educational  GCSE/O-level 5 
qualification A level/BTEC 11 
 Degree level qualification 25 
 Postgraduate qualification 26 
Ethnicity White 55 
 Black 1 
 Asian 3 
 Mixed 4 
 Other 4 
Born in UK? Yes 35 
 No 32 
Relationship status  Single 46 
 Partner, living together 15 
 Partner, living separately 6 
Number of sexual partners (any 
type of sex) in the last month 
Mean (median, IQR) 8.2 (3, 2-4) 
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Measures 
Questionnaire Development  
Detailed quantitative questionnaire data collection for both a specific adherent and 
non-adherent episode was obtained for each participant. There are no existing 
measures of psychological or situationally specific predictors of PrEP adherence. 
Therefore, to measure correlates of adherence a questionnaire was developed based 
on the IMB Skills Model questionnaire also known as the Life Windows Questionnaire 
measure (LW-IMB-AAQ) (Life Windows Project Team, 2006). The original 33-item 
scale questionnaire was developed for adults to measure adherence, specifically, IMB-
related adherence barriers and facilitators (Appendix 7). Hawkins et al (2016), adapted 
this measure to explore situationally specific (episodic) medication adherence in young 
adults with perinatally-acquired HIV. This resulted in reducing the number of items to 
specifically focus on items that could vary situationally and a further reduction of items 
due to reliability analysis. The Life Windows measure includes nine information items 
which was reduced by Hawkins et al (2016) to three (adherent episode α = 0.98; non-
adherent episode α = 0.71), ten motivation items which were reduced to seven 
(adherent episode α = 0.87; non-adherent episode α = 0.85) and fourteen behavioural 
items which were reduced to ten (adherent episode α = 0.71; non-adherent episode α 
= 0.83).  
For the current study, the items used by Hawkins et al (2016) were adapted for the 
target group (PrEP users). This was done through consultation between the author 
and internal supervisor, reviewing the literature (e.g. Shrestha et al (2016) which was 
the first study to empirically test and highlight the utility of the IMB model within the 
PrEP population) and service user feedback (described below). For example, some 
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items were rephrased to be relevant to PrEP, “I knew how taking the medication could 
make me feel” was modified to “I knew how taking PrEP could make me feel”.  
Relevant behavioural and information items within the IMB subscales were added for 
example, type of sexual activity (behavioural) and perceived judgement from others 
regarding PrEP use (information) at the time/on the day of the episode. Items were 
also added to reflect the sexually active target population for example, participant’s 
beliefs about how PrEP would impact their enjoyment of sex. Lastly, a question asking 
the length of time since the adherent/non-adherent episode was added to gauge the 
potential impact of recall bias.  
 
Service User Development 
Service user feedback was used to assist questionnaire development. Service-users 
were sought by advertising on site 1’s social media page.  Eight individuals contacted 
the author and were sent a copy of the draft questionnaire to give feedback in terms 
of the clarity, relevance, comprehensiveness and any other comments. This resulted 
in written feedback from eight individuals (2 HIV positive, 6 HIV negative) and led to 
adaptations to increase relevance for example, changing the names of street drugs, 
and formatting.   
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Final Questionnaire Items 
The final questionnaire (prior reliability analysis) can be found in Appendix 10. 
Background Data 
At the beginning of the questionnaire background data were collected including 
descriptive demographic details (i.e. age, occupational status, education, ethnicity, 
country of birth, relationship status and living situation), number of sexual partners in 
the last month, length of time PrEP taken, how PrEP was obtained, whether the person 
had a daily routine for PrEP use, clinic attended for PrEP monitoring, number of times 
PrEP had been taken in the last seven days, whether the person experienced side 
effects and whether these were distressing.   
 
Adherent and Non-adherent episodes 
For each adherent or non-adherent episode, participants were asked to think about a 
time when they did or did not take their medication. Guided by the Cognitive Interview 
to facilitate memory recall, participants were asked to try to recall details about this 
day for example, where they were or how they felt. The Cognitive Interview refers to 
techniques used to enhance eyewitness memory (as opposed to cognitive 
interviewing, a technique used in scale development) (Fisher et al, 1987).   
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Situational Context 
The following behavioural factors were assessed for each episode. Multiple questions 
were asked with a mixture of categorical and scale responses.  These included:  
 
• Day of the week 
• How many days ago the episode was 
• Whether another person or other prompts were there to remind them about 
the medication (yes/no) 
• Routine (if usual day or routine different to normal due to planned or 
unplanned activity) 
• Location (if at home; friend’s house; partner’s house; a public place such as 
work or college) 
• Whether other people were present and, if so, who (alone; friend; partner; 
family; acquaintance; work colleague) 
• If not alone, whether the other people present knew about the person taking 
PrEP (yes/no) 
• Whether street drugs or alcohol were used around the time of medication 
(yes/no). 
• How likely they thought sex was going to take place that day (5-point Likert 
scale; very unlikely, unlikely, neither likely or unlikely, likely or very likely) 
• Whether they did have sex (yes/no) 
• To what extent the individual felt they were at risk of HIV without taking PrEP 
(5-point Likert scale; very unlikely, unlikely, neither likely or unlikely, likely or 
very likely) 
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• If the individual did have sex that day; did they use a condom (yes/no), was it 
chemsex (yes/no), the HIV status of their sexual partner 
(negative/positive/don’t know), sexual positioning/activity (anal insertive/anal 
receptive/oral sex/other) and whether the partner was a casual or regular 
partner.  
 
In the non-adherent episode participants were asked two additional situational 
questions;  
• Whether non-adherence was intentional or due to forgetting (I forgot/I 
chose not to take my medication).  
• If the individual did have sex that day, they were asked if they used 
PEP medication (yes/no). 
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IMB Constructs and Reliability of Subscales 
The IMB constructs were measured by scale questions rated on a 5-point Likert scale. 
Each item was introduced with “At the time I was due to take my PrEP” and presented 
as a statement. Responses included ‘very unlikely’, ‘unlikely’, ‘neither likely or unlikely’, 
‘likely’ or ‘very likely’. This included 30 items in total (five items examined information, 
fourteen related to motivation and eleven items measured subjective behavioural skill). 
After the internal consistency for each subscale was assessed each subscale was 
refined to improve their psychometric properties. The five information items were 
reduced to three (adherent episode α = 0.79; non-adherent episode α = 0.77), the 
fourteen motivation items were reduced to thirteen (α = adherent episode α = 0.86; 
non-adherent episode α = 0.84) and the eleven behavioural items were reduced to ten 
(adherent episode α = 0.85; non-adherent episode α = 0.85). This suggests each 
subscale had either an acceptable or good level of reliability (Field, 2013). 
Mood 
Other situational variables included positive and negative affect at the time of each 
episode. The same items were used as those within The International Positive and 
Negative Affect Schedule Short Form (I-PANAS-SF) questionnaire (Thompson, 2007) 
shown to be reliable and valid within adult populations (Thompson, 2007).  This scale 
has two five-item subscales (positive and negative affect) and uses a five-point Likert 
scale (very slightly or not at all to extremely). The current study used the I-PANAS-SF 
to measure affect (adherent episode: positive affect α = 0.83, negative affect α = 0.83; 
non-adherent episode: positive affect α = 0.92, negative affect α = 0.85). These items 
were introduced with the sentence ‘How did you feel when it was time to take your 
PrEP?’.  
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Study Procedure  
A diagram of the study procedure can be found below (see Figure 3). 
Potential participants were approached by their clinician, research nurse or by the 
author (author approached at site 1 only as approved by ethics) and told about the 
study. At site 1 clinic, the author approached all individuals whom had attended an 
Impact group consent meeting. The author also attended general sexual health clinics 
and monthly PrEP clinics where an allocated clinician told all individuals on their clinic 
list about the study and were signposted to the author. At recruitment site 2, all 
DISCOVER participants were approached by a research nurse. Across sites, eligibility 
was assessed by their clinician, research nurse or by the author (author assessed at 
site 1 only).  
Eligible participants were given a paper information sheet which detailed further 
information about the study and researcher contact details. Interested and eligible 
individuals were then consented to participate by a research nurse (site 2 only) or the 
author. Participants had the option to complete the questionnaire on paper, online, 
through skype or telephone or were given a hard copy with a self-addressed envelope 
(SAE). Participants were allocated a unique study number linked to their date of birth 
to maintain confidentiality and anonymity of responses.  
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Figure 3: Study Procedure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
First Approach: individuals approached by clinician/research nurse or author 
 (author approaches directly at site 1 only) 
Consent form and questionnaire completed on paper or 
online in clinic with author. Or participant chooses to 
complete questionnaire later either online, through skype or 
phone, or they are given a hard copy form with a SAE. 
 
If individual is interested clinician/research nurse or author assesses eligibility 
(author assesses at site 1 only) 
If eligible, clinician/research nurse or author gives paper information sheet  
  
No further action. With the paper 
information sheet the individual has the 
option to complete the consent form and 
questionnaire online or contact the 
author. 
Clinician/research nurse has signed the 
delegation form (i.e. has ethical approval 
to administer the questionnaire 
themselves) 
Consent gained and paper 
questionnaire completed in clinic 
with clinician/research nurse. 
 
Author present in clinic 
Participant directed to author to continue. 
Clinician/research nurse has not signed 
the delegation form (i.e. does not have 
ethical approval to administer the 
questionnaire themselves) 
 
 
Author not present in clinic 
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Ethics and Ethical Issues  
The study was given NHS approval by the London-Surrey Borders Research Ethics 
Committee and approved by the Health Research Authority.  The study gained ethical 
approval from the Royal Holloway University of London (RHUL) College Ethics 
Committee (for approval letters, see Appendices 1-4 and 6). Confirmation of Capacity 
and Capability was gained within each recruitment site NHS trust. The main ethical 
issues were gaining client consent, confidentiality and data storage which was covered 
in the Participant Information Sheet and consent forms (please see appendices 8-9). 
A non-substantial amendment was made regarding the addition of an NHS recruitment 
site whose participation was confirmed post ethical approval. A substantial 
amendment was made so that members of the clinical team at recruitment sites could 
(once they had assessed eligibility) gain consent and administer the questionnaire 
themselves. Once approved, (please see appendix 5) all staff who agreed to do so, 
signed a delegation form in front of the principal investigator at each clinic as required. 
All staff on the delegation form had experience of gaining consent and administering 
questionnaires as part of their clinical role. 
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Analysis 
Analysis was carried out in SPSS Statistics, version 21 (IBM Corp, 2012). Data was 
screened for normality and descriptive analysis were conducted; for normally 
distributed data, means were used and for non-normally distributed data, the median 
and inter-quartile range was used.  The distributions of the difference scores for 
continuous variables were tested for skew and kurtosis to determine whether normality 
could be assumed and if parametric statistics could be used (Field, 2013). 
Bivariate analysis 
Bivariate comparisons were conducted between episodes of adherence and non-
adherence. There were seven constructs within the analysis including; Information (1), 
Motivation (2) and Behavioural skills (3) (from the IMB model), affect (positive (4) and 
negative (5)), beliefs about the likelihood of sexual activity (6) and actual levels of sexual 
activity (7). An overall total score was calculated for each construct with multiple 
questions.  Paired t-tests (for continuous variables that met assumptions for parametric 
statistics) or McNemar’s chi-squared tests (for categorical variables, using Fisher’s 
exact estimates for expected frequencies <5) were used to demonstrate possible 
differences on ratings of affect as well as situational, motivation and behavioural skills 
factors between adherent and non-adherent episodes. Uncorrected McNemar values 
were used (i.e. without Yates correction). This is recommended as a more conservative 
measure when conducting analysis of the independent 2x2 table (Fagerland, Lydersen, 
& Laake, 2013). If normality could not be assumed for continuous variables then paired 
t-tests with bootstrapping was planned. Effect sizes were calculated using Cramer’s phi 
(ϕ) for categorical variables and Cohen’s d for comparisons of means for continuous 
variables (Cohen, 1992). Conventions for Cohen’s d are as follows: .20 – small effect; 
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.50 – medium effect; .80 – large effect) and Cramer’s phi values for 2x2 contingency 
tables indicate effect sizes as follows: .10 – small; .30 – medium; .50 – large (Cohen, 
1992). The exploratory nature of the current research has implications for multiplicity 
corrections (i.e. the use of Bonferroni corrections) needed to control for the increased 
likelihood of Type I error in this study design (Bender & Lange, 2001). However, the 
current study was not conducting multiple exploratory analyses on the same constructs 
(e.g. one paired t-test was conducted for whether location differentiated adherent and 
non-adherent episodes) therefore, Bonerroni corrections were not conducted.   
 
Multivariate analysis 
Conditional logistic regression analysis investigated whether more than one 
independent variable in combination predicted the dependent variable as well as to 
investigate independent relationships with adherence. Variables were included 
dependent on their significance in the bivariate analysis (defined as a p-value >0.05) 
and relevance to the IMB model.  
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Results 
Sixty-seven participants completed a paper version of the questionnaire during their 
clinic appointment (i.e. no-one completed the questionnaire online or via skype), Table 
9, below, presents the descriptive PrEP-related information of the sample.  Due to 
small cell sizes for some categories, some variables are grouped.  
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Table 9: Descriptive PrEP-related information  
Variable  N(%) Grouped 
Categories 
Length of time PrEP 
taken 
3-4 months 18 (27)  
5-8 months 13 (19)  
 9-12 months 10 (15)  
 1 year+ 26 (39)  
How PrEP obtained Online 44 (66) Online  
44 
 Research/Study  
Participant  
14 (21) Research/Study  
Participant  
14 
 Private Prescription 7 (10) Other  
9  Friend 2 (3) 
Daily routine for PrEP Yes 60 (90)  
No 5 (7)  
 Missing 2 (3)  
Clinic attended for  Site 1 61 (91)  
PrEP monitoring Site 2 6 (9)  
How many times PrEP  
taken in the  
last 7 days 
0  4 (6) 0 doses: 4 
1  1 (2) 1-3 doses 
2  1 (2) 2 
3 0   
 4 3 (4) 4-6 doses 
 5  1 (2) 19 
 6  15 (23)  
 7  40 (61) 7 doses: 40 
Current experience of 
side effects  
Yes 7 (10)  
No 60 (90)  
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Categorical Variables: Data exploration and grouping 
Table 10 below, presents the frequencies of responses for non-adherent and adherent 
episodes for categorical variables.  Due to small cell sizes for some categories some 
variables were grouped. The mean number of days prior to the adherent episode was 
2.6 days (SD= 3.05) and 11.9 days (SD= 10.06) for the non-adherent episode. 
 
Table 10: Categorical variables between adherent and non-adherent episodes (n=67) 
Variable  Adherent episode 
 (frequencies) 
Non-adherent episode 
 (frequencies) 
Use of 
Reminders  
Yes 27  19  
No 39  47  
Missing 1  1  
Weekday  Monday 14 Mon-Fri  
 55 
3 Mon-Fri 
43  Tuesday 5 10 
 Wednesday 10 13 
 Thursday 16 12 
 Friday 10 
 
4  
 Saturday 3 Sat-Sun  
7 
9 Sat-Sun  
20  Sunday 4 11 
Missing 5  4  
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Variable  Adherent episode 
 (frequencies) 
Non-adherent episode 
 (frequencies) 
Normality of 
Day 
Normal 62 Normal 
62 
41 Normal 
41 
 Not normal: 
unexpected 
3 Not normal  
5 
10 Not normal  
26 
 Not normal: 
planned 
2 12 
 Other 0  4  
Location  Own home 59 Own home  
15 
42  Own home  
42 
 Partner’s home 1 Somewhere 
Else 
8 
0 Somewhere 
Else  
25 
 Friend’s home 0 6 
 Public place 5 7 
 Somewhere else 2 12 
Who with at 
time of 
dose/missed 
dose 
Alone 53 Alone 
 53 
42 Alone  
42 
Friend 2 Not alone  
14 
7 Not alone  
25 Partner 7 6 
Family 2 3 
Acquaintance 0  1  
Work colleague 2  5  
Someone else 1  3  
Did person 
know about 
PrEP use? 
Yes 13  19 
No 1 6 
Not Applicable 56 44 
Substance use Yes 6  14  
No 59  51  
Missing 2  2  
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Variable  Adherent episode 
 (frequencies) 
Non-adherent episode 
 (frequencies) 
Sex (any type) 
that day 
Yes 21  15  
No 46 52 
Did sexual 
partner know 
about PrEP 
use? 
Yes 13  11  
No 8 4 
Not Applicable 46 52 
Use of condom Yes 1  0  
No 20 15 
Not Applicable 46 52 
Chemsex Yes 3  5  
No 18 10 
Not Applicable 46 52 
HIV status of 
sexual partner 
HIV negative 7  7  
HIV positive 5 3 
Not known 9 5 
 Not applicable 42  56  
Type of sex: 
Top 
Yes 13  12  
No 8 3 
Not Applicable 46 52 
Type of sex: 
Bottom 
Yes 13  8  
No 8 7 
Not Applicable 46 52 
Type of sex: 
Oral 
Yes 16  8  
No 5 7 
Not Applicable 46 52 
Type of sex:  
Other  
Yes 0  1  
No 21 14 
Not Applicable 46 52 
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Variable  Adherent episode 
 (frequencies) 
Non-adherent episode 
 (frequencies) 
Casual or 
regular partner 
Casual 13  12  
Regular 8 3 
Not Applicable 46 52 
Use of PEP Yes   2  
No  13  
Not Applicable  52  
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Continuous variables: Data screening and descriptive statistics 
Descriptive statistics for psychological variables and somatic symptoms for both 
episodes are presented in Table 11 below.  
 
Table 11: Within-participant descriptive data for psychological variables and 
somatic symptoms per episode 
Variable (minimum-
maximum score) 
Episode Median 
(IQR) 
Mean SD 
Information 
(3-15) 
Adherent 15 
(14-15) 
14.36 
 
1.14 
Non-adherent 15 
 (13-15) 
14.09 1.38 
Motivation  
(13-65) 
 
Adherent 54 
(47-61) 
53.75 7.6 
Non-adherent 54 
 (48-61) 
54.1 8.05 
Behavioural Skills  
(10-50) 
Adherent 44  
(40-49) 
44.16 4.97 
Non-adherent  42.5 
(38.25-48) 
42.39 6.17 
Positive Affect 
 (5-25) 
Adherent 16 
 (12-20) 
15.82 5.47 
Non-adherent 14 
(9-19.5) 
14.42 6.27 
Negative Affect  
 (5-25) 
Adherent  5 
 (5-6) 
6.14 2.51 
Non-adherent  5 
 (5-7) 
6.4 2.53 
Somatic symptoms 
“I didn’t feel ill” 
(1-5) 
Adherent   5 
  (4-5) 
4.57 0.66 
Non-adherent   5 
  (4-5) 
4.38 0.97 
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Exploratory bivariate analysis: 
Relationships between behavioural situational factors and adherence 
 
Day of the week  
Participants were more likely to adhere on a weekday and not on the weekend, 
compared to the reverse pattern. The difference in this pattern was significant with a 
medium effect size (χ2=6.37, p=.01; ϕ= .33)  
 
Table 12: Frequencies for “Day of the week” 
 Non-adherent episode 
Adherent 
episode 
 Weekday Weekend          Total 
Weekday 38 15 53 
Weekend 4 3 7 
Total 42 18 60 
 
Use of Reminders 
Eleven people reported having used reminders to prompt them to take their medication 
at the time of adherent episode and not at the time of non-adherent episode, only three 
people reported the opposite pattern. The difference in this pattern was significant with 
a small to medium effect size (χ2=4.57, p=.03; ϕ =.26). 
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Table 13: Frequencies for "Use of Reminders” 
Non-adherent episode 
 
 
 
Adherent 
episode 
 
 
Used 
reminders 
No   
reminders Total 
Used 
reminders 16 11 27 
No 
reminders 3 36 39 
Total 19 47 66 
 
Normality of the day 
Twenty-five people reported an adherent episode on a normal day and a non-adherent 
episode on a day that was not normal, only four people reported the opposite pattern. 
The difference in this pattern was significant with a medium to large effect size, 
(χ2=15.2, p= <.001; ϕ =.48). 
 
Table 142: Frequencies for “Normality of the day” 
                              Non-adherent episode 
Adherent 
episode 
 
Day was 
normal  
Day was not 
normal 
        Total 
Day was normal 
37 25            62 
Day was not 
normal 
4 1             5 
Total 41 26            67 
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Location 
Two people reported being somewhere else at the time of the adherent episode and 
at home at the time of non-adherent episode; nineteen people reported the opposite 
pattern. The difference between these was significant with a medium to large effect 
size, (χ2=13.76, p= <.001; ϕ =.45).  
 
Table 15: Frequencies for “Location” 
                                      Non-adherent episode 
 
Adherent 
episode 
 Own Home Somewhere Else Total 
Own Home 40 19 59 
Somewhere Else 2 6 8 
Total 42 25 67 
 
Who with at time of dose/missed dose 
Five people reported being with someone else at the time of the adherent episode and 
alone at the time of non-adherent episode; sixteen people reported the opposite 
pattern.  The difference between these was significant, representing a small to medium 
effect size (χ2=5.76, p=0.02, ϕ = .29).   
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Table 16:  Frequencies for “Who with at time of dose/missed dose” 
Non-adherent episode 
Adherent 
episode 
 Alone With someone Total 
Alone 37 16 53 
With someone 5 9 14 
Total 42 25 67 
 
Substance Use 
Ten people reported that were not using substances (alcohol or drugs) at the time of 
the adherent episode and were at the time of non-adherent episode; two people 
reported the opposite pattern.  The difference, between these was significant, 
representing a small to medium effect size (χ2=5.33, p=0.02, ϕ =.29).   
Table 17: Frequencies for “Substance Use” 
Non-adherent episode 
Adherent 
episode 
 Yes No Total 
Yes 4 2 6 
No 10 49 59 
Total 14 51 65 
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Sex that Day 
Fourteen people reported having sex on the day of the adherent episode and not on 
the day of the non-adherent episode; eight people reported the opposite pattern.  The 
difference between these was not significant, representing a small effect size (χ2=1.64, 
p= 0.20, ϕ = .16).   
 
Table 18: Frequencies for “Sex that day” 
           Non-adherent episode 
 
 Yes No Total 
Adherent 
episode 
Yes 7 14 21 
No 8 38 46 
Total 15 52 67 
 
 
Somatic Symptoms 
Bivariate comparisons between episode on the measures of somatic experience were 
carried out using bootstrapped paired t-tests as the difference score was not normally 
distributed.  There was no significant difference in reports of “I felt ill” between episodes 
.18, 95% BCa CI [0, .38], (t(62)= 1.59, p =0.13). 
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Theory-driven Bivariate Analysis 
Information 
On average, participants scored higher on the information subscale during the 
adherent episode (mean= 14.37, SE= 0.14) than the non-adherent episode (mean= 
14.10, SE= 0.18). This difference, 0.27, 95% BCa CI [0.05, 0.51], was significant 
between episodes: participants rated their perceived knowledge about medication use 
more highly at the time of taking their medication than when they missed their 
medication t(62) = 2.21, p = 0.04, representing a small-sized effect d= .28. 
 
Motivation 
On average, participants scored lower on the motivation subscale during the adherent 
episode (mean= 53.51, SE = .95) than the non-adherent episode (mean= 54.1, SE= 
1.01). This difference, -.59, 95% CI [-1.56, 0.38], was not significant (t(62) = -1.21, p = 
0.23, d= 0.15).  
 
Behavioural Skills 
On average, participants rated their behavioural skills in taking PrEP higher at the time 
of the adherent episode (mean= 43.98, SE= 0.62) than at the time of the non-adherent 
episode (mean= 42.39, SE= 0.77). This difference, 1.59, 95% CI [0.68, 2.5], was 
significant t(63)= 3.5, p = <.001,  representing close to a medium-sized effect d= 0.44. 
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Affect 
On average, participants scored higher on the positive affect subscale during the 
adherent episode (mean= 16.10, SE= 0.67) than the non-adherent episode (mean= 
14.37, SE= 0.78). This difference, 1.73, 95% BCa CI [0.76, 2.73], in positive affect was 
significant between episodes: t(62) = 3.21, p = 0.002, representing close to a medium 
sized effect d= .41. 
 
On average, participants scored lower on the negative affect subscale during the 
adherent episode (mean= 6.15, SE= 0.31) than the non-adherent episode (mean= 6.4, 
SE= 0.31). This difference, -.25, 95% CI [-.76, .27], was not significant (t(64) = -.95, p 
= 0.35, d= 0.12). 
 
Theory-Driven Exploratory Multivariate Analysis 
Multivariate analysis was conducted to investigate the combined and independent 
contribution of the significant IMB predictors (information and behavioural skills) of 
non-adherent episodes. The IMB model also includes mental health alongside the 
central IMB variables. As there was a significant bivariate relationship between 
positive affect (conceptually related to mental health) and adherence, positive affect 
was added as an independent variable in the multivariate analysis. The outcome 
variable was dichotomous (adherent or non-adherent episode) and repeated, 
therefore a conditional logistic regression (CLR) model was used (Tabachnik & Fidel, 
2006).  
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Correlations between behavioural skills, information and positive affect were 
investigated as an initial test for potential mulitcollinearity problems.  To be problematic 
in CLR, correlation coefficients would need to be greater than 0.70 (Chatterjee & Hadi, 
2015). Behavioural skills and positive affect were significantly correlated for both 
adherent (r=.255, p= .04) and non-adherent (r=.449, p= <.001) episodes.  There was 
no correlation between information and positive affect for either adherent (r=.17, 
p=.18) or non-adherent (r=.241, p=.05) episodes. Behavioural skills and information 
were significantly correlated for both adherent (r=.541, p= <.001) and non-adherent 
(r=.604, p= <.001) episodes. These statistics suggested there may not be a 
multicollinearity issue with these variables. 
 
 
 
 
 
 
 
 
 
 
 
126 
 
CLR model  
The CLR assumptions were tested for this model (Table 19): VIF and tolerance values 
were both close to 1; Pearson’s standard residuals demonstrated no values higher 
than 3; DfBeta measure of leverage were not above 1, therefore no assumptions were 
violated. 
Table 19: CLR Model with information, behavioural skills and positive affect 
 
B Std. Err. 
 
Sig. Exp(B) 95% Confidence Interval 
Information -.76 .449 
 
.09 .47 .20 1.13 
Behavioural Skills -.30 .132 
 
.02 .74 .57 .96 
Positive affect -.15 .097 
 
.13 .86 .71 1.05 
 
An overall model including information, behavioural skills and positive affect was 
significantly predictive of adherent episode (χ2(3)= 14.723, p=.002).  After controlling 
for shared variance between information, behavioural skills and positive affect, there 
was not an independent relationship between information and non-adherent episode 
(AOR=0.47, 95%CI 0.20-1.13, p=0.09) or positive affect and non-adherent episode 
(AOR= 0.86, 95%CI 0.71-1.05, p=0.13). There was an independent relationship 
between behavioural skills and non-adherent episode (AOR=0.74, 95%CI 0.57-0.96, 
p=0.02) with lower behavioural skills scores associated with non-adherence. 
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Discussion 
Overview of study findings 
This study aimed to explore the situational psychological and behavioural factors 
which differentiate episodic PrEP adherence and non-adherence amongst MSM at 
high-risk of HIV acquisition. Lower reported information (small effect size), behavioural 
skills (small to medium effect size) and lower positive affect (close to a medium effect 
size) were associated with non-adherent episodes in bivariate analysis. Multivariate 
analysis including information, behavioural skills and positive affect was significantly 
predictive of non-adherent episodes, although only behavioural skills was statistically 
significant independently. Negative affect or motivation was not related to non-
adherence in bivariate analysis. Multiple behavioural factors were associated with 
PrEP non-adherence; non-normality of the day, being out of the home (close to large 
effect sizes), weekend days (medium effect size), lack of reminders, not being alone 
and substance use (close to medium effect sizes).     
 
Behavioural skills  
The finding that adherence was related to higher levels of behavioural skills is 
consistent with the IMB model which theorises a direct pathway from PrEP-related 
behavioural skills and adherence behaviour. Behavioural skills in the IMB model 
includes the objective and perceived abilities (i.e. self-efficacy) to self-cue and self-
administer PrEP, incorporate PrEP into everyday life and cope with side-effects 
(Fisher et al, 2006).  The current finding is consistent with IMB’s theoretical notion that 
behavioural skills are the most proximal factor and critical prerequisite to adherence 
behaviour (Fisher, Amico, Fisher & Harman, 2008). This result was also consistent 
with the findings from Shrestha et al (2016) conducted earlier in the PrEP cascade 
128 
 
which showed that willingness to use PrEP was mainly predicted by behavioural skills. 
Behavioural skill has shown to be related to ART medication adherence cross-
culturally in HIV positive populations (Amico et al, 2005; Horvath, Smolenski, & Amico, 
2014; Starace et al, 2006). The current finding also suggests that behavioural skills 
differ situationally. This is consistent with findings using a similar within-participant 
methodology, with young adults with perinatally-acquired HIV and adults with Beta-
Thalassaemia-Major (i.e. that adherence was related to higher levels of behavioural 
skills) (Hawkins et al, 2016; Vosper et al, in press).  Bandura (1986) theorised that in 
situations with increased challenges to achieve a behaviour (e.g. adherence), 
increased self-efficacy helps to promote an individuals’ efforts and persistence to 
problem solve. Increased behavioural skills (inlcuding self-efficacy) therefore could 
have helped promote adherence when participants faced situational challenges   
  
 
Information and Motivation 
Adherence was related to higher levels of information in bivariate analysis but this did 
not retain significance in multivariate analysis. Adherence was not associated with 
other key constructs (motivation) in the IMB model. This is inconsistent with the IMB 
model that posits adherence-related information and motivation are associated with 
adherence-related behavioural skills and are key components necessary for 
adherence (Fisher et al, 2006). However, the current finding is consistent with 
Shrestha et al (2016) whom found that willingness to use PrEP was not predicted by 
information or motivation. It is also consistent with findings where the IMB model has 
been applied to ART adherence (Amico et al, 2009; Horvath, Smolenski, & Amico, 
2014; Santillán et al, 2015; Starace et al, 2006). Furthermore, studies using a similar 
within-participant methodology, found no relationship between information and 
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motivation and ART adherence (Hawkins et al, 2013) and no relationship between 
motivation and chelation adherence (i.e. treatment for Beta-Thalassaemia-Major) 
(Vosper et al, in press). This finding might suggest that information and motivation may 
not be sufficient for PrEP adherence. These components may not have a direct impact 
on adherence behaviour when adherence requires multiple behavioural skills. 
 
Information and motivation may not differ situationally and both constructs been shown 
inconsistent relationships with other HIV-related health behaviours (e.g. protected anal 
intercourse) amongst high risk MSM (Kalichman, Picciano, & Roffman, 2008). 
Additionally, the review highlighted two studies which reported inconsistent findings 
regarding the relationship between PrEP knowledge and adherence (Liu et al, 2014; 
Liu et al, 2016).  In the current study, the information construct was only measured by 
three items. The lack of differences in scores which meant information did not maintain 
significance in multivariate analysis may have been due to ceiling effects. Due to the 
small sample size and dangers of overfitting (Babyak, 2004) results from the CLR 
model should be interpreted with caution. The information construct had high standard 
errors and confidence intervals, this could mean that findings were imprecise and 
resulted in a type II error.  This would require replication in a larger sample to 
investigate these effects further. It is possible that motivation differs between people 
but not within people. Alternatively, the lack of differences in motivation scores may 
have been due to demand characteristics influenced by the context of PrEP access; 
participants may have felt the need to express their motivation to use PrEP even in 
non-adherent episodes to support PrEP access. The review highlighted that MSM 
PrEP users can feel a social motivation for their PrEP use (i.e. a sense that 
participation and adherence could benefit their social group) (Gilmore et al, 2013; 
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Tangmunkongvorakul et al, 2013). Also, given that PrEP access is relatively novel, the 
sample mainly consists of ‘early adopters’ whom may be highly motivated for PrEP 
use, as reflected in the motivation scores. Additionally, the majority (66%) of non-
adherent episodes were reported to be due to forgetting as opposed to intentional non-
adherence which may explain the lack of differences in motivation between episodes. 
Lastly, the lack of differences in scores for both constructs may be due to the non-
validated scale used in the current study. Despite good reliability, the measurement of 
these constructs may have been imprecise and resulted in a type II error. For example, 
it may difficult to recall or endorse specific beliefs experienced at the time of the 
episode. 
 
Affect  
Non-adherence was associated with lower positive affect in bivariate analyses and 
had no association with negative affect. This is inconsistent with the theoretical IMB 
model which predicts that mental health moderates the central IMB variables. 
However, this finding is consistent with Hawkins et al’s (2016) within-participant study 
which also found lower positive affect was associated with non-adherence to ART 
amongst HIV-positive young adults. An RCT found that a patient education 
intervention enhanced with a positive-affect induction and self-affirmation led to 
significantly higher medication adherence compared to patient education alone in 
hypertensive African Americans (Ogedegbe et al, 2012). Positive affect and self-
affirmation have shown to influence the acceptance of health messages and adoption 
of positive health behaviours (Armitage et al, 2008). This finding is also consistent with 
Van Cappellen et al (2017) whom theorise an ‘upward spiral’ framework whereby 
positive affect contributes to recursive processes that support health behaviours (i.e. 
positive affect makes behaviours more likely and behaviours reinforced by positive 
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affect are more likely to be maintained). This has been supported by research using 
an ecological momentary assessment (EMA) methodology which found situational 
variations in positive affect were predictive of engagement in exercise (Emerson, 
Dunsiger & Williams 2017). One criticism of the I-PANAS-SF used is that it only 
measures one dimension of positive affect. This measure has been critiqued for only 
measuring ‘activated’ positive affect (e.g. enthusiastic and inspired) as opposed also 
incorporating ‘non-activated’ positive affect (e.g. content and satisfied) (Peterson et al, 
2013). This could have influenced positive affect scores (i.e. caused a reduction of 
differences in scores) which meant it did not maintain significance in multivariate 
analysis. Alternatively, positive affect also had relatively high standard errors and 
confidence intervals which could mean that findings were imprecise and resulted in a 
type II error. This may why explain positive affect did not retain significance in 
multivariate analysis and would require replication in a larger sample to investigate 
potential effects further. In relation to negative affect, this finding was inconsistent with 
studies that found depressive scores were associated with PrEP non-adherence 
amongst transgender women (TGW) who have sex with men (Mehrotra et al, 2015) 
and affective factors including depression acting as barriers to ART adherence 
(Uthman et al 2014). Results may be representative of the MSM PrEP-using 
population as they are not a depressed sample. Alternatively, a floor effect may have 
occurred as participant negative affect scores were clustered at the minimum possible 
score which could have resulted in a type II error (Martin, Bateson & Bateson, 1993).  
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Behavioural situational variables 
Several situational behavioural variables were also related to non-adherence. This 
finding is consistent with within-participant research findings that non-adherence was 
associated with situational behavioural variables not included in the IMB model; lack 
of routine, being out of the home and weekend days (Hawkins et al, 2016; Vosper et 
al, 2013). It is also consistent with the current review findings that having an 
established routine and use of reminders facilitated adherence whilst frequent travel, 
not being at home and busy lifestyles acted as a barrier to PrEP adherence (Gilmore 
et al, 2013; Hosek et al, 2013; Mugo et al, 2015; Storholm et al, 2017; 
Tangmunkongvorakul et al, 2013). Furthermore, it is consistent with studies with HIV-
positive individuals which found lifestyle factors (e.g. changes to daily routine or being 
away from home) can negatively influence ART adherence (Shubber et al, 2016). The 
current findings could be indicative that non-adherence is more likely when an 
individual’s usual routine is disrupted. When out of the home MSM may not have 
access to PrEP and/or lack access to usual memory cues to take their medication (i.e., 
it’s more difficult to plan and act on the intention to adhere). This disruption in routine 
may be most likely at the weekend and/or when substances are used.  Of interest, 
most studies examined in the review found no relationship between substance use 
and PrEP adherence (Grant et al, 2014; Landovitz et al, 2017; Liu et al, 2014; Liu et 
al, 2016; Mugo et al, 2015). However, comparisons between current and review 
findings are limited as the current study used a sub-set of the PrEP taking population 
(i.e. MSM with inconsistent adherence) whereas those in the review used a between-
participant design and included all PrEP users. MSM may be less likely to take PrEP 
when others are present due to fear of stigmatisation as highlighted in PrEP studies 
examined in the review (e.g. anticipated fear the individual will be perceived as 
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sexually promiscuous) (Arnold et al, 2017; Gilmore et al, 2013; Tangmunkongvorakul 
et al, 2013). Of interest, during 19 out of 25 non-adherent episodes and 13 out of 14 
adherent episodes where the PrEP user was not alone, the other person was aware 
of PrEP use (i.e., it suggests that non-adherence in the presence of someone not 
aware of the PrEP use is more common that adherence in the presence of someone 
not aware of the PrEP use). This may suggest that disclosure of PrEP use to others 
alone may not necessarily make it easier to take PrEP medication if their routine is 
disrupted (e.g. they are away from home) which may affect PrEP adherence. Overall, 
differences in behavioural factors between adherent and non-adherent episodes 
suggests that lifestyle factors which may vary over time and contexts may influence 
PrEP adherence. Sex on the day of the episode was not associated with adherence. 
This was consistent with the review which found that most studies found no 
relationship between MSM PrEP adherence and sexual behaviour (Landovitz et al, 
2017; Liu et al, 2014; Mugo et al, 2015; Sagaon-Teyssier et al, 2016; 
Tangmunkongvorakul et al, 2016). Future research could investigate numerous 
adherent and non-adherent episodes using daily diaries/EMA over a period of time to 
gain a more representative picture of the predictors (including sex) related to PrEP 
adherence. 
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Limitations 
There are no validated situational measures available to measure adherence 
cognitions. The validity and reliability of the measurement instrument developed in the 
current study should be interpreted with caution. For example, participants were asked 
about retrospective cognitions which could have been susceptible to recall bias. 
However, the items designed to measure the IMB constructs had acceptable to good 
levels of internal reliability for each episode. The overall measure was developed in 
consultation with service-users from the MSM population to explore the clarity, 
relevance and comprehensiveness of the items. The IMB constructs within the 
questionnaire were all highly correlated (not reported in the results section) which is in 
line with the theoretical model. This suggests that IMB items used in the questionnaire 
were measuring IMB constructs.  Also, there were different relationships between each 
construct and adherence, which might support the validity of the measure. 
 
The participants were recruited from two London sexual health clinics. This may 
suggest that the current findings may have limited generalizability to other 
geographical areas or people with similar access to health-care services. The sample 
were highly educated, mainly actively sought PrEP through online methods and had 
high levels of self-reported adequate adherence observed (i.e. 91% achieved 4 or 
more doses in the previous week). This suggests that participants may have been a 
highly motivated sample. Furthermore, the sample were a sub-set of the PrEP taking 
population (i.e. those who showed inconsistent adherence rather than all PrEP users) 
and may not be representative of the wider MSM population, limiting the 
generalisability of findings. This means that the predictors of PrEP adherence 
identified in the current study may differ in the wider MSM population. Therefore, when 
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delivering adherence interventions although current findings give clinicians some 
direction about what they could focus on predictors would have to be tailored to the 
individual. However, when compared to the UK PROUD RCT study the MSM baseline 
characteristics were similar to the current sample. For example, the median age of 
participants for both studies was 35 years, similar numbers were born outside of the 
UK (PROUD 40%, current sample 47%), the majority of participants were university 
graduates (PROUD 61%, current sample 76%) and a minority of participants were 
living with their partner (PROUD 30%, current sample 22%). 
Another limitation was that the study had no objective measure of adherence and 
relied upon retrospective self-report of cognitions and emotions. When giving ratings 
participants already knew that they had not adhered and responses may have suffered 
from retrospective bias or difficulties remembering the specific episodes. However, the 
questionnaire presented behavioural situational questions at the beginning to orient 
participants to the specific episode and used elements of the Day Reconstruction 
Method (Kahneman et al, 2004) to facilitate accurate recall of episodes. Furthermore, 
asking participants about episodes only in the last 30 days may have limited erroneous 
recall. Most participants described recent episodes which occurred an average of 
three (adherent) and twelve (non-adherent) days ago, which may have limited the 
impact of forgetting.  
 
Another criticism was that the questionnaire asked participants about one taken and 
missed PrEP dose which may not be representative of PrEP adherence episodes.  
Additionally, 66% of non-adherent episodes were reported to be due to forgetting as 
opposed to intentional non-adherence. There may be different predictors between 
intentional and non-intentional (i.e. forgetting) non-adherence. Previous research has 
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shown that there were different predictors associated with intentional and unintentional 
non-adherence to ART medication in an adult HIV positive sample (Wroe & Thomas, 
2003). This was not explored in the current study due to not having a large enough 
sample size and could be investigated in future research.  An oversight of the 
questionnaire used was that adherent/non-adherent episodes were not 
counterbalanced. This could have introduced order-effects which could have 
influenced study results (Gravetter & Forzano, 2018). 
 
Research Implications  
There may be different predictors of PrEP use between individuals who achieved 
adequate levels of PrEP protection (i.e. four or more doses of PrEP a week) with 
individuals who did not. Future research with larger samples would allow the 
comparison of predictors between non-clinically significant and clinically significant 
missed PrEP doses. Larger samples would also allow the comparison of predictors of 
intentionally and unintentionally missed doses.  Future research needs to continue to 
examine PrEP adherence amongst diverse populations (e.g. TGW) and MSM 
subpopulations (e.g. Black, Asian and minority ethnic [BAME] MSM) to increase the 
generalisability of findings and delineate specific facilitators/barriers to PrEP use. It 
would also be pertinent to continue to examine the predictors related to PrEP use 
within diverse implementation settings, (i.e. predictors of PrEP adherence amongst 
MSM who have PrEP freely accessible compared to those who self-fund their PrEP) 
across multiple episodes of adherence/non-adherence as well as within different PrEP 
regimens (i.e. event-based dosing).  
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Prospective studies, using EMA of adherence episodes (e.g. using smart-app 
technology to ask individuals questions about episodes through daily text), would 
reduce the reliance upon retrospective memory and could enhance measurement 
reliability and validity (Runyan et al, 2013; Shiffman et al, 2008). Future research could 
explore the feasibility and validity of using this method by comparing this with 
retrospective self-report. This would also allow more than one episode to be measured 
and may give more representative picture of PrEP adherence. Additionally, an 
experimental study randomising MSM PrEP users to either a behavioural skills 
intervention or treatment as usual could help to establish causation.  Findings give 
support to some aspects of the IMB model to help explain PrEP adherence, however, 
also highlight predictors related to PrEP adherence which are not acknowledged within 
the model (i.e. situational behavioural factors such as location or positive affect). 
Future research should incorporate but not be limited to this theoretical model when 
deciding which predictors to investigate in relation to PrEP adherence.   
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Practice Implications 
The findings suggest that across situations people may need different PrEP 
information or behavioural skills to adhere. For example, if outside of their own home, 
it may be particularly important to self-cue the administration of their PrEP medication. 
Alternatively, in a situation where alcohol is present, an individual may require the 
information regarding PrEP’s interactive effects with alcohol (whereas in other 
situations this may not be relevant). The findings suggest that modifiable situational 
psychological and behavioural factors are important for PrEP adherence. Clinically, 
this suggests that assessments of facilitators and barriers of PrEP adherence could 
focus upon situational variations in information, positive affect, behavioural skills and 
behavioural factors (e.g. location, day of the week). The barriers highlighted could then 
be used within a problem-solving based therapy to conceptualise high-risk situations 
for non-adherence and alternative strategies could be co-constructed to facilitate 
adherence in these situations. Advanced planning may take the form of 
implementation intentions (i.e. whereby an individual would plan when and how they 
to enact PrEP adherence in specific situations). Observational studies have shown a 
relationship between these interventions and behaviour (Gollwitzer & Sheeran, 2006). 
In relation to existing PrEP adherence programmes, current findings could help by 
giving conversations a specific focus (e.g. asking about a client’s time spent outside 
of the home). Only one intervention (i.e. ‘Next Step Counselling’ (NSC), a problem-
solving therapy) outlines specific barriers and facilitators to discuss with clients. The 
current findings support the categories used in NSC assessment forms (i.e. asking 
clients regarding their substance use, disruption in routine and use of reminders) 
(Amico et al, 2012). This intervention could be supplemented by the addition of the 
current findings (e.g. asking clients about their positive affect, weekends and days 
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when they are not alone). Findings also support the use of technological (e.g. two-way 
texts) and physical (e.g. pill boxes) methods as reminders used by one intervention to 
facilitate PrEP adherence (Liu et al, 2014). Current findings support WHO guidelines 
(2017) that within PrEP assessment and adherence counselling sessions clinicians 
could support adherence by increasing individuals’ information about their medication 
use (i.e. what to do when forgetting medication, side effects and interactive effects 
with other substances/medications) and behavioural skills (e.g. how to incorporate 
PrEP into their daily routine, acquiring social support and use of reminders). The 
current findings also highlight that affect and other behavioural factors may be 
important for PrEP adherence and therefore interventions should consider focusing 
upon an individual’s mood (specifically positive affect) and certain situations such as 
the weekend, when out of the home or when an individual’s day is not normal. Lastly, 
WHO guidelines (2017) recommend but give no specific guidance regarding how 
differentiated care should be implemented within healthcare settings. The current 
study findings could be used to identify when an individual may be at most at risk of 
non-adherence (e.g. when they report they are regularly out of the home, have low 
behavioural skills or low positive affect) and who may benefit from additional clinical 
support at that time (i.e. adherence interventions).  
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Integration, impact and dissemination plan 
Integration 
The systematic review provided a clear rationale and assisted the development of the 
empirical article. The literature within the review highlighted the problem, that is, the 
issue of PrEP non-adherence amongst MSM and its critical role in effective PrEP 
implementation to reduce HIV acquisition. This provided a clear rationale for the 
systematic review and empirical article which both focused on the issue of PrEP 
adherence within the MSM population. Specifically, both pieces aimed to examine the 
predictors of PrEP adherence. The review provided an up-to-date summary of the 
predictors of PrEP adherence which provided an empirical basis and informed the 
development of the empirical article (described below). 
 
The review provided a summary of the key factors related to PrEP adherence amongst 
actual PrEP users as opposed to previous reviews which had investigated adherence 
within different study populations (i.e., HIV positive individuals), at earlier points of the 
prevention cascade (e.g., predictors of uptake) or those which explored hypothetical 
facilitators and barriers to PrEP use. This meant that review findings were more 
relevant to the empirical piece and could inform questionnaire development/ the 
factors which were explored.  All key factors highlighted by the review in relation to 
PrEP adherence were incorporated within the questionnaire used in the empirical 
piece (e.g. substance use, routine and actual sexual behaviour).  
Review findings gave a strong rationale for the methodological design used for the 
empirical article. The review highlighted factors related to PrEP adherence that may 
vary situationally (i.e. lifestyle factors; changes in routine, busier schedule, frequent 
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travel or being away from home) and could influence PrEP adherence in particular 
contexts. Studies within the review reported that MSM PrEP users showed 
inconsistent adherence. However, all studies included used correlates of PrEP 
adherence (e.g. ethnicity) to make comparisons between ‘good-adherers’ and ‘poor-
adherers’ which prevented the investigation of the factors related to variability in 
adherence across situations within an individual. This gave a clear rationale that by 
using a within-participant design the empirical article could expand upon the review 
and examine situational variations in adherence.  
The review highlighted that studies had not used theory to inform the variables 
measured in relation to PrEP adherence. Consequently, research has not concluded 
whether a specific theoretical model accurately explains PrEP adherence. Therefore, 
it felt necessary that the empirical piece was closely linked to a theoretical model of 
adherence. Specifically, the review highlighted the potential utility of the IMB model to 
understand PrEP adherence (Fisher & Fisher, 2002). The review highlighted that this 
model may be well suited for the empirical piece as it was better placed to 
acknowledge the complex factors involved in PrEP adherence than other models (e.g. 
the Necessities-Concerns Framework) (Horne, 2006). Overall, this helped to guide 
and inform the key psychological constructs investigated in relation to PrEP adherence 
within the empirical article.   
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Reflections upon recruitment  
The review highlighted the need for future PrEP research to be conducted in diverse 
settings to increase the generalisability of findings. Originally, the study had intended 
to recruit from three London sexual health clinics. However, at one site recruitment 
failed due to impracticalities. For example, rooms were not available to use or clinic 
slots were not filled with PrEP users at the times I was available.   I responded by 
focusing and recruiting from two sites which were most accessible.  At one of these 
sites, recruitment was limited, mainly again due to impracticalities. In this case, I 
attended evening clinics but regularly no eligible participants had appointments at 
these times or I attended the DISCOVER research trial clinic but appointments when 
I could attend were infrequent (e.g., three participants over the course of a month). 
This recruitment site had no specific PrEP clinics and alongside my own time-limited 
restrictions this avenue was impractical. This meant that most participants were 
sourced from one recruitment site. Recruitment was more successful here as specific 
PrEP clinics were run monthly and the initiation of the PHE Impact trial meant that 
large cohorts of new or existing PrEP users were attending the clinic within allotted 
times to begin their participation in the trial. Recruitment from this one specific site 
limited the generalisability of results but meant that I could recruit the number of 
participants needed to adequately power study findings based on a priori power 
calculations and detect effects of interest.    
The review also highlighted the need for research to be conducted in diverse 
implementation settings and the limitations of examining predictors of PrEP adherence 
within RCTs. In particular, RCT designs could have overestimated PrEP adherence 
due to increased resources able to support adherence (e.g., increased monitoring) 
and different relationships between potential determinants and adherence than would 
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be found in real-world settings. Therefore, when implemented outside of the context of 
RCTs, adherence levels and relationships may differ. Originally, the study intended to 
recruit participants whom were taking part in the PHE Impact pilot project trial delivered 
through existing sexual-health clinics. This was an opportunity to explore PrEP 
adherence within ‘real-life’ clinic settings. However, the time-scales of the Impact 
implementation were not as expected with clinics projecting that the trial would start 
much later than expected. Due to time-constraints this would have meant that using 
this recruitment source for the study would not have been a realistic goal. Therefore, 
we decided that we would use alternative sources of recruitment (i.e. recruiting existing 
PrEP users whom obtained PrEP online, via private prescription or were part of the 
DISCOVER RCT research trial). However, individuals whom actively seek PrEP in this 
way may be highly motivated to take PrEP and may not be representative of the 
general MSM PrEP taking population. This meant that the study recruited a cohort of 
individuals accessing PrEP through specific methods in specific central London clinics 
which may have limited the generalisability of results.  
 
Reflections upon service user involvement 
Arnstein’s (1969) ladder of participation, describes different levels of service-user 
involvement ranging from ‘no control’ (i.e. service-users as passive consumers) to ‘full 
control’ (i.e. where service-users control decision making at the highest level). Using 
this framework, I think that the current study sits between the ‘consultation’ (i.e. 
service-users are asked but have limited influence) and ‘participation’ (i.e. service-
users can make suggestions and influence outcomes) levels. Service-users were not 
involved in the development of the systematic review and therefore for this component 
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the research sits within the ‘no control’ section of the hierarchical ladder of 
participation.  However, within the empirical article service user feedback was used to 
assist questionnaire development. Service-users were sought by advertising on one 
of the recruitment sites’ social media page.  Eight individuals contacted the author and 
were sent a copy of the draft questionnaire to give feedback in terms of the clarity, 
relevance, comprehensiveness and any other comments. This led to adaptations to 
increase relevance for example, changing the names of street drugs, and formatting. 
Service-users were sent the final questionnaire, meaning they were informed of the 
influence they had. In this example, service users’ views were sought, taken seriously 
and had a direct impact on decision making (i.e. meeting criteria for ‘participation’ level 
service-user involvement). A limitation of this was that the sample size was small and 
therefore the breadth of feedback and impact of service-user involvement was limited. 
Due to time constraints, the questionnaire development stage and therefore 
opportunity for more service-user involvement, was limited. Another limitation was that 
participants were sent a draft questionnaire and asked to comment upon its content. I 
think that service-user opinion could have been incorporated more meaningfully/ been 
more influential if they had been consulted prior to the development of a draft version 
of the questionnaire (i.e. that service-user involvement would have driven 
questionnaire development).   Further service-user involvement has been planned for 
the dissemination phase of the project (please see below). 
The empirical article met the Department of Health’s (2005) research strategy by 
involving service users in the design and reporting of research. However, service-
users were not involved in the conduct or analysis stages of research. The main 
reason for not involving service-users during the undertaking of these research 
processes was due to time and resource constraints (i.e. involving members of the 
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public to collect or analyse data may have required training which was not viable in 
the time-frame). However, it would have been useful to consult with service-users at 
the analysis stage to provide their own interpretations of the data to supplement my 
own (NIHR, 2010; 2012).  
 
Impact 
The World Health Organization (WHO) cites HIV as a major global public health issue, 
having claimed more than 35 million lives and approximately 1.8 million people 
becoming newly infected and over a million dying in 2016. While the scale‐up of ART 
treatment has contributed to saving millions of lives and reducing major illnesses, 
WHO recognises that there has not been the expected impact on HIV incidence at a 
population level. Newer preventative approaches such as PrEP have been cited as a 
crucial strategy to provide effective prevention for those at ongoing substantial risk of 
infection. PrEP implementation has the potential to dramatically reduce HIV acquisition 
and need for life-long ART adherence (Patel, 2017).   However, a barrier to successful 
PrEP implementation and cost-effectiveness has been non-adherence amongst key 
high-risk populations (Gomez et al, 2013). The current review and empirical research 
has investigated the relationship between predictors of adherence to PrEP amongst 
MSM who are most at risk of HIV acquisition in the UK. This research contributes 
knowledge regarding the factors which may influence PrEP adherence and indicates 
ways in which adherence interventions could be tailored to ensure successful PrEP 
implementation.  
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Potential Beneficiaries  
The potential beneficiaries of this work are a) PrEP users and their sexual partners, b) 
support organisations, c) clinicians administering PrEP, monitoring PrEP use or 
delivering PrEP adherence interventions d) policy makers/professionals involved in 
PrEP implementation guidelines and e) researchers (e.g. health or clinical 
psychologists) in the PrEP field or examining situationally-specific medication 
adherence on other conditions. 
Non-academic Beneficiaries 
PrEP users and their sexual partners 
PrEP users engage with PrEP medication as a HIV prevention strategy. The current 
findings highlight correlates of and situations where non-adherence may be more 
likely. By summarising and disseminating the key findings across both review and 
empirical findings for PrEP users, this population may be able to improve their PrEP 
adherence. For example, PrEP users might be able to pre-plan for high-risk situations 
for non-adherence (e.g. when they have used substances) if they are prompted to 
consider which situations are most characteristic of non-adherence for them. If this 
contributes to increased adherence amongst MSM PrEP users, this may directly 
benefit the service-user whom may no longer be at risk of HIV acquisition.  Helping to 
ensure that PrEP is an effective HIV prevention tool may also benefit the sexual 
partners of MSM PrEP users. For example, an HIV-negative MSM PrEP user and their 
HIV-positive partner may both feel less anxious about HIV transmission during sexual 
activity if the individual was able to take their PrEP as prescribed.  
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Support Organisations 
Support organisations (e.g. the Terrance Higgins Trust [THT] or the “I want PrEP now” 
campaign) offer information, support and guidance to individuals to raise awareness 
of and access to PrEP with the overarching aim to prevent HIV transmission. The 
current findings could be used and incorporated into their campaigns to help support 
MSM PrEP users adhere to their medication and potentially prevent HIV acquisition. 
For example, both THT and I want PrEP now websites give ample information 
regarding what PrEP is, eligibility, safety profile and potential regimens to follow. 
However, neither provide adherence support for current PrEP users. Key findings (e.g. 
normalising and describing potentially high-risk situations for non-adherence such as 
being away from home) could be reported on these websites.  Overall, this would help 
these organisations support MSM PrEP users during different phases of the 
prevention cascade.  
 
Clinicians administering PrEP, monitoring PrEP use or delivering PrEP adherence 
interventions 
The empirical article was the first study to explore within-participant predictors of MSM 
PrEP adherence and the review findings were not substantiated by meta-analysis 
meaning clinical implications are expressed cautiously. Both pieces highlighted wide-
ranging facilitators and barriers to PrEP adherence and the empirical piece highlighted 
that factors may vary dependent on an individual’s situation.  In combination, the 
findings suggest the utility of tailored PrEP adherence interventions which could focus 
upon situational variations (e.g. variations in mood, information, behavioural skills and 
behavioural factors). The barriers highlighted could then be used to conceptualise 
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high-risk situations for non-adherence and alternative strategies could be co-
constructed to facilitate adherence in these situations (i.e. a relapse prevention 
framework). Furthermore, normalising fluctuations of adherence may help PrEP users 
engage with conversations about their non-adherence and patterns around this. WHO 
guidelines (2017) recommend ‘brief adherence counselling’ (not described further) is 
offered at every follow-up visit. Helping to give clinicians a focus when having these 
conversations could help to ensure effectiveness and is crucial given current resource 
and time-limited service settings. Currently there are no standardised assessment 
tools for PrEP adherence or guidance of how to differentiate PrEP adherence care for 
individuals. 
 
Policy makers/professionals involved in PrEP implementation guidelines 
Policy makers and professionals involved in PrEP guidelines summarise key points 
for a range of stakeholders to support them in the consideration, planning, introduction 
and implementation of PrEP. A central aim is to ensure to PrEP effectiveness when 
implemented in real-life settings. PrEP adherence is a critical determinant of PrEP 
effectiveness. Therefore, current study findings could be outlined and summarised to 
provide helpful suggestions how guidelines can be written to facilitate MSM PrEP 
adherence and ensure PrEP effectiveness. 
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Academic Beneficiaries 
Researchers 
Findings highlighted factors that may be related to PrEP adherence and suggested 
that situational psychological factors are important. This could inform researchers 
future investigation of the predictors related to PrEP adherence (i.e. inform the 
variables under investigation or methodological design used) or those examining the 
theoretical framework which could explain PrEP adherence. Current findings also 
contribute to a wider literature using a within-participant methodological design to 
examine adherence within long-term healthcare conditions. Other studies examining 
adherence within chronic healthcare conditions (i.e. Beta-Thalassaemia-Major and 
HIV) requiring life-long adherence have also found similar findings (Hawkins et al, 
2016; Vosper et al, in. press). This suggests that across conditions there are specific 
situations that make it difficult to adhere. Therefore, the reach of the current findings 
may not be limited to researchers investigating adherence in the PrEP using 
population but also researchers using a within-participant approach to examine 
adherence within long-term healthcare conditions.  
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Significance and originality of the work in relation to clinical and health psychology  
Clinical and health psychology has a long-history of examining the predictors of 
adherence to a variety of medical regimens to bridge the gap between biological 
efficacy of a product/intervention and its effectiveness when implemented in practice 
(Christensen, 2004). Prior to the current study, no research has specifically examined 
within-participant predictors of PrEP adherence and more generally this 
methodological design has been rarely used. The empirical article supports the 
interpretation that PrEP adherence may vary situationally. This highlights the utility of 
this methodological design to be able to understand the predictors of adherence. The 
IMB model has been applied to various physical and mental-health conditions to help 
explain adherence. At present, there is no established theoretical framework to 
accurately explain PrEP adherence. Prior to the current study, no study has used 
theory to inform the choice of variables chosen to measure in relation to PrEP 
adherence. The empirical piece highlighted the potential utility and robustness of 
aspects of the IMB model to understand PrEP adherence. 
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Maximising Impact  
To maximise the impact of findings for clinicians, factors highlighted by the review and 
empirical article could be used to help prompt questions and/or inform the 
development of standardised questionnaire assessment tools which could ask 
individuals about key situational factors related to adherence. Clinicians could then 
efficiently review these forms to orientate and focus conversations on adherence. 
Alongside these discussions, the development of a standardised assessment tool 
could highlight individuals who might be most at risk for non-adherence and ensure 
additional support/service resources were allocated to those most at need (e.g. 
referrals to adherence interventions or increased monitoring). The empirical study 
highlighted specific situations where PrEP users were more likely to be non-adherent. 
These situations could be incorporated within existing problem-solving based PrEP 
adherence interventions (e.g. NSC) which could help PrEP users identify and cope 
with these situations (e.g. where they feel less positive affect, lower perceived 
behavioural skills or are away from home/out of their usual routine). 
Time and resource limitations may act as barriers to these discussions. If this were the 
case, findings could be used to develop informational leaflets regarding factors that 
may impact adherence, helpful strategies that may maximise adherence and 
normalising inconsistent use for all PrEP users. This could also be achieved/ facilitated 
by website and video mediums.  Although not a substitute for detailed clinical 
discussion, these leaflets, if given as part of standard PrEP clinic appointments, would 
ensure that key points were disseminated to service-users.  
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Dissemination 
Dissemination is one pathway to impact. It is planned that the current research will be 
made more broadly available by publishing results in a journal article. It is hoped that 
both the review and empirical article will be published in AIDS & Behavior, a high 
impact peer-reviewed journal, which focuses upon the psychological and socio-
medical aspects of AIDS/HIV and has published multiple articles related to PrEP and 
PrEP adherence. Due to this journals’ scope it is read by wide range of professionals 
(i.e. clinical and research) from different disciplines helping to facilitate dissemination 
further.  Alongside this, the empirical abstract has also been submitted to the 2018 
HIV Research for Prevention conference. This is the only international scientific 
meeting dedicated to biomedical HIV prevention research and give the opportunity for 
findings to be disseminated to multiple professionals specifically within this 
clinical/research domain.  
Service-user involvement will be crucial to establish which findings may be most of 
interest to the public and MSM population. It is planned that I will attend LGBT/MSM 
specific service-user groups at recruitment sites to not only advise on the most 
relevant findings but also advise on how results can be presented in format that offers 
clarity and can be understood by members of the public. It is also hoped that service-
users will also provide ideas about where and how findings should be disseminated 
and potentially be directly involved in presenting the findings. Once this has taken 
place, findings will be adapted into plain English for dissemination at relevant service 
user forums. This includes LGBT and MSM specific service user forums at both 
recruitment sites as well as attending community events. For example, London sexual 
health clinics run PrEP information evenings and there are independent MSM service-
user groups such as IMPULSE which meet to offer support and promote better sexual 
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wellbeing. It is planned that I will contact and deliver the key findings of the review and 
empirical project in these settings to facilitate dissemination to service-users. This will 
not only include PrEP users but those who may not have heard of PrEP, be interested 
in PrEP uptake or those who have discontinued PrEP, to help ensure that findings are 
disseminated across stages of the prevention cascade.  To not limit the dissemination 
to service-users who actively attend service-user or community groups it is planned 
that key findings will be also be disseminated through online mediums. This includes 
summarising key findings to disseminate on recruitment sites social media platforms 
such as Facebook, YouTube and Twitter. 
To facilitate dissemination to clinicians it is planned that I will attend team meetings 
and training workshops for staff at London sexual health clinics to present key findings. 
This could be achieved by contacting existing links with recruitment sites but also with 
the PrEP Impact trial whom have existing links with multiple London sexual health 
clinics. To help clinicians translate this information to their practice, leaflets will be 
made which outlines key findings. This could include a checklist for health care staff 
(e.g. did you ask whether the person uses reminders? Or has a daily routine?) which 
may make it easier to translate key findings into a standard part of the assessment 
format. The impact of this will be maximised if the clinicians see benefit to 
implementing or changing their practice. Pro-active engagement prior, during and after 
giving feedback would be crucial to ensure that impact is maximised. This could 
include conversations with clinicians prior to delivering feedback about what they think 
would be helpful to their practice. To maximise the impact of this further, I could liaise 
and develop relationships with existing members of staff. This would mean that current 
members of staff would be able to become ‘champions’ of the research helping 
findings to disseminated further.  
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Lastly, it is hoped that by developing and establishing relationships with multiple 
potential beneficiaries this will help to maximise the impact of the current study. For 
example, it is planned that I will communicate via email with drug companies providing 
PrEP, to key individuals writing PrEP guidelines and to journalists. Following the 
advice of the Economic and Social Research Journal regarding how to maximise 
impact and develop relationships with the media, I would contact a small number of 
specialist journalists who have previously written about PrEP within national papers 
and gay publications such as the Gay Times Magazine. I could also liaise with the 
communications team at Royal Holloway University of London to discuss how to draft 
a press release and where I should send relevant information about the project. 
Alongside this, it would be helpful to prepare a poster to present to these stakeholders 
as well as for any unanticipated opportunities that may arise. In sum, it is hoped that 
these various formats of communication will help to ensure findings are disseminated 
to multiple stakeholders to enhance reach. 
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Evidencing Impact 
Overall, the impact of the study detailed above suggests that effective dissemination 
would lead to increased awareness and changes in clinical practice. To demonstrate 
that these activities had been achieved the impact would have to be evaluated.  
To evidence the usefulness of training workshops, my attendance at staff meetings 
and leaflets given it would be important that clinicians were given the opportunity to 
give anonymous feedback. This would include asking how much clinicians felt this 
information had influenced their practice at a later date. This could be given in the form 
of a simple online questionnaire format which could be circulated via email. It could 
also provide opportunity for clinicians to feedback what they would find more useful 
and I could consider these as potential dissemination options. It would also be useful 
if qualitative research could take place examining the staff experiences of translating 
key findings into practice at a later timepoint. A similar approach could be taken when 
evidencing the impact of attending service-user forums.  
To gain feedback from social media platforms e.g. Facebook or Twitter a link could be 
provided to an online questionnaire. This would ask service-users regarding the clarity, 
relevance and usefulness of the content. It would also ask service-users how this 
might influence them both generally (e.g. whether they would consider PrEP uptake) 
and, if relevant, their adherence behaviours. To evidence whether establishing and 
developing relationships with multiple stakeholders (individuals writing PrEP 
guidelines, journalists etc) was successful, relevant quotes and excerpts from policy 
documents that cite the research could be collated.  
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Now that you have received approval it is time to apply for ethics.   Please keep Annette 
informed and where possible provide copies of all applications, letters and approvals.  
Also, please ensure that if RHUL is your sponsor, Annette is sent all participant signed 
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Appendix 7: Life Windows Questionnaire 
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The LifeWindows Information-- Motivation -- Behavioral Skills  
ART Adherence Questionnaire (LW-IMB-AAQ) 
ITEMS 
Note: Each LW-IMB-AAQ item represents a barrier primarily falling within the I (Information), M (Motivation), or B 
(Behavioral Skills) constructs. When used with the LifeWindows ART adherence intervention software program, a 
‘critical zone’ is superimposed for a range of response options for each item (reflected here as shaded and in red text). 
Responses within the critical zone are interpreted as signaling the presence of a deficit or potential deficit that then 
triggers the offering of intervention activities specifically developed to address the barrier reflected in the content of the 
item. 
 
I1 I know how each of my current HIV medications is supposed to be taken (for example 
whether or not my current medications can be taken with food, herbal supplements, or 
other prescription medications). 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
I2 I know what to do if I miss a dose of any of my HIV medications (for example, whether or 
not to take the pill(s) later). 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
I3 Skipping a few of my HIV medications from time to time would not really hurt my health. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
I4 I know what the possible side effects of each of my HIV medications are. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
I5 As long as I am feeling healthy, missing my HIV medications from time to time is OK. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
I6 I understand how each of my HIV medications works in my body to fight HIV. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
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I7 If I don’t take my HIV medications as prescribed, these kinds of medications may not work 
for me in the future. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
I8 I believe that if I take my HIV medications as prescribed, I will live longer. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
I9  I know how my HIV medications interact with alcohol and street drugs. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
M1 I am worried that other people might realize that I am HIV+ if they see me taking my HIV 
medications. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
M2 I get frustrated taking my HIV medications because I have to plan my life around them. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
M3 I don’t like taking my HIV medications because they remind me that I am HIV+. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
M4 I feel that my healthcare provider takes my needs into account when making 
recommendations about which HIV medications to take. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
M5 Most people who are important to me who know I’m HIV positive support me in taking my 
HIV medications. 
                                         
I strongly 
disagree 
I somewhat 
disagree 
I neither 
agree nor 
disagree 
I somewhat 
agree 
I strongly Agree No one that I 
care about knows 
I am positive 
 
M6 My healthcare provider doesn’t give me enough support when it comes to taking my 
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medications as prescribed. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
M7 It frustrates me to think that I will have to take these HIV medications every day for the 
rest of my life. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
M8 I am worried that the HIV medications I have been prescribed will hurt my health. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
M9 It upsets me that the HIV medications I have been prescribed can affect the way I look. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
M10 It upsets me that the HIV medications I have been prescribed can cause side effects. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
B1 There are times when it is hard for me to take my HIV medications when I drink alcohol or 
use street drugs. 
                                         
I strongly 
disagree 
I somewhat 
disagree 
I neither 
agree nor 
disagree 
I somewhat 
agree 
I strongly agree I don’t drink 
alcohol or use 
street drugs 
 
B2 How hard or easy is it for you to stay informed about HIV treatment? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
 
B3 How hard or easy is it for you to get the support you need from others for taking your HIV 
medications (for example, from friends, family, doctor, or pharmacist)? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
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B4 How hard or easy is it for you to get your HIV medication refills on time? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
 
B5 How hard or easy is it for you to take your HIV medications when you are wrapped up in 
what you are doing? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
 
B6 How hard or easy is it for you to manage the side effects of your HIV medications? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
 
B7 How hard or easy is it for you to remember to take your HIV medications? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
 
B8 How hard or easy is it for you to take your HIV medications because the pills are hard to 
swallow, taste bad, or make you sick to your stomach? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
 
B9 How hard or easy is it for you to make your HIV medications part of your daily life? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
 
B10 How hard or easy is it for you to take your HIV medications when your usual routine 
changes (for example, when you travel or when you go out with your friends)? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
 
B11 How hard or easy is it for you to take your HIV medications when you do not feel good 
emotionally (for example, when you are depressed, sad, angry, or stressed out)? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
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B12 How hard or easy is it for you to take your HIV medications when you feel good physically 
and don’t have any symptoms of your HIV disease?  
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
 
 
B13 How hard or easy is it for you to take your HIV medications when you do NOT feel good 
physically?  
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
 
B14 How hard or easy is it for you to talk to your health care provider about your HIV 
medications? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
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Appendix 8: Participant Information Sheet 
 
 
 
 
 
Psychological and behavioural within-participant predictors of adherence to 
oral HIV Pre- Exposure Prophylaxis (PrEP) 
 
Participant Information Sheet     
You have been asked to participate in a study about adherence to oral PrEP, 
which is being carried out by Alison Taylor, trainee clinical psychologist, in 
collaboration with Site 1, Site 2 and Site 3 clinics.  
  
Thank you for your interest in the research study. Please read the following information 
carefully:  
  
 
What is the study about? 
 
The aim is to explore adherence to oral PrEP. PrEP works to reduce HIV transmission 
but a high level of adherence is necessary for it to be effective. The study focuses on 
whether there are particular situations, beliefs and feelings which are linked with 
whether individuals take or do not take their daily oral PrEP medication. We believe 
our findings will help the development of tailored interventions to improve PrEP 
adherence.  
 
 
Who can take part in the study? 
 
You have been approached to participate because you have been prescribed oral 
PrEP medication. To participate in this study, you must have: 
 
1) been prescribed oral PrEP medication for at least three months and  
2) follow a daily dosing regimen and 
3) had at least had one day where you did and at least one day where you did 
not take your oral PrEP medication in the last month. 
 
 
What will the study involve? 
 
There is just one part to this study: you will be asked to fill out questionnaires about 
one time that you did and one time that you didn’t take oral PrEP medication in the 
previous month. You will also be asked some background questions about yourself. 
These questionnaires could be completed either online or on paper. Alternatively, you 
could choose to complete the questionnaire on the phone or in an interview with the 
researcher. These questionnaires should take no longer than 30 minutes to complete. 
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Do I have to take part? 
 
Taking part in the research is completely voluntary and you may withdraw from the 
study at any time, without giving a reason. If you decide to take part (or not) this will 
not affect the standard of your care in anyway.  
 
 
What are the risks of taking part?  
 
We do not think there are any particular risks associated with taking part in the 
research. However, if you feel worried or distressed during the study please feel free 
to contact the researcher (details provided below). A list of support services will be 
presented at the end of the survey, however, you will also be able to access support 
from the clinic (i.e. Site 1, Site 2 or Site 3) if required.  
 
 
What are the benefits of taking part? 
 
One potential benefit of taking part in this research is that you may find it helpful to 
reflect on periods when you have and haven’t taken your oral PrEP medication. You 
may also find it a positive experience to know that you are informing research which 
would go on to help other people taking PrEP. For example, results could help inform 
the way clinicians support adherence in others using oral PrEP medication.  
 
 
Is it confidential?  
 
Yes. Your information and responses will be kept completely confidential unless you 
tell us something that indicates you or someone else is at risk of harm. We would 
discuss this with you before telling anyone else. You will be assigned a unique number 
to identify you throughout the study. All data will be stored in a password-protected 
database that only the research team will have access to. The research team includes; 
Alison Taylor, (Trainee Clinical Psychologist, Royal Holloway University of London 
(RHUL)), Dr Michael Evangeli (Senior Lecturer at RHUL) and Dr Mitzy Gafos 
(Associate Professor, The London School of Hygiene & Tropical Medicine).  
 
We will ask you to provide an email address to be sent a summary of the study 
findings. This is optional. If you choose to provide this information, your email 
addresses will be stored in a separate password-protected database from your 
responses; there will be no direct association between your email addresses and your 
responses.  
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What will happen to the results of the study? 
 
The research will be submitted in partial fulfilment of a doctorate degree in Clinical 
Psychology. We aim to publish its results in a peer-reviewed journal and at 
conferences. The published data will be anonymised and no participants will be 
identified. If you would like, we will send you a summary of the findings via the email 
address you provide.  
 
Who is organising and funding the research? 
 
The research is being led by Alison Taylor and is being funded by Royal Holloway, 
University of London (RHUL), as part of the doctorate programme in Clinical 
Psychology.  This study has been reviewed and approved in accordance with xxx NHS 
ethics committee as well as the College Ethics Committee at RHUL. 
 
 
Who should you contact with questions?  
This project is supervised by Dr Michael Evangeli (Clinical Psychologist and 
Senior Lecturer at Royal Holloway University London) and Dr Mitzy Gafos 
(Associate Professor, The London School of Hygiene & Tropical Medicine). 
The main person to contact for this project is Alison Taylor, Trainee Clinical 
Psychologist as the Department of Clinical Psychology, Royal Holloway University of 
London (RHUL). You can get in touch in the following ways if you have any questions 
about the research at any time. 
• Email:  alison.taylor.2015@live.rhul.ac.uk   
• Phone: 01784 414012 (this is an answering message-  please say your 
message is for Alison Taylor, leave a message clearly stating your name and 
phone number.) 
 
Who should you contact with a complaint? 
If you have any complaints about this research or how it is conducted please contact 
the Patient Advice and Liaison Service (PALS) who can offer confidential advice, 
support and information:   
- Site 1 participants, please contact the w and x PALS on:  xxxx xxx xxxx. 
- Site 2 participants, please contact the y PALS on: xxxx xxx xxxx. 
- Site 3 participants, please contact the z PALS on:   xxxx xxx xxxx. 
 
Thank you very much for taking the time to read the information sheet. If you are happy 
to participate, please complete the consent form on the next page. 
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Appendix 9: Consent Form 
 
 
 
 
Consent form- For Participant 
 
Project Title: Psychological and behavioural within-participant predictors of 
adherence to oral HIV Pre-Exposure Prophylaxis (PrEP) 
 
Name of researcher: Alison Taylor (alison.taylor.2015@live.rhul.ac.uk) 
You have been asked to participate in a study about adherence to oral PrEP, which is 
being carried out by Alison Taylor, trainee clinical psychologist at Royal Holloway 
University of London, in collaboration with Site 1 and Site 2.  
 
 
Have you (please initial): 
 
 Yes No Not 
Applicable 
Read and understood the information sheet about the 
above study? 
 
   
Had the opportunity to ask questions? 
 
   
Got satisfactory answers to your questions? 
 
   
Understood that participation is voluntary and you are 
free to withdraw from the study at any time? (without 
giving reason and without it affecting your care) 
 
   
Understood that your information will be kept confidential 
throughout the research process, unless you tell us 
something that indicates you or someone else is at risk of 
harm. (We would discuss this with you before telling 
anyone else.)  
 
   
 
Do you agree to take part in the study? (please initial) 
Yes  
No  
 
Participant Signature: ______________________________________________ 
 
Participant please print name here: ____________________________________ 
 
Researcher Signature: ______________________________________________ 
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Appendix 10: Final Questionnaire 
 
 
 
 
 
 ART Situational Adherence Questionnaire  
 
 
Demographic Information: 
 
Your date of birth (DD/MM/YYYY) format:  
 
 …………………….. 
 
Occupational status (please tick):  
 
Employed 
Full Time 
☐ Employed 
Part Time 
☐ Unemployed      ☐  Student 
Full Time  
☐ Student 
Part Time 
☐ 
Retired ☐ Other ☐       
 
 
Highest educational qualification (please tick):  
 
Not 
Applicable 
☐ GCSE /O-
level 
☐ A-level/ 
BTEC      
☐  Degree level 
Qualification 
☐ Postgraduate 
Qualification 
☐ 
 
 
Ethnicity (please tick): 
  
White ☐ Black      ☐ Asian 
  
☐ Mixed ☐ Other ☐ 
If other, please specify: 
 
…………………………. 
 
Born in the UK? (please tick): 
 
Yes ☐ No ☐ 
 
 
Relationship status (please tick): 
 
Single ☐ 
Partner, living together ☐ 
Partner, living separately ☐ 
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Number of sexual partners in the last month (please write): 
 
  ………………….. 
 
How long have you been taking PrEP for? (please tick): 
 
3-4 months ☐ 5-8 months ☐ 9-12 months ☐ 1 year+ ☐ 
 
 
 
How do you obtain your PrEP medication? (please tick): 
 
Online ☐ Private 
Prescription 
☐   Research/Study 
Participant  
☐ Friend ☐ Other  ☐ 
 
If ‘other’ please specify where you obtain PrEP: 
 
 ………………… 
  
 
Do you have a daily routine for when/how you take your PrEP? (please tick) 
 
Yes  ☐ No     ☐ 
 
 
What clinic do you attend for PrEP monitoring? (please tick): 
 
Site 1 ☐ Site 2 ☐ Site 3 ☐ 
 
 
Following your daily dosing regimen, how many times have you taken your 
medication in the last 7 days? (please write): 
 
…………………. 
 
 
Are you experiencing side effects? (please tick): 
 
Yes ☐ No ☐   
 
 
If Yes, are these side effects distressing you? (please tick): 
 
Yes ☐ No ☐ N/a ☐ 
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Please take a moment to think about a time when you did take your PrEP. 
For example, think about where you were, how you were feeling, what 
you expected to do that day or who you expected to see. 
 
Think about the time when you did take your PrEP. 
Please answer these questions about what you thought and how you felt at 
that time. 
 
 
 
What day of the week was it (when you did take your PrEP)?: 
 
……………………………………. 
 
Please write how many days ago this was (when you did take your PrEP) e.g. 2 days ago, 
3 days ago etc?: 
 
………………………………… 
 
Was there someone there or did you have other prompts e.g. pill box or alarm to remind you 
to take your PrEP at the time?  (please circle): 
 
Yes     No 
 
Please tick which one applied to you at the time (when you did take your PrEP) (please 
tick): 
 
My day was the same as normal      ☐ 
My day was different to normal because of something unexpected             ☐  
My day was different to normal because I had made plans              ☐ 
Other          ☐ 
 
 
Where were you? (when you did take your PrEP) (please tick): 
 
Own home ☐ A friend’s house  ☐ Partner’s house ☐  
A public place (e.g. work or college) ☐                     Somewhere else          ☐ 
 
If you ticked ‘somewhere else’ please specify: 
 
……………………………………………………. 
 
Who were you with? (when it was time to take your PrEP and you did take it) (please tick): 
 
Alone ☐ With a friend ☐ With a partner ☐ With family ☐ 
With an acquaintance ☐ With a work colleague ☐         Someone else  ☐ 
 
If you ticked ‘someone else’ please specify: 
 
 ……………………………………………………. 
 
223 
 
If you weren’t alone, did this person/these people know you were taking PrEP? (please 
circle):  
 
Yes     No            N/a 
 
 
Were you using alcohol or taking drugs (e.g. cannabis, ecstasy, G, crystal meth/Tina, 
mephedrone) around the time you took your PrEP? (please circle): 
 
Yes     No  
 
 
How likely did you think it was that you were going to have sex on that day?    (please 
circle): 
 
 
Very Unlikely Unlikely Neither likely 
or unlikely 
Likely Very Likely 
1 2 3 4 5 
 
 
Did you have sex on that day?  (please circle): 
 
Yes                No    
 
 
When you were due to take your medication, to what extent did you feel you were at risk of 
HIV without taking PrEP? (please circle): 
 
 
Very Unlikely Unlikely Neither likely 
or unlikely 
Likely Very Likely 
1 2 3 4 5 
 
 
If you did have sex on that day, did the person you had sex with know you were taking 
PrEP? (please circle): 
 
Yes     No            N/a 
 
 
If you did have sex on that day, did you use a condom? (please circle): 
 
Yes                No            N/a 
 
 
If you did have sex on that day, was this chemsex?  (please circle): 
 
Yes                No            N/a 
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If you did have sex on that day, what was the status of your sexual partner (please 
circle): 
 
HIV negative               HIV positive       Don’t know      N/a 
 
 
If you did have sex on that day, was this (please circle one or more): 
 
Anal insertive (top)         Anal receptive (bottom)                     Oral sex  
 
Other          N/a              
 
 
If you did have sex on that day, was this with a casual or regular partner? (please 
circle): 
 
Casual partner         Regular partner                       N/a 
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Please again, take a moment to think about a time when you did take your PrEP. For example, 
think about where you were, how you were feeling, what you expected to do that day or who 
you expected to see. 
 
At the time I was due to take my PrEP… 
 
 1 Strongly 
disagree 
 
2 Disagree 3 Neither 
agree or 
disagree 
4 Agree 5 Strongly 
agree 
 
I knew the correct 
way to take my 
medicines      
 
I knew how taking 
PrEP could make 
me feel      
 
I understood how my 
PrEP would work      
 
I knew I should take 
the PrEP at that time      
 
I thought other 
people would notice 
I was taking my 
PrEP and think I was 
HIV positive which 
concerned me      
 
I thought that other 
people would notice 
me taking PrEP and 
think I was 
promiscuous, which 
bothered me       
 
I knew how to tell 
others about my 
PrEP use       
 
I thought I had to 
plan my life around 
my medicine, which 
frustrated me      
 
PrEP reminded me I 
was at risk of HIV, 
which bothered me      
I felt confident that 
my PrEP was going 
to work      
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1 Strongly 
disagree 
2 Disagree 3 Neither 
agree or 
disagree 
4 Agree 5 Strongly 
agree 
 
People around me 
that I care about 
were supportive 
about my PrEP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I thought that I would 
have to take these 
medicines every day 
during the time I was 
at risk, which I did 
not like      
 
I thought my PrEP 
might interact with 
other 
substances/drugs I 
was taking, which 
bothered me 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I thought that taking 
PrEP might stop me 
from taking 
precautions against 
STI’s, which 
bothered me 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I thought that taking 
PrEP was easier 
than using a condom 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I thought PrEP 
would make me 
worry less about HIV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I thought PrEP 
would make me 
enjoy sex more 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I thought PrEP was 
harming me 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I thought PrEP 
would cause side 
effects      
 
I had easy access to 
my medicines                         
 
 
 
 
 
 
 
 
 
 
 
 
 
227 
 
1 Strongly 
disagree 
2 Disagree 3 Neither 
agree or 
disagree 
4 Agree 5 Strongly 
agree 
 
I was confident I 
could find the time to 
take my PrEP 
     
 
          
 
 
 
 
 
 
  
 
I was confident I 
could manage any 
side effects      
 
I was confident that I 
could remember to 
take my medicines 
 
 
 
 
 
 
 
 
 
 
 
I was confident I 
could manage the 
size of the pills or 
the taste of the 
medicine      
 
I felt confident that I 
had enough PrEP 
for other days      
 
I felt confident that I 
could fit my 
medicines around 
what I was doing      
 
I felt confident I 
could take my 
medicines correctly      
 
I felt confident I 
could take my 
medicines even if 
other people were 
around      
 
I felt confident I 
could ask for help to 
take my PrEP if I 
needed to      
 
I felt confident I 
could take my 
medicines however I 
was feeling      
 
I felt ill      
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How did you feel when it was time to take your PrEP?  
 
 1  
Very 
slightly or 
Not at all 
2  
A little 
3  
Moderately 
4  
Quite a bit 
5 
Extremely 
 
 
 
Active      
 
Afraid      
 
Determined      
 
Nervous      
 
Attentive      
 
Upset      
 
Inspired      
 
Hostile      
 
Alert      
 
Ashamed      
      
      
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
 
      
      
      
      
229 
 
 
 
 
 ART Situational Adherence Questionnaire  
 
 
Now please take a moment to think about a time when you did not take your PrEP. 
For example, think about where you were, how you were feeling, what you expected 
to do that day or who you expected to see. 
 
 
Think about the time when you did not take your PrEP. 
Please answer these questions about what you thought and how you felt at 
that time. 
 
 
 
 
What day of the week was it (when you did not take your PrEP)?:  
 
……………………………………. 
 
 
Please write how many days ago this was (when you did not take your PrEP) e.g. 2 days 
ago, 3 days ago etc?: 
 
………………………………… 
 
  
Did you forget to take your PrEP or did you intentionally not take your medication? (please 
tick): 
 
I forgot    ☐                  I chose to not take my medication ☐ 
 
 
 
If you chose not to take your PrEP please write why:  
 
…………………………………………………………………………………………………. 
 
 
Was there someone there or did you have other prompts e.g. pill box or alarm  to remind you 
to take your PrEP at the time?  (please circle): 
 
Yes     No 
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Please tick which one applied to you at the time (when you did not take your PrEP): 
 
My day was the same as normal      ☐ 
My day was different to normal because of something unexpected             ☐  
My day was different to normal because I had made plans              ☐ 
Other          ☐ 
 
 
Where were you? (when you did not take your PrEP) (please tick): 
 
Own home ☐ A friend’s house  ☐ Partner’s house ☐  
A public place (e.g. work or college) ☐                     Somewhere else          ☐ 
 
If you ticked ‘somewhere else’ please specify: 
 
 ……………………………………………………. 
 
 
Who were you with? (when it was time to take your PrEP and you did not take it) (please 
tick): 
 
Alone ☐ With a friend ☐ With a partner ☐ With family ☐ 
With an acquaintance ☐ With a work colleague ☐         Someone else  ☐ 
 
 
If you ticked ‘someone else’ please specify: 
 
 ……………………………………………………. 
 
 
If you weren’t alone, did this person/these people know that you were taking PrEP? (please 
circle): 
 
Yes    No            N/a 
 
 
Were you using alcohol or taking drugs (e.g. cannabis, ecstasy, G, crystal meth/Tina, 
mephedrone) around the time you were meant to take your PrEP? (please circle): 
 
Yes    No 
 
 
How likely did you think it was that you were going to have sex on that day?     (please 
circle): 
 
Very Unlikely Unlikely Neither likely 
or unlikely 
Likely Very Likely 
1 2 3 4 5 
 
 
 
 
 
231 
 
Did you have sex on that day?  (please circle): 
 
Yes               No 
 
 
When you were due to take your medication, to what extent did you feel you were at risk of 
HIV? (please circle): 
 
Very Unlikely Unlikely Neither likely 
or unlikely 
Likely Very Likely 
1 2 3 4 5 
 
 
If you did have sex on that day, did this person you had sex with know you were taking 
PrEP? (please circle): 
 
Yes    No            N/a 
 
 
If you did have sex on that day, did you use a condom? (please circle): 
 
Yes    No            N/a 
 
 
If you did have sex on that day, did you use post-exposure prophylaxis (i.e. PEP 
medication)? (please circle): 
 
Yes    No            N/a 
 
 
If you did have sex on that day, was this chemsex?  (please circle): 
 
Yes                No            N/a 
 
If you did have sex on that day, what was the status of your sexual partner (please circle): 
 
HIV negative               HIV positive       Don’t know      N/a 
 
 
If you did have sex on that day, was this (please circle one or more): 
 
Anal insertive (top)         Anal receptive (bottom)                     Oral sex  
 
Other          N/a              
 
 
If you did have sex on that day, was this with a casual or regular partner? (please 
circle): 
 
Casual partner         Regular partner                       N/a 
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Please again, take a moment to think about a time when you did not take your PrEP  
medication. For example, think about where you were, how you were feeling, what 
you expected to do that day or who you expected to see. 
 
At the time I was due to take my PrEP… 
 
 1 Strongly 
disagree 
 
2 Disagree 3 Neither 
agree or 
disagree 
4 Agree 5 Strongly 
agree 
 
I knew the correct 
way to take my 
medicines      
 
I knew how taking 
PrEP could make 
me feel      
 
I understood how my 
PrEP would work      
 
I knew I should take 
the PrEP at that time      
 
I thought other 
people would notice 
I was taking my 
PrEP and think I was 
HIV positive which 
concerned me      
 
I thought that other 
people would notice 
I was taking my 
PrEP and think I was 
promiscuous which 
bothered me       
 
I knew how to tell 
others about my 
PrEP use       
 
I thought I had to 
plan my life around 
my medicine, which 
frustrated me      
 
PrEP reminded me I 
was at risk of HIV, 
which bothered me      
I felt confident that 
my PrEP was going 
to work      
233 
 
 
1 Strongly 
disagree 
2 Disagree 3 Neither 
agree or 
disagree 
4 Agree 5 Strongly 
agree 
 
People around me 
that I care about 
were supportive 
about my PrEP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I thought that I would 
have to take these 
medicines every day 
during the time I was 
at risk, which I did 
not like      
 
I thought my PrEP 
might interact with 
other 
substances/drugs I 
was taking, which 
bothered me 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I thought that taking 
PrEP might stop me 
from taking 
precautions against 
STI’s, which 
bothered me 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I thought that taking 
PrEP was easier 
than using a condom 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I thought PrEP 
would make me 
worry less about HIV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I thought PrEP 
would make me 
enjoy sex more 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I thought PrEP was 
harming me 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I thought PrEP 
would cause side 
effects      
 
I had easy access to 
my medicines                         
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1 Strongly 
disagree 
2 Disagree 3 Neither 
agree or 
disagree 
4 Agree 5 Strongly 
agree 
 
I was confident I 
could find the time to 
take my PrEP 
     
 
          
 
 
 
 
 
 
  
 
I was confident I 
could manage any 
side effects      
 
I was confident that I 
could remember to 
take my medicines 
 
 
 
 
 
 
 
 
 
 
 
I was confident I 
could manage the 
size of the pills or 
the taste of the 
medicine      
 
I felt confident that I 
had enough PrEP 
for other days      
 
I felt confident that I 
could fit my 
medicines around 
what I was doing      
 
I felt confident I 
could take my 
medicines correctly      
 
I felt confident I 
could take my 
medicines even if 
other people were 
around      
 
I felt confident I 
could ask for help to 
take my PrEP if I 
needed to      
 
I felt confident I 
could take my 
medicines however I 
was feeling      
 
I felt ill      
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How did you feel when it was time to take your PrEP?  
 
 1  
Very 
slightly or 
Not at all 
2  
A little 
3  
Moderately 
4  
Quite a bit 
5 
Extremely 
 
 
 
Active      
 
Afraid      
 
Determined      
 
Nervous      
 
Attentive      
 
Upset      
 
Inspired      
 
Hostile      
 
Alert      
 
Ashamed      
      
      
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
 
 
 
